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Definitions
Clear communication is of vital importance for scientific discussion. In order to improve the 
clarity of this thesis, I will here describe the definitions of two terms used frequently.
Neurodevelopmental disorders
According to the Diagnostic and Statistical Manual of Mental Disorders, fifth editions 
(DSM-5), neurodevelopmental disorders (NDD) are defined to have an onset during the 
developmental period1. This includes for example autism spectrum disorders (ASD) and 
attention-deficit hyperactivity-disorder (ADHD), but excludes for example schizophrenia, 
which is classified as a neuropsychiatric disorder.
However, recent studies have shown that both NDDs and neuropsychiatric disorders can 
share phenotypes, including changes to the inhibitory system. In addition, the development 
schizophrenia has been proposed to start decades before the onset of symptoms2, 
and some studies suggest that even factors during the prenatal period can affect the 
development of schizophrenia3. Therefore, for the purpose of this thesis, we define the term 
neurodevelopmental disorders to not only include all disorders as set out in DSM-5, but 
also other conditions such as schizophrenia and bipolar disorder, that have a phenotype 
affecting the inhibitory system and are believed to be influenced by development, as is 
discussed in chapter 1.
Interneuron
The term interneuron is not clearly defined, and can be interpreted in different ways 
depending on the context. In this thesis, where we focus on the cortex and the hippocampus, 
we use the terms interneuron, GABAergic neuron and inhibitory neuron as synonyms to 
describe neurons that use GABA as their neurotransmitter and have an inhibitory effect on 
their target cells. Chandelier cells are included in this definition.
References
1.  American Psychiatric Association. Diagnostic	and	statistical	manual	of	mental	disorders	(5th	
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3.  Selemon, L. D. & Zecevic, N. Schizophrenia: a tale of two critical periods for prefrontal cortical 
development. Transl.	Psychiatry 5, e623 (2015).

General introduction
Chapter 1
This chapter was previously published in adapted form as:
Selten, M., van Bokhoven, H. and Nadif Kasri, N. (2018). Inhibitory control of 
the excitatory/inhibitory balance in psychiatric disorders. F1000Research 7, 
23.
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1.1 Introduction
The human brain is a complex and wonderful organ. It gives rise to our perception of the 
world around us, and not only allows us to see, feel, smell, taste and hear, but is also the 
seat of our emotions so that we can laugh and love. At the fundamental level, the brain 
consists of billions of neurons1, forming trillions of connections between them2. 
In cortex and hippocampus, neurons can be broadly divided in two main classes: excitatory 
and inhibitory neurons. Excitatory neurons and inhibitory neurons exist in a 4:1 ratio3, and 
are interconnected. This means that excitatory and inhibitory cells receive both excitatory 
and inhibitory inputs. Signalling between neurons takes place at a site of specialized contact 
called a synapse (from the Greek συνάψις (synapsis), meaning conjunction. Synapses are the 
location where the presynaptic cell releases neurotransmitters onto the postsynaptic cell. 
At the postsynaptic side, neurotransmitter receptors are activated by the neurotransmitters, 
passing on the signal from the presynaptic neuron to the postsynaptic neuron. Excitatory 
neurons release the neurotransmitter glutamate onto their postsynaptic cells. The release of 
glutamate causes the inflow of positively charged ions, mainly Na+, into the postsynaptic cell 
through the opening of α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) and 
N-methyl-D-aspartate (NMDA) receptors. Inhibitory neurons release the neurotransmitter 
γ-Aminobutyric acid (GABA), which causes opening of GABA receptors resulting in the 
inflow of the negatively charged ion Cl-. The inflow of positively charged ions depolarizes the 
membrane potential of the neuron, bringing it closer to the action-potential (AP) threshold, 
whereas the inflow of negative ions drives the membrane potential away from the AP-
threshold. If the AP-threshold is reached, an action potential is evoked and the cell will in 
turn release its neurotransmitters onto its postsynaptic cells.
It should be noted that the balance between excitatory and inhibitory input is of vital 
importance for this system to function. For example, a marked increase in excitatory (or 
decrease in inhibitory) input would cause an increase in the amount of action potential 
evoked in the postsynaptic neuron, thereby distorting the information this neuron encodes. 
Indeed, disruptions in the ratio between excitatory and inhibitory signalling are widely 
identified in various neurodevelopmental disorders.
Neurodevelopmental disorders, including autism, schizophrenia, bipolar disorder, ADHD 
and depression, affect millions of people and are a major socio-economic burden4–6. The 
identification of underlying genetic defects and risk factors is becoming increasingly efficient 
due to genome-wide interrogation methodologies, yet due to the complex multifactorial 
origin of most cases a conclusive molecular diagnosis is made only for a minority of patients. 
Therefore, the underlying causes for these conditions are poorly understood, and treatment 
is often still based on symptomology7–9. In 2003, Rubenstein and Merzenich proposed autism 
spectrum disorders (ASD) to be caused by an increase in the ratio between excitation and 
inhibition, called the E/I balance10. Since then, this hypothesis has been substantiated by a 
vast amount of studies, and has also been implicated in other neurodevelopmental disorders 
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such as schizophrenia11, consistent with their partially overlapping phenotypes12. Recently, 
the focus has shifted to changes to the inhibitory side of the E/I balance13,14, in particular 
on one class of inhibitory neurons, parvalbumin positive (PV+) interneurons15. Here I will 
attempt to describe the current view of the field on the role of the inhibitory system in 
neurodevelopmental disorders, and explore the changes to the inhibitory systems in different 
disorders. I will then discuss the role and function of PV interneurons, and highlight the 
changes to this specific class of interneurons in the various neurodevelopmental disorders.
1.2 Evidence for inhibitory dysfunction in neurodevelopmental disorders
Since Rubenstein and Merzenich postulated their hypothesis of a reduced E/I balance in 
autism spectrum disorders, there has been an increasing amount of evidence for disrupted 
inhibitory control in neurodevelopmental disorders. This evidence comes from post-mortem 
studies and studies of patient phenotypes.
Firstly, post-mortem studies on patient brains have revealed consistent changes to the 
inhibitory system in various disorders. Studies of autistic brains revealed reduced expression 
of the GABA synthesizing enzymes GAD65 and GAD67, as well as various GABA receptor 
subunits, in parietal cortex and cerebellum16,17. In schizophrenia, reductions of interneuron 
markers have been found in the prefrontal cortex18–21, a region strongly implicated in this 
condition22. Interestingly, in recent years this reduction has been shown to be caused 
by a reduction of the expression of the interneuron markers, rather than a reduction of 
the number of interneurons23–25, which indicates reduced activity of these neurons23–25. 
In addition, both increased and decreased numbers of specific interneuronal subtypes 
are reported in bipolar disorder20,29, while a reduced inhibitory function is reported in 
depression30,31 and bipolar disorder32.
Secondly, patients with neurodevelopmental disorders display phenotypes that are strongly 
correlated to impaired inhibition. Epilepsy is a common comorbidity in neurodevelopmental 
disorders, and has consistently been linked to impaired inhibitory function33–36. In autism 
patients, it is estimated that the prevalence of epilepsy comorbidity is around 25%37,38. This 
is, however, dependent on the type of autism, and the prevalence can be as high as 80% in 
Rett syndrome39, a monogenic form of autism caused by mutation in the MeCP2 gene40. It 
is currently unclear if schizophrenia is a risk factor for epilepsy. A limited number of studies 
have been dedicated to this question, and contradicting results have been reported41,42. 
However, epilepsy patients show an increased risk of schizophrenia or schizophrenia-like 
psychosis43. Likewise, epilepsy patients show an increased risk for ADHD44,45. 
Another recurrent phenotypic change is the altered power of gamma oscillations, as 
measured with electroencephalography (EEG) or magnetoencephalography (MEG) in 
humans, indicating changes in neuronal synchrony46. Gamma oscillations are important for 
integration of information in neuronal circuits, and have been linked to various functions 
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including attention47 and memory48. It was shown that PV+ interneurons49, specifically PV+ 
basket cells (see below) play an important role in these osciliations46,50,51. Changes in gamma 
oscillation are consistently found in schizophrenia patients52, affecting different regions 
including the prefrontal cortex53,54. Interestingly, while a decrease in gamma power is linked 
to negative symptoms of this disorder such as psychomotor poverty55, increased gamma 
power has been observed during positive symptoms, such as hallucinations56. In addition, 
computational studies suggest a central role for inhibitory synaptic scaling in maintaining a 
stable neuronal network57, and found changes in inhibitory transmission to be sufficient to 
explain the changes in gamma oscillations in schizophrenia58. Together, altered inhibitory 
control is believed to lead to a change in the power of gamma oscillations, which play a 
central role in schizophrenia59.
While studied mainly in schizophrenia, changes to gamma oscillations have also been 
observed in other neurodevelopmental disorders, including autism, ADHD and bipolar 
disorder60–66. For example children with autism show reduced gamma frequency modulation 
to a visual task, where increasing speeds of presented drifting annular grating had a smaller 
effect on the increase of gamma-band frequency67, whereas in ADHD, increased power and 
gamma-band activity was observed62–65. Together, post-mortem and patient studies point to 
an important role for altered inhibitory function in various neurodevelopmental disorders, 
and indicate a vital role for inhibition in the maintenance of the E/I balance in the healthy 
brain.
1.3 The central role of PV+ interneurons in E/I balance
Cortical and hippocampal synaptic inhibition is mediated by inhibitory interneurons, most of 
which use γ-aminobutyric acid (GABA) as their neurotransmitter. While interneurons make 
up around 20% of the total neuronal population, they are highly diverse68,69. For example, 
different classes of interneurons are specialized to target either the dendrites, soma or axon 
initial segment of pyramidal neurons68. This large variety of cell types is believed to illustrate 
the distinct functions these cells have in regulation the network70. Cortical interneurons 
can be segregated in three non-overlapping groups by means of specific markers: PV, 
somatostatin (SOM) and the serotonin receptor 3a (5HT3aR), accounting for 40%, 30% 
and 30% of the total interneuron population, respectively71. 5HT3aR positive cells mainly 
originate from the caudal ganglionic eminence (CGE) and are further divided as vasoactive 
intestinal peptide (VIP) positive and VIP negative interneurons71. VIP positive interneurons 
mainly inhibit other interneurons, and play an important role in disinhibition of the local 
circuit72, where they receive excitatory input from other cortical areas73,74. VIP cells mainly 
inhibit SOM cells75, but also target PV interneurons26, and are involved in the regulation of 
behavioural state of the network74,76. Recently, studies have suggested a direct inhibition by 
VIP interneurons of pyramidal cells in cortex77,78. Despite the prominent, mainly disinhibitory, 
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function of VIP cells in the network, only a limited number of studies have implicated VIP 
cells to be involved in neurodevelopmental disorders29,79.
SOM interneurons are a diverse class of interneurons originating from the medial ganglionic 
eminence (MGE)71. These interneurons target non-somatostatin interneurons75, as well as 
the dendritic domain of pyramidal neurons, including dendritic spines80. SOM interneurons 
regulate the integration of local excitatory input81,82, and have been shown to regulate 
synaptic plasticity via the control of dendritic calcium spikes in pyramidal cells, affecting 
learning tasks83. Increasing evidence implicates SOM interneurons in neurodevelopmental 
disorders. Disinhibition of SOM interneurons leads to an anti-depressive-like phenotype 
in mice84, and reduced levels of somatostatin in cerebral spinal fluid have been linked to 
major depression and mood disorders85. In addition, a recent paper shows a role for SOM 
interneurons in gamma oscillations in the visual cortex86, hinting towards a possible role for 
SOM interneurons in the changes in gamma oscillations observed in neurodevelopmental 
disorders.
PV interneurons are MGE derived and are electrophysiologically identified by their fast-
spiking phenotype. While PV interneurons make up only a small part of the entire neuronal 
population87,88, these interneurons are strongly implicated in neurodevelopmental disorders, 
and have been shown to play an important role in the regulations of the E/I balance11,13,89. 
PV interneurons are involved in gamma oscillations (see above), and various mutations in 
disease-linked genes affect PV interneuron function (discussed below) (Table 1). Different 
subtypes of PV interneurons are distinguished: basket cells, chandelier cells, bistratisfied 
cells and, in hippocampus, oriens-alveus-lacunosum-moleculare (OLM) cell90,91 form the 
largest of these groups, the first two of which are most widely studied. Here we will discuss 
both types, and focus on their respective roles in the network.
PV Basket cells
Basket cells are the largest group of PV interneurons and specifically target the soma and 
proximal dendrite of pyramidal neurons90. The perisomatic location of these axon terminals 
allows PV basket cells to have a strong control over the excitability of pyramidal neurons. 
Among other cortical inputs, PV basket cells receive the same excitatory input as their 
pyramidal cell targets, wiring the basket cell into a feed-forward circuit: excitatory input 
will excite both the PV basket cell and the pyramidal neuron, followed by the PV basket cell 
inhibiting the pyramidal neuron (Fig. 1). The delay between the excitatory- and inhibitory 
input onto the pyramidal cell creates a coincidence detection window, in which excitatory 
input can summate to elicit an action potential in the pyramidal cell92. If inhibitory input 
arrives at the pyramidal cell before an action potential is evoked, the somatic targeted GABA 
action will prevent action potential initiation. So, PV basket cells allow action potential 
initiation in pyramidal neurons only if the excitatory information is time locked and of 
sufficient strength.
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In order to mediate fast inhibition, PV basket cells are optimized for fast signalling88. Action 
potentials are initiated at the axon initial segment, and propagate at high velocities through 
the axon93 which is enriched for the fast sodium channel Na
V
1.194. Synaptically, calcium 
inflow is mediated by fast P/Q-type calcium channels95, which are located directly adjacent 
to the release site96. The postsynaptic site, on the pyramidal neuron, contains the fast 
GABAAα1 receptor subunit97. These fast properties ensure an optimal speed of PV basket 
cell signalling, and tightly regulated coincidence detection windows of pyramidal neurons. 
1
2 3
A
+ -
RMP
AP threshold
Main synaptic input
B1 B2
+ -
Fig. 1: Principles of feed-forward inhibition. 
(A) Schematic image of feed-forward inhibitory connectivity. Excitatory input from a presynaptic pyramidal 
neuron excites both excitatory (1) and inhibitory (2) neurons. Subsequently, the inhibitory interneuron inhibits the 
postsynaptic pyramidal neuron (3). (B) Membrane potential of the postsynaptic pyramidal neuron. (B1) If excitatory 
input is time-locked an of sufficient strength, an action potential can be evoked in the postsynaptic pyramidal 
neuron. (B
2
) If excitatory input is too weak of not time-locked, inhibitory input arrived before an action potential 
is evoked in the postsynaptic pyramidal neuron. AP threshold, Action potential threshold; RMP, resting membrane 
potential. Red colour represents excitatory input from the presynaptic pyramidal neuron. Blue colour represents 
inhibitory input from the inhibitory interneuron.
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Chandelier cells
Chandelier cells, or axo-axonic cells, are a group of interneurons that target the axon 
initial segment (AIS) of pyramidal neurons98,99. These cells form vertically oriented clusters 
of axon terminals, called cartridges, giving them a chandelier like appearance. A single 
pyramidal cells receives contacts from multiple chandelier cells100, forming an average of 
3-5 boutons each101 depending on the brain region102 and age103. The synapses are enriched 
for the GABAAα2 receptor subunit104,105, and presynaptically express the high-affinity GABA 
transporter 1 (GAT1)106. The function of chandelier cells in the network remains largely 
unknown. However, chandelier cell activity has been shown to increase with increasing 
network activity107. In addition, the axon terminals of chandelier cells are specifically absent 
from the epileptic focus108,109, and pharmacological induction of seizures leads to a loss of 
chandelier cells in rats110, suggesting a role in preventing excessive excitatory activity in the 
network for these interneurons107. 
Since their discovery, there has been a debate about the actions of chandelier cells (reviewed 
by Wang et al.101). Some studies using brain slice recordings, showed a depolarizing111 
and even excitatory112 action for these interneurons, while others report an inhibitory 
action113. However, during in vivo like membrane potential fluctuations chandelier cells 
appear strongly inhibitory114, and recordings in vivo also suggest an inhibitory role for these 
interneurons115,116. 
While patient studies of schizophrenia patients consistently identify both a reduction in the 
number or length of chandelier cell cartridges117,118 as well as the deregulation of proteins 
associated with chandelier cell synapses15,119–121, mouse research on this interneuron 
class is hampered by the absence a strategy to specifically target these interneurons. As 
a result, a limited number of studies focus on chandelier cells, but instead report on PV 
interneurons in general, or PV basket cells, which provide a more accessible target of study 
due to their relative abundance (Fig. 2). Nonetheless, chandelier cells are considered to 
play an important role in neurodevelopmental disorders14,101,122, and the development of 
strategies to specifically target this interneuron subtype would be an important step towards 
understanding the role of these interneurons.
Targeting the perisomatic region (basket cells) or axon initial segment (chandelier cells) 
gives these interneurons strong control over pyramidal cell excitability, and regulation 
of the synaptic strength of these interneurons is important for normal function of the 
network. For example, Xue and colleagues have shown that pyramidal neurons receive an 
amount of synaptic inhibition that is proportional to the amount of synaptic excitation they 
receive123, maintaining the E/I balance on the pyramidal cell. Manipulation of pyramidal 
cell activity leads to a compensatory change in inhibitory drive onto these cells, specifically 
from PV interneurons123. In addition, PV interneuron activity is reduced during learning, and 
increased during fear-conditioning, and an experimental increase of PV interneuron activity 
leads to impaired learning26. Apart from synaptic connections, basket cells124 and chandelier 
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Fig. 2: Genes linked to neurodevelopmental disorders affect inhibition on different subcellular aspects. 
Left: Genes affecting the input, intrinsic properties or output of chandelier cells. Right: Genes affecting the input, 
intrinsic properties or output of PV basket cells. Middle: Genes affecting input, intrinsic properties or output of 
interneurons, without the interneuron subtype being identified. Pyramidal cells are shown in red, interneurons 
are shown in blue.
cells114,125 connect via electrical connections, called gap junctions. This electrical coupling 
synchronizes the interneurons124, which in turn allows them to synchronize the network126, 
for example in gamma oscillations127. 
Together, these studies indicate that control of the E/I balance by PV interneurons is 
important for normal network function, and that PV interneuron mediated inhibition can 
be regulated upon alterations in the network state. Changes in PV interneuron mediated 
inhibition would shift the E/I balance, and lead to a disruption in network function. Indeed, 
various parameters affecting inhibitory function of PV cells are consistently found to be 
altered in neurodevelopmental disorders. In the next section, I will focus on studies on 
animal models of these conditions, and discuss how different changes affecting PV cell 
activity lead to a shift of the E/I balance (Table 1).
1.4 Altered PV+ interneuron activity is caused by changes to different subcellular 
aspects
Alterations to the inhibitory drive, affecting the E/I balance, can arise in different ways. 
Reduced excitatory input onto interneurons, reduced intrinsic excitability of interneurons 
and a reduction in inhibitory synapse number or strength onto pyramidal cells all results 
in a shift of the E/I balance towards excitation. Indeed, patient- and animal studies of 
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neurodevelopmental disorders consistently report changes affecting inhibitory function. A 
complicating factor in the interpretation of these results comes from the dynamic ability 
of neuronal networks to adapt to changes, known as homeostatic plasticity. Homeostatic 
plasticity is the ability of neurons to maintain their levels of excitability within a narrow 
range, and is a constantly active feedback process128. For example, classic experiments have 
shown that blocking of action potentials leads to a strengthening of excitatory129, and a 
weakening of inhibitory synapses130. Apart from their synaptic input, neurons can regulate 
their intrinsic excitability131, which is observed both in excitatory and inhibitory neurons in 
culture132, and in vivo133. This means that genetic mutations affecting a specific neuronal 
property in a specific cell type, can trigger homeostatic processes affecting other properties 
or cell types. In this way, mutations affecting both inhibitory or excitatory cells could 
ultimately affect inhibitory function89. It is therefore difficult to distinguish the direct effect 
of a gene related to a neurodevelopmental disorder from the network adaptation it causes. 
Nonetheless, changes to the function of PV neurons, either direct or indirect, are consistently 
observed in neurodevelopmental disorders affecting input, output and intrinsic properties, 
that all lead to an altered inhibitory action of these cells onto their targets (Fig. 2).
Changes to the input onto PV interneurons
Excitatory inputs onto neurons drive their excitability. Depending on the brain region, PV 
interneurons receive various types of excitatory input88, and the amount of excitatory inputs 
onto PV interneurons is dynamically regulated by behaviour26. Changes in the amount of 
excitation onto PV interneurons, altering their activity, have been reported in mouse models 
of various neurodevelopmental disorders.
The tyrosine kinase receptor ErbB4 has been identified as a risk gene for schizophrenia in 
genome-wide association studies (GWAS)134,135. In the adult mouse, expression of ErbB4 is 
restricted to interneurons136,137 and localizes to both the axon terminals137,138 and postsynaptic 
densities136,137. Selective removal of ErbB4 from PV interneurons causes a reduction in 
excitatory synapses formed onto both PV basket cells and chandelier cells, as well as a 
reduced number of PV synapses formed on pyramidal neurons139,140. This reduced input- 
and output connectivity of PV interneurons is indicative of a reduced inhibitory drive onto 
pyramidal neurons. As a result of this reduced inhibition of the pyramidal neurons, these 
neurons become more active, as was seen from the increased frequency of excitatory inputs 
to both pyramidal neurons and PV interneurons139. Consequently, recording of the local field 
potential in vivo revealed a hyperactive network and increased gamma oscillations139. 
Single nucleotide polymorphisms (SNPs) in Neuregulin 1 (NRG1), a ligand of ErbB4, have 
been implicated in schizophrenia141 and bipolar disorder142,143. Treatment of neuronal 
cultures with NRG1, activating ErbB4, leads to an increase in excitatory synapses formed 
onto interneurons140. Together, these data show that ErbB4 signalling plays an important role 
in the regulation of excitatory synapse number onto PV interneurons, and that disruption of 
this system leads to a shift of the E/I balance towards excitation139.
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Also studies on animal models of ASD have reported postsynaptic changes on PV 
interneurons. Fragile X Syndrome is caused by reduced or absent levels of the RNA binding 
protein FMRP, leading to intellectual disability and, in about half of the affected males, 
autism spectrum disorder144,145. While changes to long-term depression (LTD) on excitatory 
cells have been the centre of attention for this condition146, changes to the inhibitory 
system have consistently been identified147,148. Fmr1 KO mice show a reduced expression of 
GABA
A
 receptor subunits149, as well as a reduction of PV interneurons150. In addition, these 
mice show marked reduction in local, but not thalamic, excitatory input onto fast spiking 
interneurons in layer 4 of the somatosensory cortex, while both the connectivity of fast 
spiking interneurons onto pyramidal neurons as well as excitatory inputs onto pyramidal 
neurons were unaltered151. Consistently, the resulting reduced inhibitory drive from fast 
spiking interneurons was accompanied by reduced synchrony of gamma oscillations151. These 
changes point towards an altered E/I balance towards excitation in Fragile X Syndrome152.
Mutations in another gene linked to autism, the transcriptional modulator methyl-CpG-
binding protein 2 (MECP2), the causative gene for RETT syndrome40, shows a similar 
phenotype. Selective removal of Mecp2 from PV cells leads to a specific reduction of local 
excitatory input, but not thalamocortical input, onto these cells in layer 4 of the visual cortex 
at postnatal day (P) 30153. In addition, experimentally evoked PV interneuron input onto 
pyramidal cells was unaltered153. Calcium imaging revealed that these synaptic changes 
lead to a reduced visually evoked, but not spontaneous, activity of PV interneurons153. 
Paired recordings at P15 revealed an increased inhibition from PV interneurons through 
an earlier maturation in Mecp2 KO mice154, and this earlier maturation might influence 
network development through interference with the normal critical period154,155, leading 
to the changes observed at later ages. This notion is consistent with the recent idea that 
developmental changes might play an important role the development of psychiatric 
symptoms later in life156. The exact contribution of PV interneurons to the phenotypes 
observed in RETT syndrome is still unclear. While a general interneuron removal of Mecp2 
does recapitulate most RETT syndrome phenotypes157, studies removing Mecp2 specifically 
from PV interneurons have only been able to replicate some of these phenotypes158, or 
none at all153. Of note, selective removal of Mecp2 from somatostatin interneurons also 
recapitulates part of the RETT syndrome phenotypes158, and selective removal of Mecp2 
from either PV interneurons or SOM interneurons has been reported to cause circuit wide 
deficits in information processing159.
From these studies, a picture is emerging in which excitatory inputs onto PV interneurons 
are found to be altered in different neurodevelopmental disorders, leading to a reduced 
activity of these neurons, and thereby tilting the E/I balance towards excitation.
Changes to the intrinsic properties of PV interneurons
The intrinsic properties of neurons are important in translating input into output. Altering 
these properties allows the neurons to regulate their excitability160,161, via which they play an 
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important role in the maintenance of the E/I balance128. While some of these changes might 
be causative to neurodevelopmental disorders, others are believed to be compensatory. For 
example, selective deletion of Mecp2 from PV interneurons leads to an increased membrane 
potential, as well as a hyperpolarized action potential threshold in these cells at P30153, but 
only a slight hyperpolarization of the membrane potential at P15154. These changes increase 
the cell’s excitability, and are most likely compensatory for the reduced excitatory synaptic 
changes described above153, but could still act towards deficits in information processing 
observed in these animals159. 
Family-based association data has identified Dysbindin (DTNBP1) as a susceptibility gene for 
schizophrenia162, whose dominant circuit impact is impaired inhibition163. Dysbindin KO mice 
show a reduced number of PV interneurons in hippocampal CA1163,164, and transcriptome 
changes of various proteins involved the regulation of intrinsic properties164. Recordings 
from PV interneurons in dysbindin KO mice show a reduction in action potential frequency 
resulting in a reduced inhibitory drive165. Interestingly, dopamine D2-receptor expression is 
increased in these mice, and application of the D2-receptor antagonist quinpirole increases 
PV interneuron action potential frequency more in Dysbindin KO mice then in WT mice, 
suggesting the changes in action potential frequency are compensatory165.
Intrinsic changes can also be the primary cause of neurodevelopmental disorders. Single 
gene mutations in SCN1A, encoding the sodium channel Na
V
1.1α subunit, give rise to Dravet 
syndrome, a rare genetic epileptic encephalopathy. Dravet syndrome patients suffer from 
epilepsy and have an increased risk for autism166,167. Na
V
1.1 is enriched in the axon initial 
segment of inhibitory neurons168, primarily of PV interneurons94, where axon potential 
are initiated169. Interneurons from Scn1a heterozygous and KO mice show reduced firing 
frequencies to current injections as well as a reduced action potential amplitude and an 
increased action potential width, indicating a reduced inhibitory control over downstream 
targets170. Removal of Scn1a specifically from forebrain interneurons171, or PV interneurons 
specifically172 recapitulates phenotypes found in patients. In addition, increasing GABA 
signalling by application of the positive allosteric GABA
 A
 receptor modulator clonazepam 
was sufficient to rescue the abnormal social behaviour in Scn1a+/- mice173. These data show 
that loss of SCN1A primarily affects interneurons, and that the consequently reduced 
inhibitory drive plays an important role in Dravet syndrome.
Recently, a new hypothesis has been proposed in the field of schizophrenia, focussing 
on the myelination of PV interneurons as a point of pathological convergence174. As 
discussed above, PV cells play a central role in schizophrenia. Myelination abnormalities 
have been identified in schizophrenia including white matter abnormalities175, reduced 
numbers of oligodendrocytes176 and post-mortem gene expression analysis177. Myelination 
of PV interneurons has been observed in rat178, mouse179 and post-mortem in human180. 
Myelination is important for fast action potential propagation181, and deficits in the 
myelination of PV interneurons are proposed to disrupt inhibitory network function174. 
However, this appealing hypothesis remains to be experimentally tested.
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1.5 Changes to synapses formed by PV+ interneurons
Changes to PV synapses are abundantly studied and identified in various conditions. Post-
mortem studies of schizophrenia patients consistently identify changes to the cartridges 
formed by chandelier cells, showing a decrease in presynaptic GAT1 expression119,120, and 
an increase in the expression of postsynaptic GABAAα2121. These changes would lead to 
an increased inhibitory drive from chandelier cells, and are believed to be compensatory 
for a reduced activity of these cells, as indicated by reduced levels of GAD67 in PV cells182. 
In addition, a recent study shows a reduction in the density of a specific type a cartridges, 
calbindin positive cartridges, in schizophrenia117.
Besides changes in the input to PV interneurons, mutations in Erbb4 also lead to a reduction 
in synapses formed by PV interneuron on pyramidal neurons, specifically from chandelier 
cells137,139. In addition, overexpression of Nrg1, the ligand for ErbB4, in pyramidal neurons 
increases bouton density both on the AIS and the soma of the pyramidal neuron. The 
increase in bouton density on the AIS originates from chandelier cells, since only these cells 
target the AIS. The origin of the increase in perisomatic bouton density however is not clear, 
since a recent report has shown that synapses formed by cholecystokinin positive (CCK+) 
basket cells require ErbB4 function to form perisomatic synapses183. Future research should 
unveil if the increase in perisomatic boutons density arises from PV- or CCK basket cells.
Tuberous sclerosis is a disorder which symptoms include epilepsy and autism184. Loss-of-
function mutations in the mTOR negative regulators TSC1 or TSC2 underlie this condition185. 
Slice recordings from TSC1 KO neurons revealed a reduced inhibitory drive onto CA1 
pyramidal neurons, while excitatory input was unaltered186. TSC1 KO neurons were created 
by sparsely targeting neurons in a conditional TSC1 KO mouse with a cre-expressing adeno-
associated virus186. The finding that sparse KO of Tsc1 leads to a similar phenotype as in 
neurons from full KO animals indicates that these results are cell-autonomous rather than 
compensatory186.
Angelman syndrome, caused by loss-of-function mutations or deletion of E3 ubiquitin 
ligase UBE3A187, is characterized by epilepsy and autism188,189. Mouse models for Angelman 
syndrome recapitulate human phenotypes190 and were initially found to show a reduced 
excitatory drive onto pyramidal neurons191. However, inhibitory input was also found to 
be decreased, caused by defects in synaptic vesicle cycling192. It was hypothesized that 
the reduced inhibition could outweigh the reduced excitation, leading to the epilepsy and 
autism phenotypes obeserved192,193. Consistent with this idea, a recent study using in vivo 
whole cell recordings shows that pyramidal neurons in Ube3a KO mice display  decreased 
orientation selectivity194, indicative of reduced inhibition195,196. However, these mice also 
show increased excitability of pyramidal neurons which is non-cell-autonomous, suggesting 
that pyramidal neurons homeostatically increase their excitability because of a relative 
decrease of excitation194. While it is unclear if reduced inhibition or reduced excitation have 
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a stronger impact on pyramidal neurons in Angelman syndrome, the change in their relative 
contribution, resulting in an altered E/I balance, seems to play a pivotal role in this condition.
Single SHANK3	mutations, at the level of point mutations or microdeletions, have been 
identified in patients with ASD197. In the human genome there are three SHANK genes 
(SHANK1-3), which all code for scaffold proteins located at the postsynaptic density of 
excitatory synapses and of which SHANK3 is best studied198–200. Because of this localisation, 
most studies have therefore focussed on excitatory synapses, where Shank3 deficient 
mice show reduced cortico-striatal connectivity201, impaired long-term potentiation202 and 
reduced GluA1 expression203. Recent studies however indicate that the inhibitory system 
is also affected. Shank3 mutant mice lacking exon 9 show reduced inhibitory input onto 
layer 2/3 pyramidal neurons, but an increase of these events in CA1 pyramidal neurons204. 
In addition, PV levels are reduced in Shank1 KO and Shank3b KO mice, indicating reduced 
activity25. 
Presynaptic neurexins and their postsynaptic partners neuroligins are a large class of cell-
adhesion molecules that has been shown to play important roles in synaptic specificity205. 
Overexpression or knockdown of neuroligins leads to an increase or decrease in synapse 
number, respectively206. Neuroligins are expressed at specific synapses: Neuroligin 1 (NLGN1) 
is mainly expressed at excitatory synapses207, NLGN2 is expressed at inhibitory synapses208, 
NLGN3 is expressed both at inhibitory and excitatory synapses209, and NLGN4 is expressed at 
glycinergic synapses210. Mutations and deletions affecting human NLGN3,	including a gain of 
function mutation were found in a Swedish family, and NLGN4 de	novo mutations has been 
associated with autism211. Nlgn3 deletion in mice leads to increased inhibitory transmission 
onto pyramidal neurons212, specifically from (CCK) positive interneurons due to an increased 
tonic endocannabinoid signalling, whereas PV interneuron connectivity is unaffected213. A 
recent study has shown however that conditional deletion of Ngln3 from PV interneurons 
alters AMPA/NMDA ratio of excitatory input onto these cells, and causes reduced gamma 
oscillations214. In addition to the loss of NLGN3, a gain of function amino acid substitution 
(R451C) in NLGN3 is also associated with autism211. Mice carrying this mutation show a 
strong reduction in inhibitory drive from PV interneurons, while increasing the inhibitory 
drive from CCK cells213.
Nlgn4 KO mice show reduced number of perisomatic inhibitory synapses in hippocampus, 
and a concomitant reduction in inhibitory input215. In addition, a reduced power of evoked 
gamma oscillations in acute slices was observed215. Different mutations in NLGN2 have been 
linked to autism216 and schizophrenia217. Deletion of Nlgn2 has been shown to specifically 
reduce the amount of perisomatic synapses on pyramidal neurons in hippocampus218, and 
reduce inhibitory transmission from PV interneurons, but not SOM interneurons219.
Neurexins are less well studied in the context of neurodevelopmental disorders. There 
are three neurexin genes, each coding for an α- and β-neurexin. Mutations in neurexin 
(NRXN1) have been associated with autism220 and schizophrenia, affecting both NRXN1α 
and NRXN1β221,222. Nrxn1α KO mice do not show changes in inhibitory drive, but a reduced 
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excitatory drive onto CA1 pyramidal neurons223. However, mice carrying mutations in Nrxn1β 
show a reduced frequency of both inhibitory and excitatory input onto cortical pyramidal 
neurons224 suggestive of a reduced number of synaptic contacts.
These studies show that neuroligins and neurexins mutations that are linked to autism affect 
the inhibitory system, including perisomatic-targeting interneurons.
Studies of ADHD rodent models have mainly focussed on the dopamine system and excitatory 
synapses225. However, recent studies identify changes to inhibitory connectivity. G protein-
coupled receptor kinase interacting protein 1 (GIT1) has been identified by GWAS as a risk 
gene for ADHD226, while recent studies challenge this claim227,228. Git1 KO mice show ADHD-
like phenotypes including hyperactivity226. While excitatory input to CA1 pyramidal neurons 
remains unaltered, the frequency of inhibitory inputs is reduced, suggesting a reduction 
of inhibitory synaptic contacts226, consistent with previous studies showing a role for GIT1 
in inhibitory synapses229. In addition, PV expression was reduced, while other interneuron 
markers remained unaltered226. 
Another key gene linked to ADHD is Cadherin 13 (Cdh13), which is implicated in ADHD 
in several genome wide association studies230. Cadherin 13 is an atypical member of the 
cadherin superfamily, which has previously been shown to play an important role in synapse 
specificity and have been implicated in neurodevelopmental disorders (reviewed by Redies 
et al.231). 
In 1963, Sperry proposed that the formation of neuronal connectivity was not a random 
process, but instead was chemotactically guided, even though he did not yet speculate on 
candidate mechanisms232. Since then, various families of protein have been identified to play 
an important role in synapse specificity233, including the cadherin superfamily234,235. Cadherins 
are expressed in an orderly pattern, seemingly respecting borders of brain regions236, 
cortical layers237 and hippocampal sub-fields238. This specific expression of cadherin makes 
them ideally suited to play a role in cell-cell recognition and, consequently, the formation 
of cell type specific connectivity. Indeed, neuronal hippocampal culture experiments show 
that dissociated cells preferentially form synapses with those cells they would connect to in 
vivo, showing the existence of a molecular code239. Furthermore, loss of cadherin 9 (CDH9) 
disrupts synapse formation between dentate gyrus granule cells and CA3 pyramidal neuron 
in	vitro239. In addition, reduced expression of CDH9 disrupts the formation of mossy fiber 
synapses, the synapses between dentate gyrus granule cells and CA3 pyramidal neurons, 
in	 vivo239. Together, these data show that cadherins play an important role in network 
formation.
Like other cadherins, CDH13 shows a specific pattern of expression230. Among other regions, 
in situ hybridization studies localize Cdh13 mRNA expression to the thalamic reticular 
nucleus and hippocampal Stratum	oriens, two regions know to be populated by inhibitory 
neurons240,241. The strong link of CDH13 to ADHD together with the potential localization of 
CDH13 to inhibitory neurons and the known role of cadherins in synapse specificity makes 
CDH13 an interesting gene to study in the context of neurodevelopmental disorders.
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In addition to changes in the number and strength of inhibitory synapses, changes are 
also found in the modulation of inhibitory synaptic transmission. Metabotropic GABA 
receptors, GABA
B
 receptors, are expressed both pre- and postsynaptically in GABAergic 
synapses242. Postsynaptic GABA
B
 receptors activate potassium channels that hyperpolarize 
the postsynaptic cell243. Presynaptic GABA
B
 receptors in addition can reduce calcium inflow 
and reduce neurotransmitter release244,245. A reduction of GABA
B
 subunit expression has 
been observed in post-mortem studies of schizophrenia patients246,247, bipolar disorder 
patients248 and patients suffering from major depression249 as well as animal models for 
schizophrenia250,251. However, more research is required to identify the exact role for GABA
B
 
receptors in neurodevelopmental disorders.
In summary, changes to the inhibitory drive of PV interneurons can affect the input, output or 
intrinsic properties of PV interneurons, and animal models of various neurodevelopmental 
disorders all show alterations to one or more of these aspects, tilting the E/I balance.
1.6 Scope and outline thesis
Neurodevelopmental disorders are a diverse group of disorders, but changes to the 
inhibitory system seem to be a point of convergence. Altered inhibitory activity or drive 
leads to changes in signal processing, which in turn is believed to underlie the phenotypic 
changes observed in the various neurodevelopmental disorders. However, more evidence is 
required to substantiate this idea.
In this thesis I aim to investigate the synaptic connectivity in three rodent models of distinct 
neurodevelopmental disorders. Using single-cell electrophysiological recordings, I will 
assess excitatory and inhibitory connectivity onto (excitatory) pyramidal neurons, as well as 
the short-term plasticity of these connections. Using this approach, I will be able to assess 
if inhibitory connectivity is altered in our models. Also, these experiments will give insight 
into the possible alterations of the E/I balance. Based on the previous studies discussed 
in this introduction, I expect to find a disruption in inhibitory function onto pyramidal 
neurons. However, the nature and direction of these changes are not predictable and will 
be investigated in the chapters listed below.
In chapter 2 and 3, I have investigated alterations in synaptic connectivity in the hippocampus 
of Cdh13-/- mice. As discussed above, Cdh13 has primarily been linked to ADHD and 
comorbid disorders, and has also been identified to play a role in ASD252, schizophrenia253, 
bipolar disorder254 and depression255. While CDH13 had previously been shown to play a 
role in synaptic connectivity in neuronal cultures256, network alterations have not yet been 
studied in an animal model. I localized the expression of CDH13 to interneurons, and found 
that Cdh13-/- mice show an increase in inhibitory synaptic connectivity onto CA1 pyramidal 
neurons. I showed that this increase is originating, at least in part, from PV+ interneurons. 
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In addition, I showed that CDH13 interacts with integrin beta 1 and integrin beta 3, and that 
this interaction plays a role in the regulation of inhibitory synaptic connectivity onto CA1 
pyramidal neurons. Together, these findings suggest a role for CDH13 in the regulation of 
inhibitory synaptic connectivity of PV+ interneurons and CA1 pyramidal cells.
In chapter 4, I explored alterations in excitatory and inhibitory synaptic development in 
the hippocampus of Ehmt1+/- mice. Ehmt1+/- mice are a model for Kleefstra syndrome, 
patients of which suffer from intellectual disability and ASD257–260. I found a disruption in 
the development of inhibitory synaptic connectivity onto CA1 pyramidal neurons, while 
the development of excitatory synaptic development was unaffected. Also, I identified 
an increase in the intrinsic excitability of CA1 pyramidal neurons, which was caused by a 
hyperpolarization of the action potential threshold. These changes contribute to a shift 
in the E/I balance towards excitation, and suggest a hyperactive hippocampal network in 
Ehmt1+/- mice.
In chapter 5, I investigated the APO-SUS/APO-UNSUS rat model. APO-SUS rats are a model 
for schizophrenia261–263. I showed that both excitatory and inhibitory synaptic connectivity 
are unaltered onto layer 2/3 pyramidal neurons in the prefrontal cortex of APO-SUS rats. 
However, I did find a reduction in the paired-pulse ratio a longer (≥ 150 ms) inter stimulus 
intervals, which I identified to be caused by an increase in GABA
B
 signalling. Also, I showed 
that APO-SUS rats have an increased expression of the GABA
B1
 subunit. These findings 
suggest a reduction of inhibitory drive onto layer 2/3 pyramidal cells in APO-SUS rats.
In chapter 6, I have discussed the findings described in this thesis, and attempted to put 
these findings in the context of network function. Finally, I have discussed my view on the 
possibility to restore the E/I balance as a course of treatment in patients suffering from 
neurodevelopmental disorders.
In this thesis I have investigated synaptic changes in three models of different 
neurodevelopmental disorders. I consistently identify changes in inhibitory function in these 
models. Interestingly, the three models show distinct changes in inhibitory function. The 
findings presented in this thesis underline the importance of the inhibitory system in proper 
brain function, and suggest that the imbalance between excitation and inhibition is a major 
player in the development of neurodevelopmental disorders.
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2.1 Abstract
 
Cadherin-13 (CDH13), a unique GPI-anchored member of the cadherin family of cell adhesion 
molecules, has been identified as a risk gene for attention deficit/hyperactivity disorder 
(ADHD) and various comorbid neurodevelopmental and psychiatric conditions, including 
depression, substance abuse, autism spectrum disorder and violent behavior, while the 
mechanism whereby CDH13 dysfunction influences pathogenesis of neurodevelopmental 
disorders remains elusive. Here we explored the potential role of CDH13 in the inhibitory 
modulation of brain activity by investigating synaptic function of GABAergic interneurons. 
Cellular and subcellular distribution of CDH13 was analyzed in the murine hippocampus and 
a mouse model with a targeted inactivation of Cdh13 was generated to evaluate how CDH13 
modulates synaptic activity of hippocampal interneurons and behavioral domains related to 
psychopathologic (endo)phenotypes. We show that CDH13 expression in the cornu	ammonis	
(CA) region of the hippocampus is confined to distinct classes of interneurons. Specifically, 
CDH13 is expressed by numerous parvalbumin and somatostatin-expressing interneurons 
located in the Stratum	 oriens, where it localizes to both the soma and the presynaptic 
compartment. Cdh13-/- mice show an increase in basal inhibitory, but not excitatory, synaptic 
transmission in CA1 pyramidal neurons. Associated with these alterations in hippocampal 
function, Cdh13-/- mice display deficits in learning and memory. Taken together, our results 
indicate that CDH13 is a negative regulator of inhibitory synapses in the hippocampus, and 
provide insights into how CDH13 dysfunction may contribute to the excitatory/inhibitory 
imbalance observed in neurodevelopmental disorders, such as ADHD and autism.
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2.2 Introduction
Brain development and plasticity are complex processes that require precise and specific 
interneuronal contacts to ensure the correct establishment of circuits at the cellular and 
systems level. To guarantee cellular and regional specification of synaptic contacts, the 
formation of neuronal networks is tightly controlled by a myriad of cell guidance and 
adhesion molecules, amongst which the cadherin superfamily of calcium-dependent cell 
adhesion molecules is of particular relevance1. Furthermore, after development, cadherins 
regulate the function and plasticity of mature synapses by participating in synaptic vesicle 
dynamics or controlling the stability of synaptic receptors1.
Cadherin-13 (CDH13, also known as T-cadherin or H-cadherin) is an atypical member of the 
cadherin superfamily. It lacks both transmembrane and cytoplasmic domains and is linked 
to the plasma membrane via a glycosylphosphatidylinositol (GPI) moiety2–4. Genome-wide 
genetic approaches including linkage analyses, genome-wide association studies (GWAS) 
and copy number variations (CNVs) studies have detected associations between the CDH13 
gene and various neurodevelopmental disorders. Notably, in several independent studies, 
CDH13 has been associated with the risk for attention-deficit/hyperactivity disorder (ADHD) 
and frequent comorbid conditions including drug and alcohol abuse4–17. Additionally, 
CDH13 was implicated in depression11,18, autism spectrum disorders19, schizophrenia20 and 
bipolar disorder21. Variations in CDH13 have also been associated with the personality 
trait of extraversion22 and extremely violent behavior23. The mechanism whereby CDH13 
dysfunction contributes to the pathogenesis of neurodevelopmental conditions remains, 
however, unknown.
CDH13 is expressed in the developing and adult brain, as well as in the cardiovascular system, 
where it exerts its function via low-adhesive homophilic or heterophilic interactions to 
control cell migration, neurite outgrowth and axon guidance24–28. We therefore predicted that 
CDH13, as several other cell recognition molecules, may play dual roles in the brain; namely, 
as a guidance cue for migrating neurons and/or developing axons, and as a modulator of the 
establishment of specific synaptic contacts and function of mature synapses4. The view that 
CDH13 may moderate synapse formation and plasticity is supported by a previous study29, 
showing that Cdh13 knockdown via RNA interference in hippocampal cultures resulted in a 
decrease in the density of both excitatory and inhibitory synapses. 
Here, we focused on the hippocampus to test in vivo the hypothesis that involvement of 
CDH13 in the susceptibility to neurodevelopmental/psychiatric disorders is associated with 
its potential role in the modulation of synaptic function. We investigated CDH13 expression 
and function in specific subtypes of hippocampal neurons in	vitro and in	vivo. Furthermore, 
we describe the electrophysiological and behavioral consequences of CDH13 deficiency in a 
mouse model of constitutive Cdh13 inactivation. Finally, by linking alterations in hippocampal 
GABAergic synaptic transmission with cognitive deficits, we provide evidence that supports 
a critical role for CDH13 in the synaptic activity of the hippocampal GABAergic circuitry.
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2.3 Material and Methods
Generation of a constitutive Cdh13 knockout mouse line 
A constitutive Cdh13 knockout mouse (Cdh13-/-) was generated through site-specific DNA 
recombination by crossing Cdh13loxP/loxP mice (C57Bl/6N background) with a constitutive 
Cre deleter line30 (Supplementary Fig. S1 and Supplementary Table S1). Absence of CDH13 
protein in Cdh13-/- mice was verified by Western blot and immunohistochemistry. Animal 
protocols have been approved by the boards of the University of Würzburg and the Government 
of Lower Franconia, and performed according to the European Community guidelines for 
animal care and use. Adult mice (10-16 weeks) were used if not indicated otherwise. 
Histological methods
In	situ	hybridization	(ISH). Single chromogenic ISH (CISH) to detect Cdh13 mRNA was carried 
out on 16 µm coronal brain sections. Double fluorescent ISH (FISH) were performed to 
detect Cdh13 (digoxigenin-labeled) and glutamic acid decarboxylase 1 (Gad1, fluorescein-
labeled) mRNAs.
Immunofluorescence	 and	 colocalization	 assessment. Mice (n=3) were transcardially 
perfused, 40 μm free-floating serial coronal sections generated and costained for CDH13 plus 
one of the following interneuron markers: somatostatin (SOM), parvalbumin (PV), calbindin 
(CB), neuropeptide Y (NPY), vasoactive intestinal peptide (VIP), neural nitric oxide synthase 
(nNOS) and calretinin (CR). Some sections were triple-stained for CDH13, PV and SOM. 
Double immunofluorescence stainings were examined under an inverted epifluorescence 
microscope (Olympus, Hamburg, Germany). The numbers of single- and double-stained 
cells in single and merged images were counted using the ImageJ “Cell Counter” plugin. 
Immunohistochemistry. For single CDH13 staining, 20 µm sections of perfusion-fixed brains 
on slides were incubated with primary antibody. N-Histofine Simple Stain Mouse MAX PO 
(G) (Nichirei Biosciences, Tokyo, Japan) and 3,3’-Diaminobenzidine (DAB) (Roche Diagnostics 
Deutschland GmbH, Mannheim, Germany) were used for detection.
For single staining of interneuronal markers, immersion-fixed brains (n=7-9 per genotype) 
were serially sectioned into 50 μm free-floating coronal sections. Sections were treated 
with heat-induced epitope retrieval, incubated with primary antibodies against SOM, PV 
and nNOS and detected using biotinylated secondary antibodies (Vector Laboratories, 
Burlingame, CA), AB complex (Vector) and DAB (Roche) development. Stained sections were 
then analyzed using Stereo Investigator v.11 (MBF Bioscience, Williston, VT, USA). PV-, SOM- 
and nNOS-positive cells in the SO were counted with the optical fractionator method.
Immunocytochemistry. Primary hippocampal neuron cultures were prepared from 
embryonic day 18 (E18) old rats as previously described31 and maintained in Neurobasal 
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media supplemented with B27, penicillin, streptomycin, and L-glutamine (GIBCO-Invitrogen, 
Darmstadt, Germany). Fixed (paraformaldehyde) and permeabilized (Triton X-100) 
cultures were costained for CDH13 together with one of the following synaptic markers: 
vesicular glutamate transporter (VGLUT), vesicular GABA transporter (VGAT), postsynaptic 
density protein 95 (PSD95), gephyrin and GABA-A receptor α1 subunit (GABA-Aα1). 
Double immunofluorescence stainings were examined under a Fluoview FV1000 confocal 
microscope (Olympus).
RNA isolation and semiquantitative RT-PCR (qPCR). 
Complementary deoxyribonucleic acid (cDNA) was synthesized from 1-2 µg total RNA from 
mouse brains of different ages. A 1:15 dilution of cDNA pool was used for qPCR analysis of 
Cdh13 expression. qPCR data were analyzed using comparative quantitation. Peptidyl prolyl 
isomerase (Ppia) and β-actin (Actb) served as reference genes for normalization of Cdh13 
Q-values. 
Electrophysiology
Electrophysiological experiments were conducted on horizontal slices (350-µm thick) 
from the ventral hippocampus of postnatal day (P) 20-22 mice of both genders. Miniature 
inhibitory postsynaptic currents (mIPSCs) were recorded in the presence of Tetrodotoxin 
(TTX, 1 µM), 6-Cyano-7-nitroquinoxaline-2,3-dione (CNQX, 5 µM) and D-(-)-2-Amino-5-
phosphonopentanoic acid (D-APV, 100 µM). Miniature excitatory postsynaptic currents 
(mEPSCs) were recorded in the presence of TTX and Picrotoxin (PTX, 100 µM). Paired pulse 
ratio (PPR) was recorded in the presence of CNQX, D-APV, 4 mM CaCl2 and 4 mM MgCl2. 
Traces were recorded using a Multiclamp 700B amplifier (Molecular Devices, Wokingham, 
United Kingdom). Miniature recordings were analyzed using Mini Analysis Program 
(Synaptosoft, Decatur, GA, USA). Other traces were analyzed using Clampfit 10.2. Intrinsic 
cell parameters we recorded in current clamp using Signal (CED, Cambridge, England) and 
traces were analyzed using Stimfit v0.13 following the parameter definitions used in Tricoire 
et al.32. 
Morphological reconstructions
Brain slices with biocytin-filled neurons were processed following a modified staining 
protocol based on Marx et al.33. Stained sections were imaged and somata, apical and basal 
dendrites of selected pyramidal neurons were reconstructed in Neurolucida v10 (MBF). 
Reconstructions were analyzed in NeuroExplorer (MBF) for intrinsic parameters and Sholl 
analysis. 
Behavioral assessment 
Four cohorts of adult male Cdh13+/+ (n=7-10), Cdh13+/- (n=8-10) and Cdh13-/- (n=7-10) 
mice were subjected to behavioral tests to assess anxiety-like behavior and conditioned 
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fear responses, depression-like behavior, social interaction, locomotor activity, attention, 
impulsivity and cognitive flexibility. Stress hormone levels were measured from fecal 
samples and central blood. 
Statistical analysis
Genotype effects were analyzed by univariate ANOVA and, in cases of significance (p<0.05), 
post-hoc comparisons using Bonferroni correction for multiple testing. In cases of non-
normality and/or unequal variances, non-parametric statistical analysis using the Kruskal-
Wallis test was performed instead of parametric ANOVA. For those behavioral tests with 
repeated measures, a mixed ANOVA was used, with genotype as between-subject factor 
and time or testing phase as repeated measure. Data analysis was performed using Prism 
6.04 (GraphPad Software, La Jolla, CA) or SPSS Statistics 21 (IBM, Armonk, NY). 
Detailed descriptions of all the methods are provided in the Supplementary Information.
2.4 Results
2.4.1 CDH13 is located in specific subtypes of hippocampal interneurons
We detected Cdh13 mRNA in subregions and distinct cells in the hippocampus (Fig. 1). In 
particular, the highest cellular expression was detected in the SO of the CA region, whereas 
weaker labeling was observed in scattered cells of the CA3 pyramidal layer, as well as the hilus 
and the granule cell layer of the dentate gyrus (DG). These ISH findings were complemented 
with an immunohistochemical analysis of CDH13 protein expression using an anti-CDH13 
antibody which we validated for specificity using Cdh13 null mutant mice (Fig. S1). Of 
note, intense cellular immunoreactivity was observed in cell bodies located in the SO, in a 
pattern which closely resembled Cdh13 mRNA expression. In addition, CDH13 protein was 
also distributed in the hippocampus in a characteristic laminar pattern (Fig. 1a), with the 
strongest staining in the stratum lucidum of CA3 and stratum	lacunosum-moleculare, in the 
molecular layer and hilus of the DG, as well as along the mossy fiber projections. 
The unique and distinct cellular pattern of CDH13 labeling in the hippocampal SO prompted 
us to ascertain the nature of these CDH13-positive cells. Their sparse distribution suggested 
a GABAergic nature, since it is known that the bodies of a considerable number of GABAergic 
inhibitory interneurons are located in this deep layer of the hippocampus34. As expected, a 
double-FISH approach using probes for Cdh13 and the interneuron marker Gad1 showed 
that most of the Cdh13-positive somata of the SO were indeed interneurons (Fig. 1b).
Hippocampal interneurons are a heterogeneous group of cells that differ in their 
morphological and electrophysiological properties32. To better identify the nature of 
the CDH13-immunoreactive interneurons detected in the SO, we performed double-
immunofluorescence experiments to label CDH13 with each of seven neurochemical 
markers (PV, CB, CR, SOM, NPY, VIP and nNOS) characteristically expressed in different 
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Fig. 1. CDH13 expression in murine hippocampus. 
(a) CDH13 protein and mRNA expression in the hippocampus of the adult mouse, CDH13 protein and mRNA are 
present in cell somata of the Stratum	oriens (SO) (a,a’). (ISH picture was shown as preliminary data in a review 
article by Rivero et al., 20134; reproduced with permission from Elsevier). (b) double FISH: Cdh13 is localized 
in Gad1	mRNA-positive cells of the SO (white arrows: colocalization; green arrows: only Gad1+). (c) IF images: 
colocalization study of CDH13 and Parvalbumin (PV)/Somatostatin (SOM)/neural nitric oxide synthase (nNOS) 
(white arrows: colocalization, green arrowhead: single stained cell for PV/SOM/nNOS, red arrowhead: single 
stained cell for CDH13). (d) Colocalization of CDH13 with neurochemical markers of GABAergic interneurons in 
the SO of the dorsal (upper panel) and ventral (lower panel) hippocampus. A higher degree of colocalization is 
observed in the dorsal part of the hippocampus. n=3; 100% = CDH13+ cells; percentages calculated from median. 
(e) Triple IF: CDH13 is colocalized with PV and SOM in some but not in all cells of the SO (white arrow: triple 
localization, empty arrowhead: double localization). Scale bars: 300 µm in a, 50 µm in a/a’, b, c, e.
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subpopulations of hippocampal interneurons (Fig. 1c-d). Initial qualitative assessment 
revealed that the extent of co-expression with CDH13 substantially varied depending on the 
analyzed interneuron marker (Fig. 1c). Next, a stereological approach to precisely quantify 
the degree of co-expression (Fig. 1d and S2a) was used. The highest levels of co-expression 
were found with SOM (63% of CDH13-immunoreactive cells were also positive for SOM in 
the dorsal hippocampus, 49% in the ventral hippocampus) and PV (with 50% of CDH13-
immunoreactive cells being positive for PV in the dorsal hippocampus, 35% in the ventral 
part). In contrast, very low levels of co-expression were found with nNOS (2-6%) and CR (4%). 
Additionally, the percentages of interneurons of each subpopulation that were positive for 
CDH13 were calculated (Fig. S2a). In this case, CDH13 was most frequently found in PV- (66% 
dorsal, 31% ventral), SOM- (55% dorsal, 39% ventral) and NPY- (47% dorsal, 35% ventral) 
immunoreactive cells of the SO. 
The above data indicate that, in the SO, CDH13 is most frequently found in PV- and 
SOM-positive cells. PV and SOM are thought to be representative of two interneuronal 
subpopulations that are distinct or have very little overlap. There is no co-expression of 
PV and SOM in the cerebral cortex35, whereas there is a small degree of overlap in the 
hippocampus32. Notably, we show via triple PV-SOM-CDH13 staining that some, but not all, 
of the CDH13-immunoreactive cells of the SO were positive for both SOM and PV (Fig. 1e). 
2.4.2 CDH13 is located at inhibitory synapses
To gain further insight into the function of CDH13 in the brain, we assessed its temporal 
expression pattern (Fig. 2a). Cdh13 mRNA was detected from E13.5 onwards and increased 
to reach a peak at P7 to P21, a time period that coincides with synapse formation29,36. 
Whereas previous studies showed that ectopically-expressed CDH13 localized to synapses 
in hippocampal primary cultures29, we explored endogenous labeling at the synapse in more 
detail. Hippocampal neurons at 3 days in vitro (DIV3) were transfected with a myc-tagged 
Cdh1329. Costaining for CDH13 and MYC at DIV14 showed an exactly overlapping punctated 
pattern and confirmed antibody specificity for subsequent coimmunofluorescence analysis 
(Fig. S3). To determine the specific synaptic localization of endogenous CDH13, we costained 
hippocampal neurons at DIV14 for CDH13 and the presynaptic markers VGLUT or VGAT 
(excitatory and inhibitory, respectively) or the postsynaptic markers PSD95 or gephyrin 
(excitatory and inhibitory, respectively) (Fig. 2b). CDH13 colocalized exactly with the 
presynaptic marker VGAT, but not VGLUT. At the postsynaptic side, CDH13 showed juxtaposed 
labeling with gephyrin, but not with PSD95. Since CDH13 is coexpressed in a high proportion 
of PV+ cells (Fig. S2a), we investigated whether CDH13 colocalized with the GABA-A subunit 
primarily found in synapses formed by PV+ cells, GABA-Aα1 (Fig. 2c). Indeed, CDH13 puncta 
were found juxtaposed to GABA-Aα1 puncta, consistent with a presynaptic (CDH13) and 
postsynaptic (GABA-Aα1) localization. Conversely, not all GABA-Aα1-positive puncta were 
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Fig. 2. Temporal expression pattern and subcellular localization of CDH13. 
(a) Developmental timeline of Cdh13 mRNA expression (Mean±SEM; n=3 for each time point). (b) 
Immunofluorescence staining of cultured hippocampal neurons for CDH13 (green) and the synaptic markers VGLUT, 
VGAT, PSD95 or Gephyrin (red). CDH13-positive puncta are indicated by the triangles, colored yellow for colocalized 
foci (VGAT) and green for juxtaposed foci (Gephyrin). CDH13 localizes at the presynaptic side of inhibitory synapses. 
Scale bar: 1 µm (c) Immunofluorescence staining of cultured hippocampal neurons for CDH13 (green) and GABA-A 
receptor α1 subunit (GABA-Aα1, red). CDH13-positive puncta are indicated by the triangles, colored green for 
juxtaposition with GABA-Aα1-positive puncta. Arrows indicate puncta that are CDH13-negative and GABA-Aα1-
positive. Scale bar: 1 µm.
positive for CDH13, indicating that these puncta originate from another subpopulation of 
interneurons that is CDH13-negative. Together with our finding that CDH13 is expressed in 
inhibitory neurons in the SO, these data provide evidence that, in hippocampal neurons, 
CDH13 localizes at the presynaptic compartment of inhibitory synapses.
2.4.3 Cdh13 knockout mice display increased inhibitory synaptic transmission
To investigate the functional consequences of CDH13 deficiency for the hippocampal 
inhibitory network, we generated a constitutive Cdh13 knockout mouse line (Fig. S1). In 
agreement with a previously reported mouse model of constitutive CDH13 deficiency37, 
Cdh13 null mutant (Cdh13-/-) mice exhibited normal life expectancy and breeding capacity; 
they did not present any gross morphological abnormalities of the brain (Fig. S4). Weight 
gain, daily food and water intake, as well as stress hormone levels were not affected by 
genotype (Fig. S5).
As CDH13 is localized at the presynaptic compartment of inhibitory synapses, we 
assessed basal inhibitory synaptic transmission by recording mIPSCs from CA1 pyramidal 
cells in acute slices from P20-22 Cdh13+/+, Cdh13+/- and Cdh13-/- mice (Fig. 3a-c). 
We found an increased mIPSC frequency in the Cdh13-/- mice compared to Cdh13+/+ 
(Cdh13+/+: 3.29 ± 0.47 Hz, Cdh13-/-: 4.93 ± 0.29 Hz, p<0.001) and Cdh13+/- (3.73 ± 0.29 Hz, 
p<0.05), but no change in mIPSC amplitude (Cdh13+/+: 18.25 ± 0.42 pA, Cdh13-/-: 19.31 ± 0.36
pA, p=0.07). Consistent with exclusive localization of CDH13 at inhibitory synapses, mEPSCs
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Fig. 3. Hippocampal CA1 neurons from Cdh13 null mutant mice show increased inhibitory synaptic input and 
morphological changes. 
(a) Representative traces of miniature inhibitory post-synaptic currents (mIPSCs) recorded from CA1 pyramidal cells 
from acute brain slices from Cdh13+/+, Cdh13+/- and Cdh13-/- mice (b-c) Cumulative distributions of mIPSC amplitudes 
(b) and inter-event intervals (IEI) (c) from Cdh13+/+ (n=19/3), Cdh13+/- (n=18/3) and Cdh13-/- (n=23/4) hippocampal 
CA1 neurons. (d) Representative traces of miniature excitatory post-synaptic currents (mEPSCs) recorded from 
CA1 pyramidal cells from acute brain slices of Cdh13+/+, Cdh13+/- and Cdh13-/- mice (e-f) Cumulative distributions of 
mIPSC amplitudes (e) and IEI (f) from Cdh13+/+ (n=12/3), Cdh13+/- (n=13/3) and Cdh13-/- (n=14/3) hippocampal CA1 
neurons. (g) Representative overlaid traces of two IPSCs evoked by stimuli delivered at an inter-stimulus intervals 
(ISI) of 50 ms. (h) Quantification of paired pulse ratio following stimulation in SO for Cdh13+/+ (n=15/4), Cdh13+/- 
(n=15/3) and Cdh13-/- (n=15/3). (i) Representative reconstructions of hippocampal CA1 neurons from Cdh13+/+ and 
Cdh13-/- mice. (j-k) quantification of (j) basal dendritic and (k) apical dendritic nodes and endings for Cdh13+/+ (n=6) 
and Cdh13-/- (n=7). Bar graphs are presented as mean±SEM. *p<0.05; **p<0.01; ***p<0.001. n is shown as number 
of cells/number of animals.
were unchanged in both amplitude (Cdh13+/+: 16.43 ± 0.67 pA, Cdh13+/-: 15.85 ± 0.24 pA, 
Cdh13-/-: 16.00 ± 0.32 pA, p>0.05) and frequency (Cdh13+/+: 0.34 ± 0.03 Hz, Cdh13+/-: 0.40 
± 0.03 Hz, Cdh13-/-: 0.40 ± 0.04 Hz, p>0.05) (Fig. 3d-f). As our approach was constitutive 
rather than interneuron-specific Cdh13 inactivation, we aimed to exclude the possibility 
that knocking out Cdh13 in CA1 pyramidal cells has any effects on synaptic transmission. 
To do this, we prepared organotypic hippocampal slices from wild-type rats and injected 
a lentivirus carrying a shRNA against Cdh13 previously validated by Paradis et al.29 into 
the pyramidal cell layer of CA1 and then recorded simultaneously from an infected and 
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a non-infected pyramidal neuron and compared the response to different stimulation 
locations (Supplementary Fig. S6a, e and i). We found no difference in inhibitory input 
from SO (Supplementary Fig. S6b to d) or stratum	radiatum (Supplementary Fig. S6f and 
g). Also, excitatory input from stimulation of the Schaffer collaterals was unaltered for both 
AMPA (Supplementary Fig. S6j and k) and NMDA (Supplementary Fig. S6l and m) receptor-
mediated input. We therefore conclude that it is unlikely that the constitutive nature of 
our knockout model affects excitatory pyramidal cells directly, and the observed increase in 
mIPSC frequency is more likely caused by the inactivation of Cdh13 in presynaptic inhibitory 
neurons.
Generally, changes in frequency are explained as either a change in presynaptic release 
probability, or as a change in synapse number. To enable distinction between both 
possibilities, we recorded the paired pulse ratio (PPR), a measure of the release probability, 
of inhibitory synapses following stimulation in SO at different inter-stimulus intervals. We 
found an increased PPR in Cdh13-/- compared to Cdh13+/+ mice at the 50 ms inter-stimulus 
interval (ISI) only (ISI 50ms: Cdh13+/+: 0.77 ± 0.03, Cdh13-/-: 0.93 ± 0.05, p<0.05, Fig. 3g-h). An 
increased PPR is associated with a decreased release probability. Therefore, the underlying 
cause for increased mIPSC frequency in Cdh13-/- mice is unlikely to be a change in release 
probability, but rather a change in the number of inhibitory synapses formed onto CA1 
pyramidal cells. 
To investigate whether the changes in inhibitory synapses could be due to altered 
development of interneuron subtypes we analyzed the density of PV-, SOM- and nNOS-
positive interneurons of the SO in adult Cdh13-/-, Cdh13+/- and Cdh13+/+ mice. We found no 
effect of CDH13 deficiency on the densities of nNOS-positive (which rarely colocalize with 
CDH13), PV- or SOM-positive interneurons (p>0.05, Fig. S2b). These results exclude that the 
enhanced inhibitory synaptic input on CA1 neurons in Cdh13-/- mice is due to an increased 
amount of interneurons in the SO. Furthermore, no differences in the hippocampal levels 
of transmitters (glutamate, GABA, dopamine, serotonin, and norepinephrine) or their 
metabolites were found between genotypes (Fig. S7). 
Next, we assessed the general dendritic morphology of CA1 pyramidal cells. To this end, 
CA1 pyramidal cells were loaded with biocytin for morphological reconstruction of apical 
and basal dendrites (Fig. 3i). The basal dendrites were not different between Cdh13+/+ 
and Cdh13-/- animals (Fig. 3j). The apical dendrites, on the other hand, were found to be 
significantly more complex in Cdh13-/- animals at the level of dendritic nodes and length 
(nodes: Cdh13+/+: 31.5 ± 1.6, Cdh13-/-: 40.6 ± 1.4, p<0.01; endings Cdh13+/+: 32.3 ± 1.5, 
Cdh13-/-: 41.9±1.7, p<0.01; length Cdh13+/+: 3041.5 ± 436.1 µm, Cdh13-/-: 4521.4 ± 478.9 µm, 
p<0.05; Fig. 3K, Table S2). However, analysis of the space occupied by the dendrites (Convex 
Hull analysis, Table S2) showed no difference between genotypes, indicating that the 
apical dendrite stays within the same envelope, but is more branched in Cdh13-/- animals. 
Intrinsic electrophysiological properties, such as membrane potential, input resistance, and 
action potential properties, were identical between Cdh13+/+	and Cdh13-/- animals (Table 
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S3). Together, these data indicate that CDH13 is a negative regulator of inhibitory synapse 
function. Thus, loss of function of Cdh13 could lead to a distorted excitation/inhibition 
balance within the hippocampus.
2.4.4 Behavioral alterations of Cdh13 knockout mice correlate with hippocampal 
dysfunction and ADHD phenotypes
We assessed the effects of CDH13 deficiency on different behavioral domains. The analysis 
revealed no significant genotype effect on any variable measured to assess anxiety- and 
depression-like behavior as well as social interaction (Fig. S8-S10). We also tested locomotor 
activity in an open field for 30 minutes. In a cohort of mice with prior test experience, we 
detected a significant genotype effect for distance traveled (p=0.023, Fig. 4a) and number 
of rears (p=0.039, Fig. 4b), indicating that Cdh13-/- mice displayed higher locomotor activity 
than Cdh13+/+ mice. These findings were replicated in a cohort of naïve mice (distance: 
p=0.069; rears: p=0.047). Center time, a measure of anxiety-like behavior, was not affected 
by genotype in either test-experienced or naïve cohorts (Fig. 4c).
In the 5-choice serial reaction time task (5-CSRTT), which evaluates attention and impulsivity, 
acquisition and performance of the task was similar in all genotypes, as indicated by gradually 
increasing accuracy, number of omission errors and pellets eaten, indicating unaltered 
attention in Cdh13-/- mice,  as well as decreasing number of premature and timeout responses 
and faster response latencies, findings that support no genotype-dependent differences in 
impulsivity (Fig. 5 and S11) (session effects: all p<0.001). No significant genotype effects on 
any variable measured in the 5-CSRTT were detected. However, there was a session xgenotype 
interaction for the number of timeout responses (Fig. 5d, p=0.005), showing that during the 
first training session with longer stimulus duration (SD) of 20 s, Cdh13-/- mice made significantly 
more nose-pokes after an incorrect response, but only when compared to Cdh13+/- mice.
Fig. 4. Cdh13-/- mice display novelty-induced hyperlocomotion but unaltered anxiety-like behavior in the open 
field. 
(a) Total distance traveled and (b) number of rears as measures of locomotor activity. (c) Time spent in the center 
of the open field as measure of anxiety-like behavior. Experienced: n=7-8/genotype, naïve: n=10/genotype. Data 
are presented as mean±SEM. #p<0.1, *p<0.05.
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Fig. 5. Cdh13-/- mice exhibit normal attentional performance in the 5-CSRTT but impaired spatial learning in the 
Barnes maze and deficits in cued fear memory following delay fear conditioning. 
(a) % number of correct responses, (b) % number of omission errors, (c) number of premature responses and (d) 
number of timeout responses at different stimulus durations in the 5-CSRTT (n=10/genotype). (e) Total distance 
traveled, (f) escape latency and (g) number of primary errors during acquisition and reversal phase of the Barnes 
maze (n=7-10/genotype). (h) % Freezing duration during presentation of the auditory cue and the original 
conditioning context following delay fear conditioning (n=9-10/genotype). Data are presented as mean±SEM. 
#p<0.1, *p<0.05, **p<0.01, ***p<0.001.
The assessment of hippocampus-dependent visuospatial memory in the Barnes maze 
showed that all mice learned to find the hidden escape box in both acquisition and reversal, 
as indicated by gradually decreasing distances, escape latencies, and primary errors 
throughout the successive trials (significant session effects: all p<0.001; data not shown). 
There were no session x genotype interactions, thus data were pooled across sessions to 
assess genotype effects. Distance traveled, escape latency and primary errors (Fig. 5e-g) 
did not differ between genotypes during acquisition. However, during reversal, where the 
escape box is located in a different position, Cdh13-/- mice made significantly more primary 
errors than Cdh13+/+ mice (p=0.027), indicating impaired cognitive flexibility.
During fear conditioning, all genotypes displayed similar responses to footshock as well as 
significantly increased post-shock freezing (time effect: p<0.001 compared to pre-shock), 
reflecting unaltered pain sensitivity and normal acquisition of conditioned fear in Cdh13-
/- mice (Fig. S12a-b). 24-h cued fear memory was significantly impaired in Cdh13-/- mice 
compared to Cdh13+/+ mice, as indicated by decreased freezing (genotype main effect: 
p=0.047, Fig. 5H) and increased activity (p=0.081, Fig. S12C) during tone presentation. 
Similarly, in the 48-h contextual fear memory test, Cdh13-/- mice tended to be more active 
than Cdh13+/+ mice (p=0.094), although freezing duration did not significantly differ between 
genotypes when exposed to the original conditioning chamber.
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In summary, CDH13 deficiency impacts locomotor activity as well as learning and memory, 
two behavioral domains frequently associated with ADHD and related neurodevelopmental 
disorders.
2.5 Discussion
Variation in CDH13 has been associated with a wide range of neurodevelopmental and 
psychiatric disorders, ranging from ADHD to autism spectrum disorders, among others4. 
Although functional single-nucleotide polymorphisms/variants or haplo- types in CDH13 
have yet to be linked to neurodevelopmental/psychiatric disorders, several copy number 
variant studies revealed deletions in ADHD and autism spectrum disorder patients that 
may disrupt CDH13 expression and/or function19,38,39. Our findings revealed that inhibitory 
interneurons are the primary locus of CDH13 in the murine hippocampus, and that CDH13 
deficiency affects hippocampal inhibitory function and several behavioral domains that are 
fundamentally altered across various neurodevelopmental phenotypes, thus contributing 
to shed light on the role of CDH13 in the etiopathogenesis of neurodevelopmental and 
psychiatric disorders.
We confirmed that in the hippocampal CA region CDH13 is predominantly expressed in Gad1	
mRNA-positive cells, with preference for PV- and SOM-positive interneurons, thus allocating 
CDH13-related functions to several GABAergic interneuron subpopulations: axo-axonic 
cells, basket cells, bistratified cells, and also OLM or hippocampal-septal projection cells32,40. 
Alterations in PV interneurons have previously been linked to various neuropsychiatric and 
neurodevelopmental disorders as well as related animal models41,42. Furthermore, SOM-
positive interneurons have been implicated in the acquisition of contextual fear memories 
and the regulation of hippocampal synaptic plasticity43. 
Along with several other members of the cadherin superfamily that have been demonstrated 
to regulate interneuron development and hippocampal synaptic function44–47, CDH13 
expression in the hippocampal CA region suggests a function in interneurons, particularly at 
the inhibitory synapse. Furthermore, we confirmed that Cdh13 mRNA expression reaches 
its peak in the developing brain of the mouse between P7 to P21, consistent with recent 
observations in lysates from rat cortex28, thus supporting the view that CDH13 expression 
increments coincide with peaking synaptogenesis in the neocortex29,36. Our investigations 
also show that CA1 neurons from Cdh13-/- mice receive increased inhibitory input, while no 
changes were found in excitatory input, which is likely to result in an excitatory-inhibitory 
imbalance. This notion supports the view of CDH13 being a critical regulator of inhibitory 
function in the hippocampus consistent with its localization in the GABAergic presynaptic 
compartment. The fine-tuning of hippocampal circuitry depends greatly on the precise 
activity of the inhibitory system to control hyperexcitability in the hippocampus, which 
displays the lowest seizure threshold of the entire brain48. However, alterations associated 
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with an altered inhibitory function are pathophysiologically beyond epilepsy. Multiple lines 
of evidence support the role of the inhibitory GABAergic system in the pathogenesis of 
neurodevelopmental disorders41,49. Accordingly, disturbances of the excitatory-inhibitory 
balance lead to deficits in information processing and signal gating, two key processes 
involved in attentional and executive control41,50–53. Candidate risk genes studies further 
support the view that alterations in the inhibitory system likely account for a spectrum of 
neuropsychiatric manifestations, including schizophrenia, autism spectrum disorders and 
ADHD41,54–57. As an example, ErbB4 receptor tyrosine kinase, which is almost exclusively 
expressed in interneurons, has strongly been implicated in schizophrenia55,58. In the 
hippocampus, ErbB4 is located at the postsynaptic compartment of glutamatergic synapses 
of PV+ interneurons59 and has a critical role in the regulation of long-term potentiation (LTP) 
at the SC-CA1 synapse via these interneurons60,61. In the thalamic reticular nucleus, ErbB4 is 
mainly expressed in SOM-positive interneurons and is important for sensory selection49. Of 
note, we also observed strong expression of Cdh13 in thalamic reticular nucleus neurons4. 
In autism, the different isoforms of the cell adhesion proteins neurexins and neuroligins 
have both been shown to play critical roles in inhibitory synapse function. Of particular 
relevance is the observation that neuroligins 262 and 363 have distinct functions depending 
on the interneurons with which they form a synapse. Analogously to the neuroligins, and 
since we show that CDH13 is expressed in both PV- and SOM-immunoreactive cells, CDH13 
might have distinct functions depending on the interneurons in which it is expressed. 
Although the concentrations of GABA in hippocampus appear to be unchanged in Cdh13-/- 
mice, CDH13 deficiency may have effects on the modulation of inhibitory synaptic activity 
and synapse turnover. Our electrophysiological findings support the view that CDH13 may 
act as a synapse destabilizer. Therefore, in the absence of CDH13, stability of GABAergic 
synapses might be augmented due to a reduced synapse turnover, producing an increase 
in inhibitory synapse density, consistent with the observed increase in inhibitory synaptic 
transmission. The role of cadherins in synapse (de)stabilization and plasticity has been 
well documented1,64,65. The mechanism whereby CDH13 would participate in synapse (de)
stabilization might involve heterophilic interactions in trans with elements of the postsynaptic 
compartment and/or also interactions in cis with presynaptic transmembrane molecules 
in close proximity. Among the potential candidates to interact with CDH13 in trans is the 
GABA-Aα1 subunit, expressed in PV+ hippocampal interneurons and whose association 
with CDH13 has already been described in vascular endothelial cells66. Transmembrane 
molecules of the presynaptic (or postsynaptic) compartments that could potentially interact 
with CDH13 include integrin-linked kinase67, integrins66 or receptor tyrosine kinases (RTK)4, 
among others. Such interactions may induce downstream changes in actin cytoskeleton 
organization68 which destabilize the GABAergic synapse. 
Cdh13 knockdown in dissociated primary hippocampal neurons was previously reported to 
lead to a reduced density of both excitatory and inhibitory synapses, as well as a decrease 
in mEPSCs amplitude and frequency29. In the present study, we show in organotypic slices 
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that knockdown using the same shRNA exclusively in excitatory CA1 pyramidal cells did not 
affect inhibitory or excitatory input onto these cells, consistent with the expression pattern 
of CDH13 restricted to hippocampal CA inhibitory but not excitatory neurons. In addition, 
we show that in Cdh13−/− mice, miniature excitatory postsynaptic currents amplitude and 
frequency are unaffected. Together, our data confirm that excitatory synapses are not 
directly (via shRNA-mediated knockdown of Cdh13) or indirectly (secondary to changes 
in interneuronal activity and/or connectivity) affected. The difference between the two 
studies may thus be caused by the type of experimental model (postnatal brain sections 
and organotypic slices vs. dissociated cells) rendering it difficult to accurately extrapolate 
conclusions from both studies. 
The hippocampus is central to cognition, spatial navigation, as well as memory formation 
and specifically the regulation of emotional memories34. Furthermore, altered verbal and 
visuo-spatial working memory is one of the neurocognitive alterations widely described in 
ADHD69–71. Other mouse models for neurodevelopmental disorders, such as Down syndrome 
or neurofibromatosis type 1, also present increased inhibition, which correlates with spatial 
memory deficits41,72–74. Remarkably, the excitation/inhibition imbalance triggered by the 
loss of CDH13 function in the hippocampus was consistently reflected in the behavior of 
CDH13 deficient mice. We showed that Cdh13	null mutants display alterations in cognition 
and learning/memory (i.e. spatial memory deficits during the reversal phase of the Barnes 
maze when the position of the escape box is changed), suggesting either reduced cognitive 
flexibility in Cdh13-/- mice (i.e. inability to change their search strategies during the reversal 
phase) or a learning deficit when the difficulty of the task increases. In addition, Cdh13-/- 
mice display other minor alterations in conditioned fear responses as well as in the initial 
phase of the 5CSRTT, which supports the notion of learning deficits as a consequence of 
CDH13 deficiency. For example, the increased number of timeout responses during the 
training session may also support the notion of cognitive inflexibility in these mice75. By 
contrast, during the 5-CSRTT, no modifications in attention or impulsivity were detected in 
Cdh13−/− mice. In the context of neurodevelopmental/psychiatric disorders, this suggests 
that the contribution of CDH13 variation to these disorders would be restricted to certain 
behavioral dimensions, that is, learning ability and cognitive flexibility, whereas other 
aspects (for example, attentional processes) would be less affected by CDH13 variation, at 
least under baseline conditions.
The alteration in cognitive functions observed in Cdh13-deficient mice are in general 
mild but not unexpected, given the observation that single genetic risk variants for 
neurodevelopmental disorders tend to display very modest effect sizes76. Moreover, 
considering that deficits and impairments associated with neurodevelopmental disorders, 
such as ADHD, are more poorly compensated during childhood, the effects of CDH13 
deficiency on mouse behavior might even be more pronounced in adolescent mice compared 
with adult animals investigated in our study. Finally, it is also possible that CDH13 deficiency 
may induce more extensive inhibitory dysfunction under conditions of environmental 
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adversity, similar to its role as a cardioprotector under acute or chronic cardiac stress or 
its function in angiogenesis and tumor growth in a mouse model of mammary tumor37,77. 
Further studies will be necessary to disentangle the contribution of CDH13 under different 
environmental conditions in more detail. Finally, we provide evidence that Cdh13-/- mice 
display increased locomotor activity, one of the core phenotypes in ADHD78, which is even 
more pronounced in mice following adaptation to the environment, suggesting that CDH13 
deficiency may impair the hippocampal-dependent learning process that underlies the 
habituation to consecutive behavioral tests79. 
We are aware that our study presents several limitations. While the current work focused 
on CDH13 in the hippocampus, we and others have previously reported that CDH13 is 
also expressed in other regions of the mouse brain4,28. Therefore, the use of conditional 
Cdh13-deficient mouse will clarify whether inactivation of CDH13 in other brain regions and 
neuronal cells impacts at the synaptic and behavioral levels. A cell-specific, such as PV- or 
SOM-specific, Cdh13 knockout will facilitate dissection of the specific contribution of CDH13 
to each interneuron type where it is expressed. Furthermore, following this line of reasoning, 
Cdh13 is also expressed in serotonin (5-HT)-specific neurons of the raphe complex4. Genetic 
variants of CDH13 have been associated with criminal behavior with extreme violence23, a 
domain that is profoundly influenced by the brain 5-HT system80. However, we did not find 
any indication for alterations in phenotypes related to emotion regulation in Cdh13 deficient 
mice including baseline levels of the stress hormone corticosterone. This also excludes the 
possibility that observed alterations in the cognitive domain are masked by emotional 
dysregulation. Finally, no functional CDH13 variants associated with violent behavior have 
been identified yet and it is still unknown whether the nature of these variants results in a 
loss or a gain of CDH13 function.
In conclusion, our findings demonstrate that CDH13 localizes to the presynaptic compartment 
of hippocampal GABAergic synapses and safeguards the excitatory-inhibitory balance in the 
CA1 region. CDH13 is thus essential for cognitive flexibility function and correct memory 
formation. CDH13 deficiency results in behavioral alterations associated with symptoms 
observed in neurodevelopmental disorders such as ADHD, including learning and memory 
deficits as well as locomotor hyperactivity. The present findings therefore contribute to the 
understanding of how dysregulation of CDH13 function may predispose individuals to ADHD 
and related comorbidities.
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2.7 Supplementary information
Generation of a constitutive Cdh13 knockout mouse line 
A constitutive Cdh13	knockout mouse (Cdh13-/-) was generated through site-specific DNA 
recombination using a conditional Cdh13	mouse line (Cdh13loxP/loxP), as well as a constitutive 
Cre deleter line, (C57BL/6.C-Tg(CMV-Cre)1Cgn1 both in a C57Bl/6N background (Fig. S1). 
For the generation of the Cdh13loxP/loxP mouse line, two independent positive ES cell JM8.
N4 clones (HEPD0516_5_C09 and HEPD0516_5_F10), containing a Cdh13	modified locus 
(Cdh13	knockout first allele), were purchased from EUCOMM CONSORTIUM (2; http://www.
eucomm.org). Briefly, this knockout first allele contained a 4.78 kb 5’ homology arm, a FRT-
flanked cassette driven by Cdh13	promoter containing both a LacZ	 reporter gene and a 
neomycin resistance gene for positive selection (both separated by a loxP sequence), 2 loxP 
sites flanking exon 3 of Cdh13	gene as well as a 5.88 kb 3’ homology arm. To confirm the 
presence of the second loxP site flanking the exon 3 in these ES clones, long-range PCR was 
used to amplify the 3’ modified homology arm. The presence of the loxP site generates a 
new restriction site for the restriction endonuclease SacI. Thus, digestion with this enzyme 
and sequence analysis allowed us to confirm the presence of this modification and therefore 
the presence of the Cdh13	modified locus. 
Two positive HEPD0516_5_C09 and HEPD0516_5_F10 JM8.N4 clones containing Cdh13	
knockout first alleles were subsequently injected into C57Bl/6N blastocysts. Only one of 
the resulting chimeric male mice (six animals from clone HEPD0516_5_F10, one from clone 
HEPD0516_5_C09) was positive for germ-line transmission, and was therefore used as the 
founder of the Cdh13	knockout first mouse line. Removal of the FRT cassette to generate the 
conditional Cdh13loxP/loxP mice was achieved by constitutive FLP-mediated recombination: 
Cdh13	knockout first offspring were crossed to C57BL/6J congenic constitutive FLP-deleter 
mice3 and further backcrossed to C57BL/6N mice for several generations. Subsequently, 
Cdh13loxP/loxP mice were finally intercrossed with C57BL/6N congenic constitutive Cre-deleter 
mice1 and additional rounds of breeding were then performed in order to produce animals 
that were negative for Cre	transgene. 
Mouse genotyping was performed with genomic DNA samples isolated from tail biopsies 
that were taken from each animal at weaning. Standard PCR protocols were used to amplify 
the wild-type, knockout first, floxed and knockout alleles of the Cdh13	gene, as well as to 
detect the presence of Cre	or Flp. The specific primers used in each case are indicated in 
Supplementary Table S1. The amplification program was the following: 94ºC 1min; 2 cycles 
of 95ºC 15s, 64ºC 15s and 72ºC 1min; 2 cycles of 95ºC 15s, 61ºC 15s and 72ºC 1min; 20 
cycles of 95ºC 15s, 58ºC 15s and 72ºC 1min; 10 cycles of 95ºC 15s, 55ºC 15s and 72ºC 1min; 
72ºC 10min. 
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Animal husbandry 
All animals were kept in the Animal Core Facility at the University Hospital of Würzburg on a 
regular 12h light/12h dark cycle in a temperature (21±1°C) and humidity (50±5%) controlled 
environment. Food and water were provided ad	 libitum. All animals used for the studies 
came from matings between Cdh13+/- males and Cdh13+/- females. The use of heterozygote 
animals for the breeding allows controlling for any potential effects of genotype on maternal 
care, and ensures an appropriate distribution of the different genotypes among the litters 
to be used for experiments. 
Brain dissection for molecular analysis 
For quantitative molecular analysis of CDH13 protein levels, as well as for the analysis of 
neurotransmitter levels, adult mice (between 12 and 16 weeks of age) were anesthetized 
with a lethal dose of isoflurane and euthanized by cervical dislocation. Afterwards, brains 
were dissected, immediately frozen in dry ice-cold isopentane and stored at -80ºC until 
further use. The isolation of brain areas (including complete hippocampus) was conducted by 
slicing the brains in thick sections on a pre-cooled plate. Brain regions were then separated, 
frozen in dry ice and stored at -80ºC until needed. 
Western blotting 
Hippocampal samples were homogenized by sonication in RIPA (Radio-Immunoprecipitation 
Assay) buffer (Sigma-Aldrich Chemie Gmbh, Munich, Germany), supplemented with 
protease and phosphatase inhibitor tablets (Roche Diagnostics Deutschland GmbH, 
Mannheim, Germany). 15 μg of total protein were loaded on 4-12% Bis-Tris polyacrylamide 
gels (Life Technologies, Darmstadt, Germany), electrophoresed under reducing, denaturing 
conditions, electroblotted to a 0.45 μm-pore nitrocellulose membrane (Life Technologies) 
and probed using a goat anti-Cadherin-13 antibody (1:200, R&D systems, Wiesbaden-
Nordenstadt, Germany) and mouse anti- α-tubulin (1:5000, Sigma-Aldrich) or rabbit anti-
GAPDH (1:2500, Abcam, Cambridge, United Kingdom) antibodies as loading controls. Finally, 
membranes were incubated in secondary fluorescent donkey anti-goat 680 and donkey anti-
mouse 800CW or donkey anti-rabbit 800CW antibodies (1:10000, Li-Cor Biosciences GmbH, 
Bad Homburg, Germany). Detection and quantification was conducted using the Odyssey 
infrared imaging system and Image Studio Lite version 3.1 software (Li-Cor Biosciences). 
CDH13 protein relative levels were normalized to the internal loading control and the data 
were expressed as percentages of the average control value. 
Analysis of hippocampal neurotransmitter levels 
Hippocampal concentrations of different neurotransmitters and their metabolites were 
also detected via high performance liquid chromatography (HPLC). Total hippocampus 
samples of Cdh13+/+, Cdh13+/- and Cdh13-/- mice were homogenized by sonication in 
buffer containing H3PO4 (150 mM) and DTPA [Bis-(2-aminoethyl)-amine-N,N,N’,N’’,N’’-
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penta-acetic acid; 500 μM] on ice under an argon atmosphere. 140 μL buffer were used 
per 10mg of tissue. Homogenates were then centrifuged at 19000 rpm for 20 min at 4°C. 
Supernatants were used for the analysis of neurotransmitters and metabolites on an Agilent 
1100 HPLC system (Agilent Technologies, Waldbronn, Germany). According to previously 
described methods, electrochemical detection (model 1640; Bio-Rad, Munich, Germany) 
was used for monoamines and fluorescence detection with precolumn derivatization for 
amino compounds4. The analyzed neurotransmitters and metabolites were gamma-butyric 
acid (GABA), glutamate, norepinephrine (NE), 3-methoxy-4-hydroxyphenylglycol (MHPG), 
dopamine, (DA), 3,4-dihydroxy-phenylacetic acid (DOPAC), homovanillic acid (HVA), 
serotonin (5-HT) and 5-hydroxyindoleacetic acid (5-HIAA). 
Histological methods 
Nissl staining 
Slide-mounted 20 μm thick coronal sections of adult mouse brain were rinsed 2x2 min in 
ddH
2
O and afterwards immersed in filtered 0.1% cresyl-violet solution for 8 min. Subsequently, 
sections were transferred to 70% EtOH for destaining and the process briefly judged by 
light microscopy. Sections were then transferred to ascending alcohol concentrations and 
covered with Vitro-Clud and cover glasses. 
In situ hybridization 
In	 situ	 hybridization (ISH) experiments were carried out as previously described5. In 
summary, a probe against mouse Cdh13	 mRNA (GenBank accession: NM_019707) was 
generated with the following primers: Forward: 5’-TCCATTGTGGTGTCCCCCA-3’; reverse: 
5’-TGGGTTGGTGTGGATCTCGA-3’. A probe against mouse Gad1	mRNA (GenBank	accession: 
NM_008077) was produced via amplification with the following primers: forward: 
5´-ACGTGAAGGGATGATGGATG-3´ (2417-2436); reverse: 5´-GCGAAGGCTACTGAAGCAAG-3´ 
(2917-2888). 
cDNA fragments were cloned into Dual promoter PCR®II according to the manual of the TA 
Cloning® Kit using One Shot® TOP10F’ chemically competent E.coli	for transformation (Life 
Technologies). Plasmids were isolated following instructions of Wizard Plus SV Miniprep 
and PureYieldTM Plasmid Midiprep (Promega, Mannheim, Germany). Cdh13	probes were 
digoxigenin-labelled, Gad1	probes were fluorescein-labelled using SP6/T7 RNA polymerase 
(New England Biolabs, Frankfurt, Germany) and 10x DIG/Fluorescein labeling mix (Roche 
Diagnostics). For later reproduction of probes from linearized plasmid stocks, the protocol 
for direct purification of PCR products of the NucleoSpin® Extract II kit (Macherey-Nagel, 
Düren, Germany) was followed. After in	vitro	transcription, RNA probes were cleaned up 
using the RNeasy Mini® instructions for RNA cleanup (Qiagen, Hilden, Germany) 
Snap-frozen native adult mouse brains were coronally sectioned in 16μm-thick slices with a 
cryostat microtome (Leica Mikrosysteme Vertrieb GmbH, Wetzlar, Germany) and afterwards 
stored at -80°C until the beginning of the experiment. 
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Pre-hybridization and hybridization procedures were carried out as described5, with alcohol 
rehydratation being omitted for FISH experiments and hybridization temperatures at 58°C 
for single Cdh13	CISH and 60°C for double FISH. Stringent post-hybridization washes were 
carried out (room temperature if not mentioned otherwise): 2 x 10 min in 2x sodium saline 
citrate buffer (SSC, Sigma-Aldrich), 50% formamide in 2x SSC at 58°C/60°C for 30 min, 2 x 10 
min in 2x SSC, RNase A (40 mg/ml, Roche Diagnostics) in RNase buffer (50 mM NaCl, 10 mM 
Tris, 1 mM EDTA) at 37°C for 30 min, 3 x 2 min RNase buffer without RNase, 30 min RNase 
buffer without RNase at 58/60°C, and 5 min in wash buffer (wB; 100 mM Tris, 150 mM NaCl, 
pH 7.5). In the following steps, wB was used for washing and solutions if not mentioned 
otherwise. 
Detection	 for	 single	 CISH: Sections were incubated with 0,5% Blocking Reagent (Roche 
Diagnostics) for 60 min, briefly treated with 0,3% Triton X-100 and incubated for 60 min with 
aP-conjugated anti-DIG Fab fragment (Roche Diagnostics) diluted 1:500 in 0.25% blocking 
reagent, 0.15% Triton X-10. Subsequently, sections were rinsed 2 x 5 min and 5 min with 
reaction buffer (rB; 100 mM Tris, 100 mM NaCl, 50 mM MgCl2, pH 7.5) before being incubated 
16-20 h in the dark with aP substrate (0.4 M 5-bromo-4-chloro-3-indolyl-phosphate (BCIP) 
and 0.4 M 4-nitro blue tetrazolium chloride (NBT) in rB). Development of the reaction and 
intensity of the signal were observed with a light microscope and the reaction stopped by 
rinsing and mounted with Aquatex (Merck Millipore, Darmstadt, Germany). 
Detection	 for	 double	 FISH:	 Based on previous literature6, the following protocol was 
used for fluorescent detection. Sections were treated with 0.5% PE Blocking Reagent (PE 
block) (Perkin Elmer, Rodgau, Germany) for 60 min and subsequently incubated with POD 
conjugated anti-Fluorescein Fab fragments (Roche Diagnostics) diluted 1:3000 in 0.5% PE 
block for 2 h. Subsequently, sections were rinsed 3 x 6 min with TN buffer (0.05% Tween 
20 in wB), incubated for 10 min with DNP reagent (from TSATM PLUS DNP kit, Perkin Elmer) 
that had been diluted 1:100 in 50% 1x Diluent/ 50% H
2
O (Merck Millipore) and rinsed again 
3 x 5 min with TN buffer. To detect digoxigenin-labeled probes, slides were subjected to 
overnight incubation (4°C) with aP-conjugated anti-DIG Fab fragments (Roche Diagnostics) 
1:2000 and anti-DNP Alexa Fluor 488 (Life Technologies) 1:500 in PE block. After rinsing 3 x 
7 min in TN buffer and 1 x 4 min in TS8 buffer (0.1 M Tris-HCl, 0.1 M NaCl, 0.01M MgCl2, pH 
8.0), a reaction with 2-hydroxy-3-naphtoic acid-2’-phenylalanide phosphate and 4-chloro-
2-methylbenzenediazonium hemi-zinc chloride salt (HNPP/FR, Roche, 1:100 in TS8 buffer 
and sterile-filtered before use to remove precipitates) was carried out under coverslips. 
After 45 min, the outcome was microscopically observed and the HNPP/FR replaced if 
further development was desired (repeated up to three times). The reaction was stopped 
by washing 5 min in ddH
2
O, and 300 nM DAPI was applied as a nuclear counterstain. Finally, 
the slides were rinsed, mounted with Fluoro-Gel (Electron Microscopy Sciences, Hatfield, 
PA, USA) and stored at -20°C. 
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Immunofluorescence 
Adult mice (aged between 12 and 16 weeks of age) were anaesthetized with isoflurane 
and transcardially perfused with 4% PFA (8 min, pH 6,5) followed by 4% PFA including 
0.02% glutaraldehyde (12 min, pH 11). Brains were postfixed in 4% PFA overnight and 
subsequently incubated in 10% and 20% sucrose solutions before freezing them in dry ice-
cooled isopentane. For double immunofluorescence, 40μm free-floating coronal sections 
were generated in 8 series from 3 brains. Afterwards, one series of each brain was stained 
with goat CDH13 antibody (1:500, R&D Systems) in combination with one of the following 
antibodies against different interneuron markers: rat anti-somatostatin (SOM) (1:400, 
Merck Millipore), rabbit anti-parvalbumin (PV) (1:250, Swant, Marly, Switzerland), rabbit 
anti-calbindin (CB) (1:800, Swant), rabbit anti-neuropeptide Y (NPY) (1:100, Sigma-Aldrich), 
rabbit anti-vasoactive intestinal peptide (VIP) (1:300, Immunostar, Hudson, WI, USA), rabbit 
anti-neural nitric oxide synthase (nNOS) (1:250, Merck Millipore), rabbit anti-calretinin 
(CR) (1:4000, Swant). Subsequently, sections were incubated with secondary fluorescent 
antibodies (Life Technologies): donkey anti goat-Alexa Fluor 555 (1:600), donkey anti-rabbit-
Alexa Fluor 488 (1:1000) and donkey anti-rat-Alexa Fluor 488 (1:800). 1x PBS was used for all 
washing steps and as diluent for all blocking (10% normal horse serum, 0.25% Triton-X 100) 
and antibody solutions (5% normal horse serum, 0.125% Triton-X 100). Primary antibody 
incubation was carried out overnight at 4°C, secondary antibodies were incubated 2 h at 
room temperature. Slides were mounted with Fluoro-Gel and coverslipped to be stored at 
4°C. The same staining principle and antibodies were applied for triple staining of CDH13 
with PV and SOM. In this case secondary antibodies were: donkey anti goat-Alexa Fluor 555 
(1:600), donkey anti-rabbit-Alexa Fluor 350 (1:1000) and donkey anti-rat-Alexa Fluor 488 
(1:800). 
Immunohistochemistry 
For single immunohistochemical staining of interneuronal GABAergic markers, native brains 
of adult mice (12-16 weeks of age, n=7-9 per genotype) were extracted after euthanizing 
the animals with an overdose of isoflurane. Brains were postfixed in 4% PFA over 48 h, and 
cryoprotected and frozen as described above. The brains were sectioned in 50 μm free-
floating coronal sections in 6 series covering the whole dorsoventral axis of the hippocampus. 
Free-floating immunohistochemistry was carried out as previously described7. Heat induced 
epitope retrieval was performed for 20 min and blocking with 10% normal goat serum, 
0.25% Triton-X 100 for 90 min. One complete series of free-floating sections was stained 
with one of the following primary antibodies: rat anti-SOM (1:1000, Millipore), rabbit anti-
PV (1:12000, Swant) and rabbit anti nNOS (1:6000, Millipore) in 5% normal goat serum, 
0.25% Triton X-100. Biotinylated secondary anti-rabbit or anti-rat antibodies (1:1000, 
Vector Laboratories, Burlingame, CA) were incubated for 2 h, followed by incubation in AB 
complex (each 1:100, 90 min, Vector Laboratories) and 3,3’-Diaminobenzidine (DAB) (Roche 
Diagnostics) until the staining developed to the desired intensity. 
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For single CDH13 staining, adult mice (12-16 weeks of age) were anaesthetized with 
isoflurane and transcardially perfused with 4% PFA (8 min, pH 6.5) followed by 4% PFA 
including 0.02% glutaraldehyde (12 min, pH 11.0). Brains were postfixed in 4% PFA overnight 
and subsequently cryoprotected and frozen as described above. Brains were coronally 
sectioned into 20 μm-thick slices with a cryostat microtome and thaw-mounted onto slides. 
Sections were treated as indicated in the instructions for N-Histofine Simple Stain Mouse 
MAX PO (G) (Nichirei Biosciences, Tokyo, Japan). Briefly, sections were blocked with 10% 
normal rabbit serum, CDH13 primary antibody was diluted 1:500 in 1xPBS and incubated 
at 4°C overnight. 1x PBS was used for all washing steps and other solutions. DAB was used 
as a substrate for peroxidase coupled to the secondary antibody polymer supplied in the 
Histofine kit. 
In this case, the use of sections from Cdh13-/- animals as negative controls allowed us to 
better adjust the conditions for the immunohistochemical staining and therefore to ensure 
that the observed signal is completely specific and originates from CDH13 protein (Fig. S1). 
Immunocytochemistry 
Primary hippocampal neuron cultures were fixed using 4% paraformaldehyde/4% sucrose 
in PBS and stored at 4°C in PBS. Cells were permeabilized, blocked for 1h and incubated 
with primary antibody overnight. Secondary antibody was applied for 1h and cells were 
mounted using DAKO fluorescent mounting medium. Primary antibodies against the 
following proteins were used: CDH13 (1:500, Millipore, Darmstadt, Germany); vesicular 
glutamate transporter (VGLUT) (1:100, Synaptic Systems, Goettingen, Germany); vesicular 
GABA transporter (VGAT) (1:200, Synaptic Systems); postsynaptic density protein 95 (PSD95) 
(1:50, Thermo Scientific, Waltham, MA, USA); gephyrin (1:500, Synaptic Systems); GABA-
Aα1 (1:250, Synaptic Systems). Secondary antibodies were goat anti-rabbit-488 or goat anti-
mouse-568 (1:2000, Invitrogen). 
Picture processing 
Light microscopic images were obtained with an Olympus BX51 microscope and CX9000 
camera (Olympus, Hamburg, Germany) using Neurolucida software v.11 (MBF Bioscience, 
Willsiton, VT, USA). Pictures were taken with 10x or 20x objectives and processed for overall 
brightness and contrast with ImageJ v. 1.47 or Photoshop 9.0 (Adobe Systems Software 
Ireland Limited, Dublin, Ireland). 
Fluorescence images were obtained using an inverted epifluorescence Olympus IX81 
microscope with a XM10 camera (Olympus) and cellSens Dimension 1.4 software (Olympus). 
Pictures were taken with 10x and 20x objectives and processed with ImageJ or Photoshop. 
Fig. containing images were composed using Photoshop and Illustrator 12.0 (Adobe). 
Confocal images were acquired using a Fluoview FV1000 confocal microscope (Olympus). 
Pictures were taken with a 63x objective and processed for overall brightness and contrast 
with Photoshop 12.1 (Adobe). 
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Colocalization assessment 
Of each series, only 7-8 sections contained the Stratum	oriens (SO) and were selected for 
co-expression assessment. Single-channel fluorescence images, taken from each section to 
cover the complete dorsoventral extent of the hippocampal SO 9 
(corresponding to DAPI, CDH13 and one of the GABAergic interneuron markers), were 
subsequently merged and combined in a stack. The ImageJ “Cell Counter” plugin was used 
to identify and count the number of GABAergic positive cells as well as the CDH13 positive 
cells in each single channel image separately. Finally, those cells that were coexpressing 
both proteins were identified by showing all marked cells and also counted. It was verified in 
the single channel, as well as the merged images that the marked cells indeed coexpressed 
both proteins. Co-expression percentages of each marker with CDH13 were calculated. It 
should be noted that co-expression of both markers in one cell was only considered if the 
cell somata could be clearly identified in both the red and the green channels. Despite this 
method can underestimate the actual degree of co-expression, this conservative approach 
also reduces the possibility of false positives and can be therefore considered to show the 
lower level of the co-expression range. 
After the countings, sections were assigned to ventral or dorsal hippocampus, considering 
a section to be the beginning of the ventral hippocampus when the corpus callosum was 
separated and no longer connecting both hemispheres. All sections before that point were 
considered as dorsal hippocampus (interaural 1.26-1.34 mm, according to Paxinos and 
Franklin8). 
Quantification of immunolabeled cells 
DAB-stained sections of Cdh13-/- (n=8), Cdh13+/- (n=8) and Cdh13+/+ (n=9) mice were analyzed 
using Stereo Investigator imaging software v.11 (MBF), which allows the application of a 
stereological approach to evaluate the number and density of PV-, SOM- and nNOS-positive 
GABAergic cells in each brain. Particularly, 8-9 sections corresponding to one complete series 
of a total of six, covering the whole dorsoventral axis of the hippocampal SO, were counted 
per mouse. The region of interest, in this case the SO, was traced at 4x magnification in each 
section, whereas the cells where counted at 10x (nNOS) or 20x (PV, SOM) magnification, 
using the optical fractionator method. In coherence with the co-expression study, a 
differentiation between dorsal and ventral hippocampus was made. The volume (mm3) 
of the SO, the estimated population numbers of PV-, SOM-, and nNOS-positive cells were 
calculated for each brain using the section thickness, number of sections and section 
evaluation interval. The numerical density (cells/mm3) was calculated form the volume and 
population number given in the output data from Stereo Investigator. The experimenter 
was blind to the genotype of the animals at all times of the experiment. Statistics were 
calculated with Prism 6.04 (GraphPad Software, La Jolla, CA) using Kruskal-Wallis test. 
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RNA isolation and semiquantitative RT-PCR (qPCR) 
Total RNA from brains of different ages was extracted with TRIreagent (Sigma-Aldrich) 
and 1-2μg total RNA was used for cDNA synthesis using the RevertAid H-minus first 
strand cDNA synthesis kit (Thermo Scientific). A 1:15 dilution of cDNA pool was used in 
a 10μl reaction for qPCR analysis using the Sensifast SYBR no ROX qPCR kit (Bioline, 
Luckenwalde, Germany) and a Rotor-GeneTM 6000 real-time analyzer (Qiagen). qPCR 
program used was (2 min 95oC , (5 s 95oC, 10 s 60 or 65oC and 15 s 72oC)x40 cycles). 
The intron-spanning primers for Cdh13	used are: Forward GCTTGCTGCTGCTCTTCTC, reverse 
CTTGGGAGTCAAGCTTCAGG. As reference transcripts, peptidyl prolyl isomerase (Ppia) 
(Forward AGCCATGGAGCGTTTTGGGTCC, reverse AGCAGATGGGGTAGGGACGCT) and β-actin 
(Actb) Forward CTGACCCTGAAGTACCCCATT, reverse AGAGGCATACAGGGACAGCA) were 
used. qPCR data were analyzed by using comparative quantitation and the relative Q-values 
of Cdh13	calculated by equalizing the lowest Ct value to 1. The normalization factor for the 
reference genes was determined using the GeNORM program (medgen.ugent.be/genorm) 
and used to normalize the Q-values. Individual experiments were performed in triplicate 
with three independent mouse brain RNA pools. 
Electrophysiology 
Mice (P20-22) of both genders were anesthetized with isoflurane before decapitation. 350 
μm-thick horizontal slices of the ventral hippocampus were prepared (HM650V vibratome, 
Thermo Scientific, Waltham, MA USA) in ice cold ACSF containing (in mM): 87 NaCl, 11 
Glucose, 75 Sucrose, 2.5 KCl, 1.25 NaH2PO4, 0.5 CaCl2, 7 MgCl2, 26 NaHCO3, continuously 
oxygenated with 95% O2/5% CO2 and incubated for 1 h at 32°C after which they were 
allowed to cool down to room temperature. Before recording, slices were transferred to the 
recording setup and incubated in recording artificial cerebrospinal fluid (ACSF) containing 
(unless otherwise stated) (in mM): 124 NaCl, 1.25 NaH2PO4, 3 KCl, 26 NaHCO3, 10 Glucose, 
2 CaCl2, 1 MgCl2 and continuously oxygenated with 95% O2/5% CO2 at 30°C and incubated 
15 minutes prior to recording. Cells were visualized with an upright microscope (Olympus). 
Patch pipettes (3-5 MΩ) were made from borosilicate glass capillaries and filled with 
intracellular solution containing (in mM): 115 CsMeSO3, 20 CsCl, 10 HEPES, 2.5 MgCl2, 4 
Na2ATP, 0.4 NaGTP, 10 Na-Phosphocreatine, 0.6 EGTA (pH 7.2-7.3, 285-295 mOsm). Traces 
were recorded using a Multiclamp 700B amplifier (Molecular Devices, Wokingham, United 
Kingdom), sampled at 10 kHz and filtered at 2 kHz. Cells were excluded from analysis if 
the access resistance exceeded 25 MΩ. Miniature inhibitory postsynaptic currents (mIPSCs) 
were recorded in the presence of Tetrodotoxin (1 μM), 6-Cyano-7-nitroquinoxaline-2,3-
dione (CNQX, 5 μM) and D-(-)-2-Amino-5-phosphonopentanoic acid (D-APV 100 μM). 
Miniature excitatory postsynaptic currents (mEPSCs) were recorded in the presence of TTX 
and Picrotoxin (PTX, 100 μM). Paired pulse ratio (PPR) was recorded in the presence of 
CNQX and D-APV, the recording ACSF contained 4 mM CaCl2 and 4 mM MgCl2, and was 
calculated as peak2/peak1 after correcting for any residual current at the second pulse. 
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Miniature recordings were analyzed using Mini Analysis Program (Synaptosoft, Decatur, GA, 
USA). Other traces were analyzed using Clampfit 10.2. All drugs were purchased from Tocris 
(Abingdon, United Kingdom). 
Intrinsic cell parameters we recorded in current clamp with intrinsic solution containing (in 
mM): 13 KCl, 117 K-Gluconate, 10 K-HEPES, 1 CaCl2, 2 MgCl2, 11 EGTA, 2 Na2ATP, 0.5 Na3GTP 
(pH 7.2-7.3, 300-310 mOsm). Traces were amplified with a SEC-05X amplifier (npi, Tamm, 
Germany), sampled at 10 kHz and filtered at 2 kHz using an CED 1401 digitizer (Cambridge 
Electronics Devices, Cambridge, UK), and recorded using Signal (CED, Cambridge, England). 
Traces were analyzed using Stimfit v0.139, following the parameter definitions used by 
Tricoire et al. (2011)10. 
Morphological reconstructions 
For morphological reconstructions, the internal solution was supplemented with 0.4% 
biocytin (Sigma-Aldrich). The brain slices with biocytin-filled neurons were fixated at 4°C in 
4% paraformaldehyde in 0.1 M PBS for several days, and subsequently processed following 
a modified staining protocol based on Marx et al. (2012)11. Briefly, after fixation, slices were 
rinsed in 0.1 M PB, incubated in 3% H2O2 in 0.1 M PB for 30 min, rinsed in 0.1 M PBS, then 
incubated in Avidin-Biotin-Peroxidase solution (Vectastain Elite, with 1% v/v Triton-100) 
overnight on a shaking platform at 4°C. The next day, slices were washed with 0.1 M PBS 
and pre-incubated with DAB solution with nickel enhancer (Vector Peroxidase substrate kit, 
SK-4100) for 30 min. Then, the DAB solution was replaced with the same solution plus H
2
O
2
, 
and incubated for ca. 30 sec. Slices were then rinsed in 0.1 M PB, mounted on gelatinized 
coverslips, and dried for 3-6 h in a custom-made moist chamber at room temperature. The 
slides were then dehydrated in an ethanol series and xylene, and then sealed with Eukitt 
(Sigma). Slices were imaged on a Zeiss Axioskop 1 upright brightfield microscope with 20x and 
40x objectives (Zeiss EC Plan-Neofluar, NA 0.5 and 0.75, respectively) and motorized stage 
(MBF). The camera and motorized stage were connected to a desktop computer running 
Neurolucida v10 (MBF). Cells were selected based on position (in CA1 stratum	pyramidale), 
pyramidal morphology, staining intensity, and patch depth (>50 μm to safeguard against 
cutting artefacts). Somata, apical and basal dendrites were reconstructed in Neurolucida as 
three-dimensional drawings overlaid over the video image. Reconstructions were analyzed 
in NeuroExplorer (MBF) for intrinsic parameters and Sholl analysis. 
Hippocampal organotypic slice preparation and infection 
Organotypic hippocampal slice cultures were prepared from postnatal day 6 to 8 rat pups 
as has been described previously (Stoppini, Buchs, & Muller, 1991) and maintained in a 5 
% CO2 humidified 35°C incubator on slice culture medium consisting of MEM, 20 % horse 
serum, 1 mM L-Glutamine, 1 mM CaCl2, 2 mM MgSO4, 0.25 mg Insulin, 1.25 mM Ascorbic 
acid, 12.87 mM D-Glucose, 5.25 mM NaHCO3 and 30 mM Hepes (pH 7.3, 325 mOsmol). 
Slices were infected at day in vitro (DIV) 1 by injection of a lentivirus into the CA1 pyramidal 
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cell layer using a PLI-10 pico-injector (Warner Instruments) and used for electrophysiological 
experiments DIV 12-13. The lentivirus carried an shRNA directed against Cdh13	 (5’ 
ACGATCGCTACTTATCAAC 3’) that has been previously described (Paradis et al., 2007). 
Behavioral assessment 
Animals 
Mice were group-housed in Macrolon type III cages in age- and genotype-matched pairs. 
Prior to the beginning of the behavioral testing, mice were allowed to adapt to the test room 
for two weeks. The sequence of experiments was designed to minimize the suffering and 
stress of the animals, beginning with less stressful measurements and finishing with more 
demanding ones. Behavioral tests were separated from each other by at least one week. All 
experiments were performed during the light phase (10:00-16:00. Behavioral test batteries 
lasted for approximately 8-12 weeks. 
Beginning at 10 weeks of age, one cohort of mice (7 Cdh13+/+, 8 Cdh13+/-, 7 Cdh13-/-) 
was tested for anxiety-like behavior in the elevated plus maze (EPM), marble burying test 
(MBT) and light/dark box (LDB) as well as locomotor activity in the open field (OF) and social 
interaction (SI) in a test for sociability and preference for social novelty. The OF test was 
repeated in an independent cohort of age-matched mice (10 Cdh13+/+, 10 Cdh13+/-, 10 
Cdh13-/-). This cohort was further subjected to the novelty-suppressed feeding test (NSF) to 
assess anxiety-like behavior, the Porsolt swim test (PST) to measure behavioral despair, and 
a delay fear conditioning paradigm to examine associative learning and memory. Another 
naïve cohort of 15-18 week old mice (7 Cdh13+/+, 9 Cdh13+/-, 10 Cdh13-/-) was tested for 
visuospatial learning and memory in the Barnes maze (BM) and behavioral despair in the 
PST. Finally, beginning at 32 weeks of age, a fourth batch of mice (10 Cdh13+/+, 10 Cdh13+/-
, 10 Cdh13-/-) was subjected to the 5-choice serial reaction time task (5-CSRTT) to assess 
attentional performance and impulsivity. In all cohorts, body weights as well as food and 
water intakes were monitored weekly throughout the entire testing period. In addition, mice 
of the 1st and 3rd cohort were used to determine baseline stress hormone levels from fecal 
samples and blood as well as anhedonia-like behavior in a sucrose preference test (SPT). 
Sucrose preference 
Prior to the beginning of the behavioral test battery, mice were given concurrent access to 
one bottle of 1% (w/v) sucrose solution and one bottle of tap water for 48 h. The bottles 
were weighed after 24 h and their positions switched in order to minimize possible effects 
of side-preference. Sucrose preference was calculated as the percentage of sucrose solution 
consumed relative to total liquid intake, with a reduced sucrose preference being an 
indicator of anhedonic behavior. 
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Elevated plus maze 
Mice were individually placed in the center of a maze in the shape of a cross12,13, elevated 
approximately 60 cm from the floor and consisting of two closed, dark arms (15 cm high 
walls, illumination of 5 lx) and two open arms (illumination of 50 lx), all of them with a 
dimension of 30x5 cm and semi-permeable to infrared light (TSE Systems, Bad Homburg, 
Germany)14. The duration of the test was 10 min, and during this time the animals were 
tracked with a CCD camera and their behavior was analyzed by VideoMot2 software (TSE 
Systems). Particularly, the software was used to calculate the total distance traveled as 
well as the number of entries and time spent in the open arms as measures of anxiety-like 
behavior. 
Light-dark box 
The light-dark box (LDB) consisted of an opaque white box (50x50x40 cm) with a black insert, 
measuring one third of the total box size and semi-permeable to infrared light (TSE Systems). 
The illumination in the dark compartment was between 0 and 5 lx, whereas the illumination 
in the lit compartment was approximately 100 lx. Each mouse was individually placed in 
the dark section of the box and behavior was automatically recorded with VideoMot2 (TSE 
Systems) for 10 min. The analyzed measures were distance traveled as well as number of 
entries and time spent in the lit compartment as measures of anxiety-like behavior. 
Marble burying 
The marble burying test is a common test to assess anxiety- and compulsive-like behaviors. 
Mice were individually placed into cages (42.5x26.6x15.5 cm) filled with clean bedding to 
a depth of 5 cm and 15 identical glass marbles that were evenly spaced across the bedding 
surface. After 30 min, mice were returned to the home-cage and all marbles covered by 
bedding to two-thirds or more were scored as buried. 
Novelty-suppressed feeding 
The novelty-suppressed feeding (NSF) test is based on a conflict between food-seeking 
induced by hunger and the aversion to explore a novel, brightly illuminated environment15. 
Food-deprived (~20 h) mice were placed in a corner of a brightly lit arena (50x50x40 cm; 
the same box that was used for the light/dark test) with a single food pellet (~2.5 g) located 
at the center. After the first feeding event or a maximum duration of 10 min, mice were 
individually placed in a new home-cage for 5 min and allowed to eat a pre-weighed food 
pellet. The latency to feed was recorded as a measure of anxiety-like behavior. The amount 
of food consumed in the home-cage and the body weight loss during the food deprivation 
period was calculated to determine the animal’s appetitive drive. 
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Open field 
The open field (OF) consisted of an opaque quadratic box (50x50x40 cm) semi-permeable to 
infrared light (TSE Systems) with an illuminated floor (between 50 and 100 lx from the walls 
to the center of the arena)14. Mice were individually placed in one corner of the arena and 
their movements were automatically recorded during a 30-min period using an infrared-
sensitive CCD camera that was positioned above the center of the box and was controlled 
by VideoMot2 software (TSE Systems). This software was also used to evaluate the distance 
traveled and the number of vertical rears as measures of locomotor activity, as well as the 
time each mouse spent in the central area as a measure of anxiety-like behavior. 
Sociability and preference for social novelty 
The test apparatus was of a black quadratic open field (50x50x40 cm) semi-permeable to 
infrared light (TSE Systems). Mice were habituated to the testing chamber during the 30-min 
OF test, which was performed prior to the 2-trial social interaction test. In the first 10-min 
trial (sociability test), mice were given a choice between exploring an unfamiliar mouse 
that was enclosed in a small wire cage or an empty cage. The small cages were located 
in the upper left and upper right corner of the OF and the position of the cage containing 
the stranger mouse vs. the empty cage was randomly alternated between animals to 
prevent possible effects of side preference. In the second 10-min trial (test of preference 
for social novelty), mice were given a choice between exploring the first, now familiar 
mouse or a novel, unfamiliar mouse. Behavior was recorded and analyzed with VideoMot2 
(TSE Systems). Measures taken included the total distance traveled as well as the number 
of visits and time spent in each interaction zone (empty vs. mouse and familiar vs. novel, 
respectively). 
Barnes maze 
The Barnes maze was performed to assess visuospatial learning and memory. The apparatus 
consisted of a circular grey platform (120 cm in diameter) with 40 holes around its 
circumference (each with 5 cm in diameter) with one of them containing an escape box (TSE 
Systems). Visual cues were located around the platform to allow visuospatial orientation. 
Each mouse was individually placed in the center of the maze and behavior was recorded 
until the mouse found the escape box or for a maximum duration of 3 min. Mice were 
trained to find the hidden box for 8 days (18 trials; acquisition phase). Afterwards, the 
position of the escape box was changed and the mice were tested for 5 additional days (12 
trials; reversal phase). Behavior was automatically recorded using VideoMot2 (TSE Systems) 
and various parameters were measured, namely latency to escape, distance traveled and 
velocity. The number of primary errors, defined as the number of times a mouse poked its 
head around a wrong hole before the first encounter with the escape hole, were manually 
scored. 
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5-choice serial reaction time task 
The 5-choice serial reaction time task (5-CSRTT) was used to assess attention and impulsivity16. 
Mice were trained in an operant conditioning chamber (20x15x15 cm), enclosed within a 
housing and connected to a computer system with software (OBS V3.07, TSE Systems). The 
rear wall of the chamber had a curved shape and carried an array of five stimulus holes (2 
cm in diameter, 3 cm deep and 1.5 cm above the floor), each equipped with an infrared 
photocell beam to detect nose-pokes, a LED stimulus light to provide illumination of the 
hole, and a pellet dispenser to deliver a 20 mg dustless food pellet (Bio-Serv, Flemington, 
NJ) directly into the hole. In addition, the chamber was equipped with a house light (30 lx) 
mounted in the front wall. 
Food	restriction:	
Throughout testing, mice were maintained at 80-85% of their free feeding weight by 
restricting the access to food to 1.5-2.5g/day/mouse (depending on the daily weight loss 
and the number of pellets eaten during testing). Food restriction started 4 days prior to the 
beginning of the experiment. 
Habituation:	
During habituation, mice were familiarized with the testing chamber and trained to associate 
nose-poking into a lit hole with reward. Each trial started with simultaneous illumination of 
all five holes and immediate delivery of two food pellets into each hole (10 pellets in total) 
and lasted for 5 min or until the mouse made a nose-poke in each of the five holes. Mice 
received 8 habituation sessions on 4 consecutive days. 
Autoshaping:	
In 5 autoshaping sessions (1 session/day), mice were trained to discriminate between 
nose-pokes that lead to reward (lit holes) and those that do not (unlit holes). A session was 
terminated after 30 completed trials or a maximum duration of 20 min. Each trial started 
with the illumination of one of the five holes (in pseudo-random order). The hole remained 
illuminated until a response was made into that hole. If an animal made a nose-poke into the 
lit (correct) hole, a pellet was delivered immediately and the stimulus light was extinguished. 
The next trial was initiated after an intertrial interval (ITI) of 5 s. Responses into unlit holes 
were counted but had no further consequences. Parameters measured included the total 
number of nose-pokes, the average latency to complete a trial (correct response latency), 
the number of trials completed, the number of pellets eaten, and the total duration of the 
session. 
Training:	
During acquisition of the 5-choice visual discrimination task, mice were trained for one 
session/day. Each session started after a 5 s habituation period and terminated after 60 
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trials or a maximum duration of 20 min. Each trial started with an ITI of 10 s, followed by 
the illumination of one of the five holes (in pseudorandom order) for a predefined stimulus 
duration (SD). The SD was initially set to 20 s and gradually decreased to 10, 5 and 2 s. The 
SD was followed by a limited hold (LH) period of 2 s, during which the stimulus light was 
switched off but a nose-poke was still considered a correct response. A nose-poke into the 
correct hole during the SD or LH was rewarded with a food pellet and followed by the next 
ITI. A nose-poke into one of the four unlit (incorrect) holes was punished by a timeout period 
of 5 s, signaled by the illumination of the house light. A response during the last second of 
the ITI prolonged this interval for another second in order to prevent stimulus presentation 
while an animal was not able to pay attention17. Mice received one training session for 
the 20 s stimulus and 5 sessions for the 10, 5 and 2 s stimuli. The software automatically 
recorded the number of correct responses (nose-pokes into lit holes during the SD or LH), 
incorrect responses (nose-pokes into unlit holes during the SD or LH), premature responses 
(nose-pokes during the ITI), omission errors (number of trials without response), correct 
and incorrect response latencies (time between stimulus onset and response), the number 
of trials completed and the duration of the session. Accuracy was calculated as percentage 
of correct responses [= correct responses / (correct+incorrect responses) x 100]. Timeout 
responses were calculated as the difference between the total number of nose-pokes, 
premature nose-pokes, correct and incorrect nose-pokes. 
Porsolt swim test 
This test is used to assess learned helplessness as a hallmark of depression-like behavior. 
Mice were placed in a 1000 ml glass beaker filled with water (~27°C) to a height of 15 cm. 
Behavior was automatically recorded for 6 min using VideoMot2 (TSE Systems), and the 
percentage of time each mouse spent floating, swimming and climbing was calculated. 
Fear conditioning 
An automated fear conditioning chamber (TSE Systems) was used to assess associative 
fear learning and memory. During conditioning (day 0), mice were subjected to a 60 
s habituation phase followed by the presentation of an auditory cue (80 dB, 4 kHz tone; 
conditioned stimulus, CS) for 20 s that co-terminated with a 0.80 mA scrambled footshock 
(unconditioned stimulus, US) during the last 2 s. Mice received three CS-US pairings with an 
intertrial interval of 60 s. On day 1, mice were tested for cued fear memory by presentation 
of the auditory cue for 180 s in a modified environment. On day 2, mice were exposed to the 
original conditioning chamber for 300 s to assess contextual fear memory. During the entire 
experiment, behavioral responses like distance traveled, rearing, activity (the duration of 
movement above a speed threshold of 2cm/s), maximum speed, jumping and freezing 
(complete immobility for a duration of >2s) were automatically recorded via infrared light 
beams. 
CADHERIN 13 87
2
Corticosterone measurements 
Baseline stress hormone levels were assessed prior to the beginning of the emotionality test 
battery trough the measurement of corticosterone (CORT) metabolites in fecal samples18. For 
sampling, the mouse cages were changed the day before feces collection and fecal samples 
were pooled according to genotype (n=6-7 samples/genotype consisting of 2 mice/sample). 
Following collection, fecal samples were stored at -20°C for further use. 0.05 g of the dried 
sample were extracted using 80% methanol and corticosterone metabolite levels were 
determined in a 5alpha-pregnane-3beta,11beta,21-triol-20-one enzyme immunoassay. 
One week after completion of the behavioral test batteries, mice were anesthetized with 
isoflurane and blood samples were collected from the heart. Plasma CORT concentrations 
were determined by enzyme-linked immunosorbent assay (ELISA, Demetitec Diagnostics 
GmbH, Kiel, Germany) following manufacturer´s instructions.
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Fig. S1. Generation of a constitutive Cdh13 knockout mouse. 
(A) Schematic representation of the Cdh13	 knockout first targeting construct expressed in ES cells that were 
injected into C57Bl6/N blastocysts. Afterwards, Cdh13	 knockout first mice were bred with Flp-deleter mice in 
order to remove the FRT-flanked cassette (containing both the LacZ	reporter gene and the neomycin resistance 
gene). The resulting Cdh13	conditional (floxed) mice were intercrossed with constitutive Cre-deleter mice, which 
induced the recombination of exon 3 and the generation of a truncated protein in the Cdh13	knockout (Cdh13-/-) 
mice. (B) Western blot analysis of mouse brain lysates shows, in wild-type (Cdh13+/+) mice, a prominent band of 
approximately 90 kDa corresponding to the mature CDH13 protein. This band could not be detected in Cdh13-/- 
 mice, whereas reduced levels were observed in heterozygote (Cdh13+/-) mice, suggesting a gene dose effect. 
GAPDH antibody was used to confirm the equal loading in all lanes. (C) Absence of CDH13 protein in the brains of 
Cdh13-/- mice was also confirmed by immunohistochemistry. No stained cells or fibers were found in any region of 
the brain (i.e. cortex or hippocampus). Scale bars 300μm. Abbreviations: FRT, Flippase Recognition Target; En2 SA, 
splice acceptor of mouse En2 exon; IRES, Internal Ribosome Entry Site; ßgal, ß-galactosidase; pA, polyadenylation 
sequence; loxP, locus of X-over P1; ßact: ß-actin; Neo, Neomicin resistance gene; ACTB, ß-actin gene; Flp, Flippase; 
hCMV, human cytomegalovirus; +, wild-type; -, knockout; GAPDH, Glyceraldehyde 3-phosphate dehydrogenase.
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Fig. S2. Histological investigation of CDH13 in GABAergic interneurons of adult mouse Stratum oriens (SO). 
(A) Colocalization of CDH13 with neurochemical markers of GABAergic interneurons in the SO of the dorsal and 
ventral hippocampus. Higher colocalization was observed in the dorsal part of the hippocampus, n=3; 100% = 
GABAergic marker-positive cells; percentages calculated from median. (B) Stereological quantification of PV, SOM 
and nNOS-positive cells in the SO of Cdh13+/+, Cdh13+/- and Cdh13-/-	mice; n=7-9 per group; bars represent mean 
of estimated population number (first row), mean SO volume (second row), and mean of cell density (calculated 
from the population numbers and volumes). Error bars represent SEM; Kruskal-Wallis test revealed no significant 
differences between genotypes.
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CDH13 MYC Merged
Fig. S3. Confirming the specificity of CDH13 rabbit antibody.
Immunofluorescence staining for CDH13 (green) and MYC (red). Triangles indicate CDH13 and MYC double-positive 
puncta. Scale bar: 1μm.
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Fig. S4. Nissl staining in Cdh13+/+ and Cdh13-/- adult mouse brains. 
No gross morphological defects were detectable in Cdh13-/- mice. Scale bar: 500μm.
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Fig. S5. Body weight gain, feeding behavior and stress hormone levels are not affected by Cdh13 genotype. 
(A) Body weight gain at different stages of age did not significantly differ between Cdh13-/-, Cdh13+/- and Cdh13+/+ 
mice (n=7-36/genotype). (B) Food intake and (C) water intake were similar in all three genotypes (n=13-15 cages/
genotype, 2 mice/cage). (D) Fecal CORT (n=6-7 cages/genotype, 2 mice/cage) and (E) plasma CORT (n=6/genotype) 
levels were not significantly altered in Cdh13-/- and Cdh13+/- mice as compared to Cdh13+/+ mice. Data are shown as 
mean±SEM. Abbreviations: CORT, corticosterone.
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Fig. S6. Postsynaptic knockdown of Cdh13 in CA1 pyramidal cells has no effect on synaptic transmission. 
(A-D) Stimulation in Stratum	oriens (A) layout experiment (B) example trace of IPSC (C) IPSC amplitude for each 
recorded pair (gray dots) and average (black dot) (D) bar graph showing average IPSC amplitude (n=13/3). (E-
H) Stimulation in stratum	radiatum (E) layout experiment (F) example trace of IPSC (G) IPSC amplitude for each 
recorded pair (gray dots) and average (black dot) (H) bar graph showing average IPSC amplitude (n=17/4). (I-M) 
Stimulation of Schaffer collaterals for AMPA- (J,K) and NMDA response (L,M) (I) layout experiment (J) example 
trace of EPSC (K) bar graph showing average AMPA amplitude (n=13/2) (L) example trace of mEPSC (M) bar graph 
showing average NMDA amplitude (n=13/2). Bar graphs are shown as mean±SEM. N is shown as number of cells/
number of animals.
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Fig. S7. No differences in the concentrations of the most important neurotransmitters and some of their 
metabolites were found in total hippocampal samples of Cdh13+/+, Cdh13+/- and Cdh13-/- mice. 
(A) Levels of GABA and Glutamate. (B) Concentration of monoamines and their metabolites. Data are presented 
as mean±SEM; n=7 per group. Concentrations were statistically compared between genotypes using Kruskal-
Wallis test. Abbreviations: Glu, glutamate; GABA, gamma-butyric acid; NA, norepinephrine; DA, dopamine; MHPG, 
3-methoxy-4-hydroxyphenylglycol; DOPAC, 3,4-dihydroxyphenylacetic acid; 5-HT, serotonin; 5-HIAA, 5-hydroxy 
indole acetic acid; HVA, homovanillic acid.
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Fig. S8. Anxiety-like behavior is not affected by Cdh13 genotype. 
(A) Total distance traveled, (B) % number of open arm entries and (C) % time spent on the open arms of the 
elevated plus maze did not significantly differ between Cdh13+/+, Cdh13+/- and Cdh13-/- mice (n=7-8/genotype). 
(D) Total distance traveled, (E) latency to enter the lit area and (F) % time spent in the lit area of the light/dark 
box were not significantly altered in Cdh13-/- and Cdh13+/- mice as compared to Cdh13+/+ mice. (G) No genotype 
differences were found for the number of marbles buried (n=7-8/genotype). (H) The latency to feed and (I) food 
consumption during 5 min after the novelty-suppressed feeding test revealed no significant differences between 
Cdh13+/+, Cdh13+/- and Cdh13-/- mice (n=10/genotype). Data are presented as mean±SEM.
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Fig. S9. Cdh13-/- and Cdh13+/- mice show normal social behavior. 
(A) Total distance traveled was significantly decreased during the test of preference for social novelty as compared 
to the sociability test. However, no significant genotype effect was observed for the total distance traveled. (B) 
Total interaction time was significantly increased during the test of preference for social novelty as compared to 
the sociability test. However, no significant genotype effect was observed for total interaction time. (C, left panel) In 
the first trial, all mice showed significant levels of sociability (preference towards the cage containing an unfamiliar 
mouse over an empty cage). (C, right panel) In the second trial, all mice showed preference for social novelty 
(significantly increased interaction time with the novel mouse compared to the familiar mouse). N=7-8/genotype. 
Data are presented as mean±SEM. *p<0.05, ***p<0.001.
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Fig. S10. Depression-like behavior is not affected by Cdh13 genotype. 
(A) Sucrose preference, a measure of anhedonia, was not significantly altered in Cdh13-/- and Cdh13+/- mice compared 
to Cdh13+/+ mice (n=6-7 cages/genotype, 2 mice/cage). (B) Floating duration in the Porsolt swim test, a measure of 
behavioral despair, was similar in all three genotypes (n=17-20/genotype). Data are shown as mean±SEM.
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Supplementary figure 10
Fig. S11. Cdh13-/- and Cdh13+/- mice show normal habituation, autoshaping and training performance in the 
5-CSRTT. 
(A) The average response latency did not significantly differ between genotypes and habituation sessions. (B) The 
number of pellets eaten significantly increased over habituation sessions in all mice. (C) The average latency to 
make a correct response significantly decreased and (D) the number of pellets eaten increased in all genotypes 
over autoshaping sessions. (E) The latency to make a correct response significantly decreased and (F) the number 
of pellets eaten significantly increased in all mice when the stimulus duration decreased. N=10/genotype. Data are 
shown as mean±SEM. *p<0.05, ***p<0.001.
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Fig. S12. Footshock reactivity and acquisition of conditioned fear is not affected by Cdh13 genotype. 
(A) Reactivity to footshock, as measured by the maximum velocity, did not significantly differ between Cdh13+/+, 
Cdh13+/- and Cdh13-/- mice. (B) Pre-shock freezing (before the first CS-US pairing) and post-shock freezing (after the 
last CS-US pairing) was similar in all three genotypes. However, post-shock freezing was significantly higher than 
pre-shock freezing, indicating normal acquisition of conditioned fear in all mice. (C) Locomotor activity tended to 
be higher in Cdh13-/-	mice compared to Cdh13+/+ mice during both cued and contextual fear memory test. N=9-10/
genotype. Data are shown as mean±SEM. #p<0.1, ***p<0.001.
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Table S1. Primer oligonucleotide sequences used for the genotyping of Cdh13-modified mouse 
lines
Mouse line/allele Forward Primer (5’→3’) Reverse Primer (5’→3’) Amplicon size (bp)
Flp CACTGATATTGTAAGTAGTTTGC CTAGTGCGAAGTAGTGATCAGG 725
hCMV-Cre GCGCGGTCTGGCAGTAAAAAC CGCCGCATAACCAGTGAAACA 117
Cdh13 ko first ATCACGACGCGCTGTATC ACATCGGGCAAATAATATCG 108
Cdh13 floxed TGGTTCTGCTCCAAGACTCAG ATTAGGGACTATCCTGGGCTA 437 (fl) 233 (wt)
Cdh13 ko TGGTTCTGCTCCAAGACTCAG CCAGGAAGAGATAAAGCCAGG 478 (ko) 1190 (wt)
Abbreviations: bp, base pairs; fl, floxed; ko, knockout; wt, wildtype.
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Table S2. Morphological parameters of reconstructed CA1 pyramidal cells in Cdh13-/- and Cdh13-/- 
mice
Morphology Cdh13+/+ SEM Cdh13-/- SEM P (T-test) Significance
Basal Dendrites
Quantity 4.3 0.6 4.6 0.6 0.773  
Nodes 17.0 1.9 13.0 1.4 0.117  
Ends 21.3 2.2 17.6 1.9 0.212  
Length(µm) 1631.4 263.3 1398.2 173.1 0.463  
Mean length 384.9 71.9 314.2 25.5 0.345  
Apical Dendrite
Nodes 31.5 1.6 40.6 1.4 0.001 **
Ends 32.3 1.5 41.9 1.7 0.002 **
Length(µm) 3041.5 436.1 4521.4 478.9 0.046 *
Convex Hull
Area (µm²) 89281 16353 86809 5788 0.959  
Perimeter (µm) 1322 88 1297 37 0.908  
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Table S3. Intrinsic properties of CA1 hippocampal neurons
Electrophysiology WT SEM KO SEM P (T-Test) Significance
Basal Properties
V
Rest
-61.7 2.0 -60.7 1.3 0.214  
I
sag 
(mV) -86.1 2.0 -87.9 2.3 0.082  
Sag Index 0.8 0.1 0.7 0.1 0.205  
RM (MΩ) 166.4 44.7 158.1 42.7 0.689  
Tc (ms) 21.9 5.3 26.3 4.6 0.065  
Action Potentials
APs at Rheobase 6.8 6.9 8.1 5.7 0.639  
APs at 2x Rheobase 15.6 7.4 16.7 5.5 0.752  
AP Threshold (mV) -40.6 2.9 -41.0 4.7 0.830  
AP Amplitude (mV) 85.5 6.3 90.5 5.0 0.069  
Rise Time (20-80%) 0.2 0.0 0.2 0.0 0.304  
Half-width (ms) 1.2 0.1 1.2 0.1 0.892  
Slope Rise (mV/ms) 276.2 54.5 306.0 37.1 0.173  
Slope Decline (mV/ms) 66.8 6.6 66.8 7.5 0.989  
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3.1 Abstract
Cortical networks require a finely tuned coordination of excitatory and inhibitory inputs in 
order to function normally. However, the mechanisms underlying this coordination remain 
elusive. Here, we investigated the role of the ADHD-linked protein Cadherin 13 (CDH13) in 
the regulation of parvalbumin positive (PV+) perisomatic inhibitory synapses formed onto 
pyramidal neurons in the CA1 region of the mouse hippocampus. We show that conditional 
removal of CDH13 from PV+ interneurons leads to an increase in PV+ perisomatic puncta. 
Consistently, we show that CDH13 is localized to perisomatic synapses both in	 vitro and 
in	vivo. Western blot analysis and cell-adhesion assays reveal interaction between CDH13 
with both integrin (ITG) β1 and ITGβ3. Interestingly, co-expression of the GABAA receptor 
subunit α1 with ITGβ3, but not with ITGβ1, abolished aggregation in the cell-adhesion assay, 
indicating opposite roles for these integrins in	vivo. Application of echistatin, an inhibitor of 
ITGβ1/3 interaction, reduces IPSC amplitude in acute slices from Cdh13+/+, but not in Cdh13-
/- mice, indicating that CDH13-ITGβ1/3 interaction plays an important role in the regulation 
of inhibitory synapses in the hippocampus. In sum, our data suggests ITGβ1 and ITGβ3 have 
opposite roles in the regulation of inhibitory synaptic strength via interaction with CDH13.
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3.2 Introduction
The brain is a complex neural network that requires a precisely tuned interplay of excitatory 
and inhibitory signals in order to function properly. Disruptions in synaptic connectivity 
have been shown to underlie neurodevelopmental disorders1. In recent years, research 
has focussed on the role of the inhibitory system in these conditions, including autism and 
schizophrenia, and epilepsy2. 
One of the genes implicated in neurodevelopmental disorders is Cadherin 13 (CDH13, 
also known as T-Cadherin or H-Cadherin)3. CDH13 has been linked to attention-deficit/
hyperactivity disorder (ADHD)4–6 and comorbid disorders such as autism, schizophrenia, 
alcohol dependence and violent behaviour7–10. CDH13 is an atypical member of the 
cadherin superfamily since it lacks a transmembrane- and intracellular domain, and instead 
is anchored to the membrane via a glycosylphosphatidylinositol (GPI) anchor11,12. Because 
of this relatively weak connection to the outer membrane13, CDH13 has been proposed to 
serve as a regulatory protein, rather than an adhesion molecule14,15, as evidenced by its role 
in axon guidance and outgrowth16,17, as well as a recent report describing a role for CDH13 
in regulating apoptosis during cortical development18. We recently showed that CDH13 is 
localized to the presynaptic compartment of inhibitory interneurons, and that Cdh13 knock-
out mice (Cdh13-/-) show an increased inhibitory, but not excitatory, drive onto hippocampal 
CA1 pyramidal neurons3. In addition, these mice display deficits in learning and memory3. 
However, the mechanism via which CDH13 regulates inhibitory synapses and impacts 
learning and memory remains unknown.
Since CDH13 is an extracellular, GPI-anchored protein it requires binding partners to exert its 
regulatory properties8. Previous studies have shown CDH13 to interact with various proteins 
(for review see Rivero et al., 2012), including the GABAA receptor α1 subunit (GABAAα1) 
and integrin β3 (ITGβ3)20. In addition, CDH13 regulates the internalization of β1 integrin 
(ITGβ1)21. Interestingly, ITGβ1 and ITGβ3 have opposite functions in regulating synaptic dwell 
time of glycine receptors in spinal cord neurons, thereby acting as bidirectional regulators of 
the synaptic strength of these inhibitory synapses22. Both ITGβ1 and ITGβ3 are expressed in 
hippocampal pyramidal neurons, where they play a role in regulating glutamatergic synaptic 
function23,24. However, no role in GABAergic synapses has been described for these integrins 
in the hippocampus. 
In this study, we investigated the role of CDH13 in the regulation of inhibitory synaptic 
transmission. We show that CDH13 is localized to perisomatic synapses where it colocalizes 
with GABAAα1, suggestive of synapses from parvalbumin positive (PV+) interneurons. 
Consistent with a role as a negative regulator of GABAergic synapses, a PV+ interneuron 
specific knock-out mouse for Cdh13 shows an increase in PV+ puncta onto CA1 pyramidal 
neurons. We then show that CDH13, ITGβ1, ITGβ3 and GABAAα1 can bind in	 vitro, and 
facilitate cell adhesion. Interestingly, while both ITGβ1 and ITGβ3 are able to bind with 
CDH13 in a trans-synaptic fashion, co-expression of GABAAα1 with ITGβ1, but not with 
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ITGβ3, disrupts this interaction. These data suggest regulation of PV+ synapses is mediated 
through a CDH13-ITGβ1/ITGβ3 interaction. Finally, we show that echistatin, an inhibitor of 
ITGβ1 and ITGβ3 function25, reduces inhibitory synaptic strength onto CA1 pyramidal neurons 
in wild-type (WT) mice, but not in Cdh13PV-/- mice. These data point towards an important 
role for CDH13 in PV+ synapses via CDH13-ITGβ1/ITGβ3 interaction, and indicates a that 
ITGβ3 has opposite functions at inhibitory synapses, compared to its previously described 
role in excitatory synapses26, which could play an important role in the maintenance of the 
excitatory/inhibitory (E/I) balance.
3.3 Results
3.3.1 Increased number of perisomatic PV+ puncta in Cdh13PV-/- mice
We have previously shown that in hippocampus, CDH13 is localized to the presynaptic 
compartment of inhibitory synapses3, and that Cdh13-/- mice show an increase in inhibitory 
synaptic transmission onto CA1 pyramidal neurons. However, the mechanism underlying 
this increase remains unknown.  In order to further investigate the function of CDH13 at 
inhibitory synapses, we first performed an immunocytochemical staining on dissociated 
rat hippocampal neurons for CDH13 and GABAAα1. Consistent with our previous findings3, 
we observed colocalization of CDH13 and GABAAα1 on dendrites. In addition, we found 
colocalized puncta on neuronal somata (Fig. 1A). DAB-staining for CDH13 on postnatal day 
(P) 21 hippocampal sections revealed intense staining in stratum	pyramidale, suggestive 
of perisomatic synapses targeting the soma of pyramidal neurons (Fig. 1B). Perisomatic 
synapses are formed by two distinct type of basket cells, PV+ and cholecystokinin (CCK) 
positive27. GABAAα1 is most abundant in PV+ synapses, while CCK-positive synapses are 
enriched for GABAAα227,28. Therefore, these data suggest that CDH13 is localized to PV+ 
synapses. 
To focus specifically on the role of CDH13 in PV+ synapses we conditionally deleted Cdh13 
from PV+ cells by crossing Cdh13lox/lox mice with PV-cre mice, to create Cdh13PV-/- mice. 
Three-week old mice were sacrificed and immunohistochemistry was performed to label 
PV synapses. We quantified the density of PV+ puncta/µm cell perimeter in CA1 stratum	
pyramidale, where most PV synapses are formed29. Cdh13PV-/- mice showed an increased 
density of PV puncta compared to Cdh13+/+ mice (Cdh13+/+ 0.18 ± 0.01 puncta/µm; Cdh13PV-/- 
0.23 ± 0.01 puncta/µm ; P = 0.03 : Fig. 1C-E). This is consistent with our previous data 
showing an increased frequency of miniature inhibitory postsynaptic currents (mIPSCs) in 
Cdh13-/- mice3, and indicates that this phenotype is, at least in part, caused by an increase in 
the number of PV+ synapses. 
PV cell activity is important for normal network function2,30,31, and PV staining intensity has 
been shown to correlate with PV cell activity32. We therefore wondered if PV cell activity was 
affected by the increase in synapse number. We quantified the intensity of PV in our slices 
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Fig. 1: CDH13 is localized in perisomatic synapses and regulate synapse number.
A) Immunocytochemical staining showing colocalization (arrows) of CDH13 and GABAAα1 in dissociated cultures. 
B) DAB staining of CDH13 expression in hippocampus. C) Immunohistochemical staining of the CA1 for parvalbumin 
(PV) and DAPI in CDH13+/+ and	Cdh13PV-/- mice. D,E) Cumulative plot (D) and quantification (E) of PV puncta/µm 
circumference for CDH13+/+ and	 Cdh13PV-/- mice. F-H) Cumulative plot (F), quantification (G) and representative 
images (H) showing the intensity of PV immunoreactivity for CDH13+/+ and	Cdh13PV-/- mice. (I) Quantification of the 
number of PV+ cells/section in CDH13+/+ and	Cdh13PV-/- mice. S.O., Stratum	oriens; S.P., Stratum	pyramidale; S.R., 
Stratum	radiatum; O.L.M., Stratum	lacunosum-moleculare . Scale bars are 10µm. Data are presented as average ± 
SEM. N is indicated in the bars for each condition. * P˂0.05 ; ** P˂0.01. Student’s t-test.
and found PV intensity to be reduced by 11% in Cdh13PV-/- compared to Cdh13+/+ mice (P = 
0.001, Fig. 1F-H), indicating reduced activity of PV cells. 
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A recent study has shown that CDH13 has a protective role in apoptosis of cortical 
interneurons18. Thus, the increased PV+ synapse number could be caused by either an 
increase in PV+ cells, or by the number of synapses formed by each PV+ cell. To distinguish 
between these possibilities, we quantified the number of PV+ cells per section. We found 
that the number of PV+ cells is unchanged between Cdh13+/+ and Cdh13PV-/- mice (Cdh13+/+ 
29.0 ± 1.98 cells/section ; Cdh13PV-/- 28.7 ± 2.51 cells/section; P = 1.00 : Fig. 1I), showing that 
deletion of Cdh13 from PV cells does not affect the number of PV cells in the hippocampus 
at P21. This suggests that the observed increase in PV+ puncta is due to an increased 
number of synapses formed by individual PV+ interneurons. Together, these data show that 
deletion of Cdh13 in PV cells negatively regulates the number of PV+ synapses, and affects 
PV interneuron activity in general.
3.3.2 Interactions between CDH13, ITGβ3 and GABAAα1 in vitro
The observed increase of PV+ puncta suggests that CDH13 is a negative regulator of 
synapse number. However, the underlying mechanism remains unknown. The fact that 
CDH13 is a GPI-anchored protein suggests binding to other membrane bound proteins 
is required to exert its function8. Since CDH13 is not expressed in pyramidal neurons in 
the hippocampus3, a heterophilic interaction is likely to be required for CDH13 to exert its 
function. Interactions of CDH13 with ITGβ1 an  ITGβ3 have previously been suggested20,21. 
Overexpression of CDH13 increases ITGβ1 expression in squamous carcinoma cells21, even 
though a direct interaction has not been reported. However, ITGβ3 has been reported to 
co-immunoprecipitate with CDH13 from endothelial cells20. Additionally, ITGβ1 and ITGβ3 
have been shown to differentially regulate lateral diffusion of glycine receptors in spinal cord 
neurons22. Lateral diffusion is regulated by stabilizing or destabilizing gephyrin via ITGβ1 
and ITGβ3, respectively22, which is important for the stabilization of both GABA- and glycine 
receptors33. PV+ synapses are GABAergic and are enriched for the GABA receptor subunit 
α1 (GABAAα1)28. We asked ourselves whether CDH13 could play a role in regulation of PV 
synapse stability onto pyramidal cells via ITGβ1 and ITGβ3.
We started by confirming the interactions between ITGβ1, ITGβ3, GABAAα1 and CDH13. We 
co-transfected GFP-tagged Itgβ3 and myc-tagged Cdh13	into HEK293T cells and performed 
co-immunoprecipitation (co-IP) experiments with an anti-GFP antibody (Fig. 2A). Western-
blot analysis using an anti-myc antibody to detect myc-tagged CDH13 revealed a ~95 kDa 
band, consistent with the predicted size of CDH133,12. Conversely, co-IP using anti-myc and 
subsequent western blot using anti-GFP revealed the presence of ITGβ3 (Fig. 2B). These 
data indicate an interaction between CDH13 and ITGβ3 in	 vitro. We performed similar 
experiments using GFP-tagged GABAAα1 and myc-tagged CDH13, showing an interaction 
between these proteins (Fig. 2C). Finally, we showed interaction between myc-GABAAα1 
and GFP-tagged ITGβ3 (Fig. 2D). Unfortunately, we did not manage to obtain an antibody 
against ITGβ1 that worked in our hands. 
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Fig. 2: CDH13 interacts with integrinβ3 (ITGβ3) and GABAAα1 in vitro. 
A-D) Western blot showing coimmunoprecipitation of A) CDH13 with ITGβ3 and B) ITGβ3 with CDH13. C) CDH13 
with GABAAα1 and D) ITGβ3 with GABAAα1. E) Immunohistochemical staining for parvalbumin (PV) and ITGβ3 
showing colocalization (arrows). Scale bar is 10µm.
In addition to the ability to bind in	vitro, in	vivo interaction of CDH13, ITGβ3 and GABAAα1 
requires these proteins to be expressed in close proximity. CDH13 and GABAAα1 are 
expressed in the presynaptic compartment of PV cells, as shown above. We performed 
immunohistochemistry on Cdh13+/+ brain slices in stratum	pyramidale for PV and ITGβ3, and 
show that these proteins are juxtaposed (Fig. 2E). These results indicate that CDH13, ITGβ3 
and GABAAα1 are present in the same synapse, allowing them to interact. 
3.3.3 Differential roles for ITGβ1 and ITGβ3 in cell-adhesion assays
Since our data indicate that CDH13, ITGβ3 and GABAAα1 are present in the same synapse, 
we wanted to know their role in adhesion. To this end we used a cell-adhesion assay34. In 
this assay, we transfected HEK293T cells with a vector expressing CDH13, ITGβ1, ITGβ3 or 
GABAAα1 and quantified the degree of aggregation. As a positive control we first transfected 
HEK293T cells with either a cytosolic mCherry, Cadherin 2 (CDH2) or CDH13 (Fig. 3A), of 
which the relative strengths of binding are known13,35. mCherry-expressing HEK293T cells 
showed very little aggregation (T60/T0: 0.94 ± 0.01) consistent with its cytosolic expression, 
and indicative of very low baseline levels of adhesion of HEK293T cells in this 
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Fig. 3: Interactions of CDH13 in a cell-adhesion assay. 
A-G) Quantification of cell aggregation for indicated proteins. H) Visual summary of cell aggregation data: in 
the presence of GABAAα1, integrin (ITG) β1-expressing HEK293T cells, but not ITGβ3 expressing HEK293T cells, 
aggregate with CDH13-expressing HEK293T cells. N is indicated in the bars for each condition. * P˂0.05 ; ** P˂0.01 ; 
*** P<0.001. Student’s t-test.
assay. CDH2 has previously been shown to exert strong homophilic interaction35,36, and 
consistently showed strong aggregation in our assay (T60/T0: 0.58 ± 0.01). The aggregation 
of CDH2-expressing cells was depended on extracellular Ca2+, since we did not observe 
aggregation after replacement of Ca2+ with 2 mM of the calcium chelator ethylene glycol-
bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA), consistent with the reported 
Ca2+ dependence of cadherin interactions37. Homophilic interactions of CDH13 have been 
proposed, but are predicted to be weak compared to CDH2 homophilic interactions13. 
Indeed, in our assay CDH13-expressing HEK293T cells showed an intermediate value (T60/
T0: 0.68 ± 0.01). These experiments show that this assay has the sensitivity to distinguish 
between different strengths of cell-adhesion.
We then investigated the interactions between CDH13, ITGβ1, ITGβ3 or GABAAα1. GABAAα1 
was co-transfected with GABAAβ3 to ensure surface expression of these proteins38. An assay 
with GABAAα1 expressing HEK293T cells showed a weak homophilic interaction (T60/T0: 
0.79 ± 0.04 ; Fig. 3B). We then combined HEK293T cells expressing either CDH13 or GABAAα1. 
The resulting T60/T0 ratio (T60/T0: 0.78 ± 0.06) shows a value between the assays with 
only CDH13 and GABAAα1, indicating that there is no heterophilic adhesion between these 
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proteins (Fig. 3B). Conversely, while ITGβ1 shows no homophilic interaction, consistent with 
previous reports39, CDH13 and ITGβ1 showed homophilic interaction (T60/T0: 0.62 ± 0.02 
; Fig. 3C). ITGβ3 showed the same pattern as ITGβ1, displaying a stronger interaction with 
CDH13 (T60/T0: 0.60 ± 0.04 ; Fig. 3D) than either CDH13 or ITGβ3 alone. Next, we looked 
at the interaction between integrins and GABAAα1 in trans-synaptic conformation. A mix of 
ITGβ1 expressing and GABAAα1 expressing cells did not show interaction (Fig. 3E). We also 
found no interaction between ITGβ3 and GABAAα1 (Fig. 3F). 
We then wanted to investigate the aggregation using a protein arrangement as expected 
in	vivo. We expressed either ITGβ1 or ITGβ3 together with GABAAα1 in one population of 
HEK293T cells, representing the postsynaptic side. To represent the presynaptic side, we 
transfected HEK293T cells with CDH13. Surprisingly, we found that while ITGβ1/GABAAα1-
expressing cells displayed a strong interaction with CDH13 expressing cells (T60/T0: 0.63 
± 0.004), ITGβ3/	GABAAα1 expressing cells did not interact with CDH13 expressing cells 
(T60/T0: 0.93 ± 0.06 ; Fig. 3F), showing a T60/T0 ratio comparable to mCherry (P = 0.93). 
In conclusion, while both ITGβ1 and ITGβ3 show interaction with CDH13, co-expression 
of GABAAα1 with the integrins leads to a loss of interaction between CDH13 and ITGβ3, 
specifically (Fig. 3H). These data suggest that surface expression of ITGβ1/ITGβ3 might play 
a role in regulating the stability of CDH13-expressing synapses. 
3.3.4 Inhibition of ITGβ1 and ITGβ3 function reduced IPSC amplitude
If ITGβ1 and ITGβ3 play a role in inhibitory synapse stabilization via their interaction with 
CDH13, disruption of integrin function should affect inhibitory transmission. In order 
to investigate this, we performed whole-cell patch clamp recordings of CA1 cells of P21 
Cdh13+/+ mice, and recorded the IPSC following stimulation in Stratum	oriens, where CDH13 
expression is most abundant3. We recorded a baseline IPSC amplitude before performing 
a wash-in with either 100 nm Echistatin, an inhibitor of ITGβ1 and ITGβ325, or vehicle. 
We stimulated at 0.1 Hz and binned in 1 minute intervals. Amplitude was normalized to 
baseline to compare between cells. Echistatin wash-in caused a significant reduction in IPSC 
amplitude compared to the vehicle (Normalized amplitude: Vehicle 0.93 ± 0.04 , Echistatin 
0.73 ± 0.04 , P = 0.047 ; Fig. 4A,B), indicating that ITGβ1/ITGβ3 signalling plays a role in 
inhibitory synapse stability. To investigate if CDH13 is required for the stabilizing function of 
ITGβ1/ITGβ3 we repeated the experiment in Cdh13-/- mice3. Interestingly, Echistatin had no 
effect on IPSC amplitude compared to vehicle control in these mice (Normalized amplitude: 
Vehicle 0.79 ± 0.04 , Echistatin 0.80 ± 0.05 , P = 0.86 ; Fig. 4C,D). Together, these data indicate 
that ITGβ1/ITGβ3 play a role in synapse stability, and that this role is dependent on the 
presence of CDH13.
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Fig. 4: The integrin inhibitor echistatin reduces IPSC amplitude in Cdh13+/+, but not in Cdh13-/- mice. 
A,B) Example trace (A) and quantification (B) of IPSC amplitude following wash-in of vehicle or 100nM echistatin in 
Cdh13+/+ mice. Values are normalized to IPSC amplitude before wash-in. C,D) Example trace (C) and quantification 
(D) of IPSC amplitude following wash-in of vehicle or 100nM echistatin Cdh13-/- mice. Values are normalized to IPSC 
amplitude before wash-in. Data are presented as average ± SEM. N is indicated in the bars for each condition. * 
P˂0.05. Student’s t-test. 
3.4 Discussion
In this study we have shown that CDH13 plays an important role in the regulation of 
inhibitory synapses, and that deletion of Cdh13 from PV+ cells leads to an increase in 
PV+ puncta in stratum	pyramidale. Using co-immunoprecipitation experiments, we show 
that CDH13 has the ability to bind both GABAAα1 and ITGβ3, with which it colocalizes in 
perisomatic synapses. We then performed a cell-adhesion assay, and showed that HEK293T 
cells expressing either ITGβ1 or ITGβ3 form aggregates with CDH13-expressing HEK293T 
cells, indicative of a functional interaction between these proteins. Interestingly, while co-
expression of GABAAα1 with ITGβ1 does not affect aggregation, expression of GABAAα1 
with ITGβ3 completely abolishes aggregation with CDH13-expressing HEK293T cells, 
indicating opposing roles for ITGβ1 and ITGβ3. Finally, we show that echistatin, an inhibitor 
of ITGβ1 and ITGβ3 function, reduces the IPSC amplitude onto CA1 pyramidal cells in acute 
hippocampal slices from Cdh13+/+ mice, but not in Cdh13-/- mice. These data show that 
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CDH13 has a role in the maintenance of inhibitory synaptic connectivity, and that ITGβ1/
ITGβ3 are involved in this pathway.
The observation that deletion of Cdh13 from PV+ cells leads to an increase in PV+ puncta 
is consistent with our previous study3, where we show an increase in mIPSC frequency 
in Cdh13-/- mice. This increase in PV+ synapses is caused by an increase in the number of 
synapses formed by an individual PV+ cell, rather than by an increase in the number of PV+ 
cells, since we find no difference in PV cell number between Cdh13+/+ and Cdh13PV-/- mice. 
This observation seemingly contradicts a recent report, where it is shown that CDH13 plays 
a role in apoptosis and deletion of Cdh13 leads to a reduced number of interneurons at 
embryonic stages18. However, deletion in our mouse model is achieved by crossing Cdh13lox/
lox mice with PV-cre mice. In these mice, expression of Cre only start around P1440, leaving 
CDH13 expression unaltered at embryonic stages.
The increase in PV+ synapse number is accompanied by a reduction in PV intensity. 
PV intensity is closely linked to PV+ cell activity32, and thus suggests reduced PV cell 
activity in Cdh13PV-/- mice. While we cannot rule out a direct effect of CDH13 on intrinsic 
electrophysiological properties of PV+ interneurons, it is tempting to speculate about this 
reduced activity being the result of changes at the network level. An increased number of 
PV+ synapses onto pyramidal cells would reduce pyramidal activity, mainly via feed-forward 
inhibition27,41. The reduced activity of pyramidal neurons would in turn reduce reciprocal 
excitatory input to the PV+ neuron, thereby reducing their activity42,43. 
Consistent with previous findings, we show that CDH13 coimmunoprecipitates with ITGβ320, 
and that CDH13 has the ability to bind both ITGβ1 and ITGβ3 in the cell-adhesion assay. 
Interestingly, while co-expression of GABAAα1 does not affect the interaction between 
CDH13 and ITGβ1, co-expression of GABAAα1 with ITGβ3 completely abolishes interaction 
between CDH13 and ITGβ3. Both ITGβ1 and ITGβ3 are expressed by pyramidal neurons23,24, 
and as such would be expressed postsynaptically, together with GABAAα1. This points to the 
intriguing possibility that ITGβ1 and ITGβ3 would function as a molecular switch for synapse 
maintenance. A similar function for ITGβ1/ITGβ3 has been described previously in spinal 
cord neurons, where these integrins have opposite functions in the regulation of synaptic 
dwell time of glycine receptors through stabilisation (ITGβ1) and destabilization (ITGβ3) 
of the inhibitory synaptic scaffold protein gephyrin22, and via this mechanism regulate the 
strength of glycinergic synapses.
The differential function of ITGβ1/ITGβ3 would allow pyramidal neurons to control the 
amount of inhibitory input they receive. For example, a pyramidal neuron that needs to 
increase its inhibitory input could increase its ITGβ1/ITGβ3 ratio, thereby promoting the 
formation of inhibitory synapses onto itself via the stabilizing action of ITGβ1. This could be 
important in the maintenance of the E/I balance of individual pyramidal neurons44. It has 
recently been shown that cortical pyramidal neurons receive an amount of inhibitory synaptic 
input from PV+ interneurons that is proportional to the excitatory drive onto that pyramidal 
neuron, maintaining the E/I balance45. Since individual PV+ interneurons can differentially 
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regulate their inhibitory strength onto individual postsynaptic pyramidal neurons45, it is 
likely that pyramidal neurons instruct the regulation of inhibitory synapses onto themselves. 
The complex of CDH13, ITGβ1 and ITGβ3 could have a role in this regulation. Fig. 5 shows 
our model of the regulation of inhibitory synapse strength. Changes in pyramidal cell 
activity lead to changes in expression of ITGβ1/ITGβ3, possibly through activity-dependent 
gene expression46,47. By regulating the ratio of ITGβ1/ITGβ3, the pyramidal cell can control 
the relative abundance of these integrins expressed at the membrane in the synapse. By 
controlling the synaptic expression of these integrins, PV+ synapses can be stabilized (ITGβ1) 
or destabilized (ITGβ3) to strengthen or weaken these synapses, respectively. In this model, 
CDH13 functions as a partner for ITGβ1/ITGβ3 signalling, and might convey the molecular 
identity of the presynapse, a PV+ synapse, to the postsynaptic pyramidal neuron. Loss of 
CDH13 leads to the inability of the postsynaptic pyramidal neuron to regulate inhibitory 
synapses formed onto itself via regulation of the ITGβ1/ITGβ3 ratio. Indeed, in Cdh13PV-/- 
mice we observed an increased number of PV puncta formed in stratum	pyramidale, and 
in Cdh13-/- mice we previously reported an increase in inhibitory synapses3. The importance 
of CDH13 in this mechanism is underlined by our finding that while echistatin reduced 
inhibitory synaptic transmission in WT mice, it has no effect in Cdh13-/- mice. Of note, 
vehicle-treated Cdh13-/- mice show a trend (P=0.14) towards a reduced amplitude compared 
to vehicle treated Cdh13+/+	mice. While this could mean echistatin application on the Cdh13-
/- mice does not show additional reduction of the IPSC amplitude due to a flooring effect, 
these findings underline the role of CDH13 in the regulation of synapse stability. Future 
experiments knocking down either ITGβ1 or ITGβ3 in both Cdh13+/+	and	Cdh13-/- mice are 
required to dissect the precise contribution of these proteins in synaptic regulation and 
stability. 
Why does PV+ cell regulation require two integrins to be regulated, instead of just the 
regulation of ITGβ1 at the postsynaptic membrane? While our data does not answer this 
question, the answer most likely relates to the other functions these integrins have. ITGβ1 
is involved in excitatory long-term potentiation48,49, while ITGβ3 regulates AMPA receptor 
expression and is engaged in homeostatic scaling26,49,50.
 
Homeostatic scaling regulates 
neuronal activity via regulation of synaptic strength51,52. Indeed, surface expression of 
ITGβ3 is increased in response to blockade of network activity in cultured hippocampal 
neurons, and increases excitatory input onto pyramidal neurons50. Conversely, expression 
of dominant-negative ITGβ3 reduces excitatory inputs50. This action of ITGβ3, strengthening 
of excitatory synapses, is opposite as the function we hypothesize in our model. This leads 
to the exciting possibility that ITGβ3 has opposite functions in excitatory and inhibitory PV+ 
synapses. For example, when pyramidal cell activity decreases, ITGβ3 surface expression 
is increased. While in excitatory synapses this leads to an increase in synaptic strength50, 
inhibitory synapses get weakened. 
In summary, while ITGβ1 is required for the stabilization of GABAAα1-containing receptors at 
the inhibitory PV+ synapse via interaction with CDH13, ITGβ3 is important for the regulation 
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Fig. 5: Proposed model of the role of CDH13 in regulations of perisomatic PV synapses. 
The postsynaptic pyramidal neuron can increase the integrin (ITG) β1/β3 ratio to stabilize synapses (top half) or 
downregulate the ITGβ1/β3 ratio to destabilize synapses (bottom half).
of inhibitory synaptic strength. Due to the dual function of ITGβ3 at both inhibitory and 
excitatory synapses, it is able to link inhibitory and excitatory synaptic scaling in opposite 
ways towards increased or decreased activity, showing a very intimate link between these 
two opposing types of input during activity regulation.
3.5 Materials and Methods
Animals
Cdh13+/+ and Cdh13-/- mice were bred and reared in the Central Animal Facility of the Radboud 
University Nijmegen, Nijmegen, the Netherlands. Food pellets and water were provided ad 
libitum. The experimental procedures were approved by the Animal Ethics Committee of 
the Radboud University Nijmegen and conducted in accordance with the Dutch legislation. 
Cdh13PV+/+ and Cdh13PV-/- mice were bred and reared in the Central Animal Facility of the 
University of Würzburg, Würzburg, Germany. The experimental procedures were approved 
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by the boards of the University of Würzburg and the government of Lower Franconia, and 
performed according to the European Community guidelines for animal care and use.
For both lines, animals of both genders were sacrificed at P20-22. Every effort was made to 
minimize the number of animals used and their suffering.
Fluorescent	immunohistochemistry
Animals were anesthetized with isoflurane. Following decapitation, the brain was removed 
and fixated for 24h in 4% paraformaldehyde (PFA) at 4⁰C before being stored in phosphate 
buffered saline (PBS) at 4⁰C. Brains were embedded in agarose (2%, in PBS) and 100 µm 
coronal sections were cut using a vibratome (Leica, VT1000S). Free floating slices were 
incubated in blocking buffer containing 5% normal goat serum, 5% normal donkey serum, 
5% normal horse serum, 1% Bovine serum albumin, 1% glycine, 0.1% lysine and 0.4% Triton 
X-100 in PBS (blocking buffer) overnight (O/N) before incubation with primary antibody 
(parvalbumin, 1:250, Swant; integrin β3, 1:500, Abcam) O/N at 4⁰C. Sections were incubated 
with secondary antibody (goat anti-rabbit Alexa fluor 488, 1:2000, Invitrogen) for 3 hours 
(h) at room temperature (RT) and counterstained with Hoechst stain. Sections where then 
mounted using DAKO mounting medium and imaged using an apotome on an Axio Imager 
Z1 fluorescence microscope (Zeiss).
DAB	histochemistry
Animals were anesthetized with isoflurane. Following decapitation, the brain was removed 
and fixated for 24h in 4% paraformaldehyde at 4⁰C before being stored in PBS at 4⁰C. Before 
sectioning, brains were cryoprotected in 30% sucrose in PBS. Coronal sections (10 µm) were 
cut on a cryostate, collected on SuperFrost glass slides and stored at -20°C until further 
processing. Sections were incubated in blocking buffer for 2h and subsequently incubated 
in primary antibody (CDH13, 1:250, Millipore) O/N at 4⁰C. Sections were incubated with 
HRP-conjugated anti-rabbit secondary antibody, and stained using Di-aminobenzidine (DAB) 
solution with Nickel enhancer using the DAB peroxidase substrate kit (Vector, SK-4100).
Immunocytochemistry
Low-density primary hippocampal neuronal cultures were prepared from embryonic day 
18 rat pups as previously described53. Before fixation cells were gently rinsed with ice-cold 
PBS, followed by application of 4% PFA/4% sucrose in PBS for 15 min. Cells were incubated 
in blocking buffer for 1h and subsequently incubated in primary antibody (CDH13, 1:250, 
Millipore; VGAT, 1:500, Synaptic systems) O/N at 4⁰C. Sections were incubated with 
secondary antibody (goat anti-rabbit Alexa fluor 488, 1:2000, Invitrogen; goat anti-mouse 
Alexa fluor 568, 1:2000, Invitrogen) and mounted using DAKO mounting medium. Images 
were acquired using a Fluoview FV1000 confocal microscope (Olympus).
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Western	blot
Precleared HEK293T cell lysates co-transfected with myc-tagged Cdh13, GFP-tagged Itgβ3 
and myc-tagged GABAAα1 for 24 hours were incubated with mouse IgG (eBioscience), anti-
myc (Abcam) or anti-GFP (Invitrogen) antibodies (2.5 µg/ml lysate) at 4°C for 1h. Dynabeads® 
Protein G (50 µl per sample, Invitrogen) were then added and incubated for 1h at 4°C 
under gentle rotation. Samples were washed three times with lysis buffer (20 mM Tris, 150 
mM NaCl, 2 mM EDTA, 1 mM DTT and protease inhibitor, pH7.4). Co-immunoprecipitated 
proteins were detected by Western blotting. Samples were fractionated on 4%- 15% precast 
SDS-PAGE gels (Bio-Rad) and then blotted onto a nitrocellulose membrane (Bio-Rad). 
Membranes were subsequently incubated for 1h at RT in 5% milk in PBS-Tween to prevent 
non-specific binding. Primary antibodies used were: anti-myc (Abcam), anti-GFP (Invitrogen) 
or anti-Υ-Tubulin (Sigma) as loading control. Secondary antibodies used were: goat anti-
mouse HRP (Jackson Immuno Research Laboratories) and goat anti-rabbit HRP (Invitrogen). 
Images were acquired with ChemiDocTM imaging system (Bio-Rad).
Cell-adhesion	assay
The cell aggregation assay was performed as described previously34. HEK293T cells were 
transfected with indicated constructs via calcium phosphate transfection when they reached 
a confluency of 50%. To assess the rate of transfection, additional vectors encoding GFP or 
mCherry were used to mark the transfected cells. At least 26h after transfection the rate of 
successfully transfected cells was determined. In case the transfection rate was above 75% 
aggregation assays were performed.
Cells were trypsinized and collected by centrifugation for 5 min at 4°C and 1000 rpm and 
washed once with serum-free medium, before being resuspended by pipetting in Hank´s 
Balanced Saline Solution (HBSS) (55 mM NaCl, 40 mM KCl, 15 mM MgSO4, 10mM CaCl2, 
20mM glucose, 50 mM sucrose, 2 mg/ml bovine serum albumin, and 20 mM Tricine, pH 
6.95). Cell concentration was determined by counting with a hemocytometer. HBSS was 
used to dilute the cell suspension to a final concentration of 1.2x 106 cells/ml for single 
line experiments, or 6x 105 cells/ml when two different cell lines were incubated. 1 ml 
cell suspension was filled into 1.5 ml Eppendorf tubes and incubated at 4 °C under gentle 
agitation for 1 hour. Aggregation was quantified by counting the cells with a hemocytometer. 
Cell aggregation was plotted as the ratio T0/T60, where T0 is the total number of cellular 
particles before incubation, and T60	 is the total number of cellular particles after 1 hour 
incubation, with cellular aggregates counting as single particles. 
Electrophysiology
Mice (P20-22) of both genders were anesthetized with isoflurane before decapitation. 350 
μm-thick horizontal slices of the ventral hippocampus were prepared (HM650V vibratome, 
Thermo Scientific, Waltham, MA USA) in ice cold ACSF containing (in mM): 87 NaCl, 11 
Glucose, 75 Sucrose, 2.5 KCl, 1.25 NaH2PO4, 0.5 CaCl2, 7 MgCl2, 26 NaHCO3, continuously 
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oxygenated with 95% O2/5% CO2 and incubated for 1 h at 32°C after which they were 
allowed to cool down to RT. Before recording, slices were transferred to the recording setup 
and incubated in recording artificial cerebrospinal fluid (ACSF) containing (unless otherwise 
stated) (in mM): 124 NaCl, 1.25 NaH2PO4, 3 KCl, 26 NaHCO3, 10 Glucose, 4 CaCl2, 4 MgCl2 
and continuously oxygenated with 95% O2/5% CO2 at RT and incubated 15 minutes prior 
to recording. Cells were visualized with an upright microscope (Olympus). Patch pipettes 
(3-5 MΩ) were made from borosilicate glass capillaries and filled with intracellular solution 
containing (in mM): 115 CsMeSO3, 20 CsCl, 10 HEPES, 2.5 MgCl2, 4 Na2ATP, 0.4 NaGTP, 10 
Na-Phosphocreatine, 0.6 EGTA (pH 7.2-7.3, 285-295 mOsm). Traces were recorded using 
a Multiclamp 700B amplifier (Molecular Devices, Wokingham, United Kingdom), sampled 
at 10 kHz and filtered at 2 kHz. Cells were excluded from analysis if the access resistance 
exceeded 25 MΩ. CA1 pyramidal cells were recorded at a holding voltage of +10mV. 
Responses were evoked using electrical stimulation in Stratum	oriens at 0.1Hz. Excitatory 
inputs were blocked using 6-Cyano-7-nitroquinoxaline-2,3-dione (CNQX, 5 μM) and D-(-)-
2-Amino-5-phosphonopentanoic acid (D-APV 100 μM). Recording was started after a stable 
baseline was reached. Echistatin (100nM) or vehicle (mQ) was washed in after 5 minutes, 
and washed out 15 minutes after the start of the recording. The amplitude of individual 
sweeps was analysed using Clampfit 10.2 (Molecular Devices) and binned in 1 minute bins 
(6 sweeps). All bins were normalized to the average amplitude of the last 3 minutes before 
wash-in. Data was analysed as the last 5 minutes of the wash-in.
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Ehmt1 haploinsufficiency causes an 
increased excitatory/inhibitory balance 
through altered synaptic connectivity and 
intrinsic properties in hippocampal CA1 
pyramidal neurons
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4.1 Abstract
The brain consists of a large amount of neurons that need to communicate in an orchestrated 
way in order to allow for normal function. The balance between excitatory and inhibitory 
synaptic input, together with the intrinsic properties of a neuron, regulates a neuron’s activity 
within the network, and changes in these properties have been consistently identified in 
neurodevelopmental disorders. Here, we study the role of the histone methyltransferase 
EHMT1, the causative gene for Kleefstra syndrome, in CA1 pyramidal neurons. We use 
whole-cell patch clamp recordings to study the development of both excitatory and 
inhibitory synapses onto these cells. While excitatory synapses are indistinguishable 
between Ehmt1+/+ and Ehmt1+/- mice throughout development, inhibitory synapses show an 
altered development leading to a reduced mIPSC amplitude and frequency at postnatal day 
21 in Ehmt1+/- mice. In addition, CA1 pyramidal neurons are more excitable at this age, which 
is caused by a hyperpolarization of the action potential threshold. Together these changes 
lead to increased activity of these neurons, which is likely to contribute to in the symptoms 
observed in patients with Kleefstra syndrome.
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4.2 Introduction
The brain is a complex network of highly interconnected neurons that have to communicate 
in an orchestrated way in order to allow for normal function. Changes in neuronal 
communication lead to an imbalance in the network and have been identified in various 
neurodevelopmental disorders including autism, schizophrenia and intellectual disability 
(ID)1–4. Mutations underlying these disorders have been identified in various types of 
proteins, including ion channels, cell-adhesion molecules and transcription factors2,5. In 
recent years, mutations in proteins involved in epigenetic regulation, leading to changes in 
gene expression, have been identified in various neurodevelopmental disorders4,6–8.
We and others have previously identified heterozygous deletions and loss-of-function 
mutations affecting Euchromatin Histone Methyltransferase 1 (EHMT1, also known as GLP) 
to underlie Kleefstra syndrome (KS), a condition that is characterized by moderate to severe 
ID, autism, microcephaly and dysmorphic features9. EHMT1 is a highly conserved histone 
methyltransferase which, together with its paralog EHMT2 (also known as G9a), catalyses 
mono- and dimethylation of histone 3 lysine 9 (H3K9me1 and H3k9me2, respectively), 
leading to gene repression10. 
Heterozygous loss-of-function mutations of EHMT1 in mice show reduced activity and 
increased anxiety11, as well as deficits in fear extinction and spatial object recognition12. At the 
cellular level, CA1 pyramidal cells show a reduced spine density and a reduced arborization of 
the apical dendrite. Recently, EHMT1 has been implicated as an important factor in neuronal 
network development13 and homeostatic plasticity14, a form of plasticity that keeps neuronal 
activity within an optimal window15,16. However, changes to inhibitory synaptic transmission 
and intrinsic properties of these neurons have not yet been investigated.
Development of synaptic connectivity is important for normal brain function in adult life17. 
Ehmt+/- mice show a disrupted development of network function in cortical cultures18, and 
both Ehmt+/- mice and human neurons differentiated from induced pluripotent stem cells 
from KS patients19 show a decrease in spine density. Therefore, we set out to investigate the 
development of both excitatory and inhibitory synaptic inputs onto CA1 pyramidal neurons. 
In order to get a more complete view of the signal processing at these cells, we assessed 
the intrinsic properties of these cells. Using whole-cell electrophysiological recordings, 
we show that CA1 pyramidal neurons receive a reduced number of inhibitory inputs at 
all investigated developmental time points. Surprisingly, excitatory synaptic inputs were 
found to be unaltered both in amplitude and frequency. The reduction in inhibitory drive 
was accompanied by an increase in intrinsic excitability, caused by a hyperpolarization of 
the action potential threshold. Finally, we show that these changes lead to an increase in 
spontaneous action potential frequency. Together, these changes are believed to change 
signal processing, and may ultimately underlie the phenotype observed in KS patients.
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4.3 Results
4.3.1 No changes in excitatory synaptic connectivity between Ehmt1+/+ and Ehmt1+/- mice
Hippocampal CA1 pyramidal neurons in Ehmt1+/- mice have previously been shown to have 
a reduced dendritic arbour, as well as a reduced spine density12. In addition, hippocampal 
organotypic slices of Ehmt1+/- mice show a reduced miniature excitatory postsynaptic 
current (mEPSC) amplitude12. However, recordings from acute slices from visual cortex 
showed no change in both mEPSC amplitude and frequency14. To assess the role of EHMT1 
in development of synaptic integration in the hippocampus, we recorded mEPSCs from CA1 
pyramidal neurons at postnatal days (P) 7, P14 and P21 in Ehmt1+/+ and Ehmt1+/- mice (Fig. 
1a-i; Table 1). 
Table 1: mEPSCs and paired pulse ratio from excitatory synapses onto CA1 pyramidal cells for Ehmt1+/+ and 
Ehmt1+/- mice.
   Ehmt1+/+ n Ehmt1+/- n P-value Change
mEPSC             
 Amplitude            
  P7 12.21 ± 0.33 16 12.18 ± 0.65 11 0.958 -
  P14 13.50 ± 0.52 18 12.80 ± 0.51 19 0.362 -
  P21 15.42 ± 0.32 17 14.86 ± 0.43 15 0.319 -
 Frequency            
  P7 0.06 ± 0.01 16 0.11 ± 0.04 11 0.205 -
  P14 0.23 ± 0.02 18 0.24 ± 0.02 19 0.828 -
  P21 0.37 ± 0.04 17 0.34 ± 0.04 15 0.572 -
PPR             
 ISI            
  50 1.36 ± 0.05 13 1.35 ± 0.02 17 0.954 -
  100 1.28 ± 0.03 13 1.26 ± 0.01 17 0.502 -
  150 1.17 ± 0.03 13 1.18 ± 0.01 17 0.773 -
  200 1.08 ± 0.02 13 1.11 ± 0.02 17 0.267 -
  500 0.94 ± 0.02 13 1.00 ± 0.01 17 0.038 -
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Fig. 1: Excitatory connectivity onto CA1 pyramidal neurons. 
(a-c) (a) example traces (b) amplitude and (c) frequency of mEPSCs at postnatal day (P)7. (d-f) (d) example traces 
(e) amplitude and (f) frequency of mEPSCs at P14. (g-i) (g) example traces (h) amplitude and (i) frequency of 
mEPSCs at P21. (j,k) Development of (j) amplitude and (k) frequency of mEPSCs at investigated time points. (l,m) 
(l) example traces and (m) quantification of paired pulse ratio (Ehmt1+/+ n=13, Ehmt1+/- n=17). For bar graphs, n is 
presented as number of cells/number of animals in the respective bar graphs. Data are presented as mean ± SEM.
mEPSC amplitude, a measure for excitatory synaptic strength, did not show differences 
between Ehmt1+/+ and Ehmt1+/- mice at any of the investigated time points (Fig. 1j). In 
addition, mEPSC frequency was unaltered between the two groups (Fig. 1k). We then 
recorded the paired pulse ratio (PPR) at P21 by stimulating the Shaffer collaterals, the main 
excitatory input to CA1 pyramidal neurons, using a stimulation electrode at an inter-stimulus 
interval (ISI) of 50, 100, 150, 200 and 500 ms (Fig. 1l,m; Table 1). We found no differences in 
the PPR at any of the tested ISIs between Ehmt1+/+ and Ehmt1+/- mice. These data indicate 
that reduction of EHMT1 during development does not lead to a difference in the strength, 
number or release probability of excitatory synapses onto CA1 pyramidal neurons.
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Fig. 2: Inhibitory connectivity onto CA1 pyramidal neurons. 
(a-c) (a) example traces (b) amplitude and (c) frequency of mIPSCs at postnatal day (P)7. (d-f) (d) example traces 
(e) amplitude and (f) frequency of mIPSCs at P14. (g-i) (g) example traces (h) amplitude and (i) frequency of mIPSCs 
at P21. (j,k) Development of (j) amplitude and (k) frequency of mIPSCs at investigated time points. N is presented 
as number of cells/number of animals in the respective bar graphs. Data are presented as mean ± SEM. *p<0.05, 
**p,0.01, ***p,0.001.
4.3.2 Altered inhibitory synaptic connectivity between Ehmt1+/+ and Ehmt1+/- mice
We next investigated inhibitory synaptic inputs. We recorded miniature inhibitory 
postsynaptic currents (mIPSCs) from Ehmt1+/+ and Ehmt1+/- mice at P7, P14 and P21 
(Fig. 2a-i, Table 2). We found the mIPSC amplitude to be reduced in Ehmt1+/- mice at all 
investigated time points, suggesting a weakening of inhibitory synapses formed onto CA1 
pyramidal neurons throughout development (Fig. 2j). mIPSC frequency was increased at P7 
in Ehmt1+/- mice, but recovered at P14, and showed a strong reduction at P21 (Fig. 1k). Since 
mIPSC frequency can be influenced by both the number of synapses as well as the release 
probability of these synapses, we recorded the PPR of inhibitory synapses. The somata of 
inhibitory cells in hippocampus are mainly located in two distinct regions: Stratum	oriens 
and stratum	radiatum. We investigated the release probability from both strata individually
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Table 2: mIPSCs and paired pulse ratio from inhibitory synapses onto CA1 pyramidal cells from Ehmt1+/+ and 
Ehmt1+/- mice.
  Ehmt1+/+ n Ehmt1-/- n P-value Change
mIPSC             
 Amplitude            
  P7 15.63 ± 1.20 11 12.22 ± 0.35 16 0.004 ↓
  P14 19.76 ± 0.74 17 16.80 ± 0.45 17 0.002 ↓
  P21 22.65 ± 0.38 19 19.96 ± 0.45 22 0.000 ↓
 Frequency            
  P7 0.22 ± 0.03 11 0.35 ± 0.04 16 0.047 ↑
  P14 2.35 ± 0.22 17 1.83 ± 0.15 17 0.071 -
  P21 3.50 ± 0.19 19 2.46 ± 0.25 22 0.002 ↓
PPR             
 SO            
 ISI            
  50 0.87 ± 0.08 10 0.85 ± 0.07 8 0.913 -
  100 0.83 ± 0.05 10 0.77 ± 0.04 8 0.383 -
  150 0.77 ± 0.01 10 0.82 ± 0.04 8 0.186 -
  200 0.82 ± 0.02 10 0.73 ± 0.02 8 0.030 -
  500 0.79 ± 0.02 10 0.79 ± 0.03 8 0.897 -
 SR            
 ISI            
  50 0.73 ± 0.03 8 0.90 ± 0.04 8 0.006 ↑
  100 0.77 ± 0.03 8 0.88 ± 0.03 8 0.023 -
  150 0.73 ± 0.03 8 0.84 ± 0.04 8 0.099 -
  200 0.70 ± 0.02 8 0.74 ± 0.02 8 0.286 -
  500 0.68 ± 0.02 8 0.77 ± 0.02 8 0.014 -
by placing the stimulation electrode in the respective regions in CA1 while recording from 
a pyramidal neuron. Stimulation in Stratum	oriens did not reveal any changes in the PPR at 
50, 100, 150, 200 or 500 ms ISI, suggesting that the release probability from cells located 
in this region is unaltered in Ehmt1+/- mice (Fig. 3a-c). Conversely, stimulation in stratum	
radiatum revealed an increased PPR at 50 ms ISI, suggestive of a reduced release probability 
(Fig. 3d-f). 
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Fig. 3: Inhibitory paired pulse ratio onto CA1 pyramidal neurons. 
(a-c) (a) experimental design, (b) example traces and (c) quantification of the paired pulse ratio following 
stimulation in Stratum	oriens	(Ehmt1+/+ n=10, Ehmt1+/- n=8). (d-f) (d) experimental design, (e) example traces and 
(f) quantification of the paired pulse ratio following stimulation in stratum	radiatum (Ehmt1+/+ n=8, Ehmt1+/- n=8). 
Data are presented as mean ± SEM. *p<0.05. S.O. Stratum	oriens; S.P. stratum	pyramidale; S.R. stratum	radiatum.
Previous studies from our lab have proposed EHMT1 to function as a cell-autonomous 
regulator of synaptic scaling in excitatory neurons, and Ehmt1+/- mice show reduced 
homeostatic scaling in these cells14. The reduced inhibitory drive onto pyramidal neurons 
could be due to reduced levels of EHMT1 in the pyramidal neurons, or to reduced levels of 
EHMT1 in the presynaptic interneurons. However, expression of EHMT1 in CA1 inhibitory 
neurons has not been reported previously. Therefore, we performed immunohistochemical 
colocalization experiments against EHMT1 and either parvalbumin (Fig. 4a-c) or somatostatin 
(Fig. 4d-f), markers of two of the major interneuron subgroups20. We found EHMT1 both in 
parvalbumin- and somatostatin-expressing interneurons, showing that EHMT1 is expressed 
in at least a subset of interneurons. This result indicates that observed changes in inhibitory 
connectivity onto CA1 pyramidal neurons might be caused by changes in both the presynaptic 
inhibitory neuron and the postsynaptic pyramidal neuron.
Together, these data indicate that inhibitory drive at P21 is reduced in Ehmt1+/- mice, and 
that this reduction is, at least in part, caused by a weakening of inhibitory synapses as 
well as a reduced release probability from a subset of inhibitory neurons. Together with 
the unaltered excitatory input, this  leads to a shift in the balance between excitation and 
inhibition towards excitation.
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Fig. 4: Colocalization of EHMT1 with interneuron markers. 
(a-c) Image of immunohistochemical staining showing (a) Parvalbumin, (b) EHMT1 and (c) merge. (d-f) Image of 
immunohistochemical staining showing (d) Parvalbumin, (e) EHMT1 and (f) merge. Arrows indicate colocalization. 
Scale bar equals 10 μm. S.O. Stratum	oriens; S.P. stratum	pyramidale.
4.3.3 Ehmt1+/- pyramidal neurons show reduced intrinsic excitability
The observed reduction in inhibitory drive, together with the unaltered excitatory drive, is 
expected to lead to an increase in pyramidal cell excitation. We wondered if the intrinsic 
properties of pyramidal neurons would show a compensatory change to this altered 
synaptic input. Surprisingly, when we recorded the number of action potentials (APs) evoked 
by increasing current injection, we found the intrinsic excitability of Ehmt1+/- pyramidal 
neurons to be increased (Fig. 5a,b). Consistently, we found the rheobase to be decreased in 
these animals (Ehmt1+/+ 42.11 ± 2.64 mV; Ehmt1+/- 23.85 ± 2.99 mV; p = 0.000; Fig. 5c). The 
reduction of the rheobase was caused by a hyperpolarization of the AP threshold (Ehmt1+/+ 
-36.98 ± 0.72 mV; Ehmt1+/- -42.64 ± 0.83 mV; p = 0.000), while all other recorded parameters 
were unaltered (Fig. 5d-f; Table 3). 
Next, we investigated if the combination of reduced inhibitory input and increased intrinsic 
excitability led to an increase in the spontaneous activity of CA1 pyramidal cells in Ehmt1+/- mice. 
We performed cell attached recordings of CA1 pyramidal neurons to record basal AP frequency. 
Cell attached recordings do not disturb the intracellular conditions of the recorded cell, and were 
therefore preferred to record the spontaneous AP frequency. In standard recording solution (3 
mM KCl), CA1 pyramidal cells are inactive, as reported previously21 (spiking observed during a 
10 minute recording in 0/5 Ehmt1+/+ cells, 2/6 Ehmt1+/- cells). Increasing the concentration of 
extracellular potassium in the recording solution increased neuronal excitability (5 mM KCl: 4/6 
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EHMT1+/+ cells, 6/7 EHMT1+/- cells). A total of 7 mM KCl in the recording solution resulted in APs 
in all recorded cells, and revealed a higher AP frequency in EHMT1+/- compared to EHMT1+/+ mice 
(Ehmt1+/+ 0.32 ± 0.28 Hz, Ehmt1+/- 0.74 ± 0.73 Hz, p=0.005; Fig. 5 g,h), consistent with a higher 
excitability of CA1 pyramidal neurons in Ehmt1+/- mice.
In conclusion, Ehmt1+/- mice show a reduction of inhibitory synaptic inputs and hyperpolarized 
AP threshold, leading to an increased activity of CA1 pyramidal neurons.
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Fig. 5: Altered excitability of CA1 pyramidal neurons. 
(a,b) (a) quantification and (b) example traces of input/output curve (Ehmt1+/+ n=19, Ehmt1+/- n=13). (c) Rheobase. 
(d) Phase plot of first action potential. (e,f) (e) Example trace and (f) quantification of the action potential threshold. 
(g,h) (g) quantification and (h) example traces of cell attached recording in increasing potassium concentrations. For 
bar graphs, n is presented as number of cells/number of animals in the respective bar graphs. Data are presented 
as mean ± SEM. *p<0.05, **p,0.01, ***p,0.001.
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Table 3: Intrinsic properties of CA1 pyramidal neurons from Ehmt1+/+ and Ehmt1+/- mice.
 Ehmt1+/+ Ehmt1+/- P-value
RMP (mV) -67.21 ± 0.76 -66.62 ± 0.82 0.618
Capacitance (pF) 184.69 ± 9.27 170.39 ± 12.83 0.374
AP Peak (mV) 45.47 ± 0.90 46.17 ± 0.97 0.621
Input resistance (MΩ) 210.90 ± 10.02 191.02 ± 7.72 0.525
Half width (ms) 0.92 ± 0.02 0.91 ± 0.02 0.520
Rise Time (ms) 0.16 ± 0.00 0.15 ± 0.01 0.301
Decay Time (ms) 0.52 ± 0.01 0.51 ± 0.01 0.905
AP threshold (mV) -36.98 ± 0.72 -42.64 ± 0.83 0.000
Rheobase (pA) 42.11 ± 2.64 23.85 ± 2.99 0.000
AP adaptation ratio 1.70 ± 0.07 1.89 ± 0.17 0.244
4.4 Discussion
In this study, we focused on the role of EHMT1 in synaptic integration and intrinsic excitability 
of CA1 pyramidal neurons. We show that Ehmt1+/- mice show a normal development of 
excitatory synaptic inputs, but an altered development of inhibitory synaptic inputs, leading 
to a reduced inhibitory drive at P21. This reduced inhibitory drive is in part caused by a 
reduced release probability, as seen from an increased PPR following stimulation in stratum	
radiatum. In addition to receiving a reduced inhibitory drive, CA1 pyramidal neurons 
showed an increased intrinsic excitability, which was caused by a hyperpolarization of the 
AP threshold. Finally, we showed that these changes lead to an increased spontaneous 
activity of CA1 pyramidal neurons in Ehmt1+/- mice.
A previous study has shown the apical dendritic arbour of CA1 pyramidal neurons to be less 
complex in Ehmt1+/- mice, accompanied by a reduction in spine density. In addition, the release 
probability of excitatory synapses was reduced in Ehmt1+/- mice12. Surprisingly, our data does 
not reveal a difference in mEPSC amplitude or frequency between Ehmt1+/+ and Ehmt1+/- mice, 
nor in excitatory release probability. This discrepancy could be explained by the different ages 
at which the experiments were performed. Our experiments were performed at juvenile and 
adolescent ages up to P21, while the previous study focussed on adult animals (3 to 7 months). 
This idea is substantiated by the finding that mEPSC amplitude and frequency are unaltered 
between Ehmt1+/+ and Ehmt1+/- mice in visual cortex at P2114. In addition, mEPSC development 
in dissociated cortical cultures is indistinguishable between the two genotypes18. Therefore, 
it seems that while reduced expression of EHMT1 does not affect excitatory synaptic 
development, disruptions of the excitatory system may develop at later time points.
In contrast to excitatory synapses, development of inhibitory synapses is severely altered 
in Ehmt1+/- mice. We found mIPSC amplitude to be reduced at all investigated time points. 
The development of mIPSCs showed an increased frequency at P7 which had recovered by 
138 CHAPTER 4
P14. At P21, the mIPSC frequency was strongly reduced in Ehmt1+/- mice. This reduction 
can be partially explained by a reduced release probability of inhibitory synapses following 
stimulation in stratum	 radiatum, but not Stratum	 oriens. While stimulation in Stratum	
oriens or stratum	radiatum excites a different subset of interneurons, it is difficult to identify 
which interneurons are responsible for the observed reduction in release probability 
due to interneuron morphology spanning multiple hippocampal layers22,23. For example, 
somatostatin positive (SOM+) oriens lacunosum moleculare (OLM) interneurons have a 
soma located in Stratum	 oriens, and an axon crossing stratum	 pyramidale and stratum	
radiatum to form synaptic connections with the dendritic tuft of pyramidal neurons in 
stratum lacunosum moleculare22. 
A previous study from our lab has identified EHMT1 to be required for methylation of the 
promoter region of BDNF, specifically promoter IV, leading to a reduction in expression14. 
BDNF promoter IV plays an important role in the activity-dependent expression of BDNF24,25, 
and previous studies report that a mouse model with reduced activity-dependent BDNF 
expression show a reduction in inhibitory, but not excitatory, inputs, specifically from 
parvalbumin-positive (PV+) interneurons26,27. The idea that activity-dependent expression 
of BDNF could strengthen inhibitory connectivity is in line with studies showing a specific 
tuning of inhibitory strength to the amount of excitatory input an individual pyramidal 
neuron receives, which is also regulated through PV+ interneuron synapses28.  It would be 
of great interest to see if reduction in inhibitory inputs observed in this study is indeed 
due to changes in inputs from PV+ interneurons. The use of interneurons specific cre-
lines to specifically express channelrhodopsin in these cells would allow to investigate the 
interneuron subtypes involved in the reduced inhibitory drive we observe.
It should be noted that previous studies of BDNF promoter IV used a mouse with reduced 
activity-dependent expression of BDNF. In this study, we use Ehmt1+/- mice that show 
an impaired repression of BDNF expression, leading to increased expression of BDNF14. 
Unexpectedly, we observed a similar phenotype of reduced inhibitory inputs. This 
discrepancy might be caused by the different nature of the model. While the mice from 
previous studies had a disrupted expression of BDNF, our model does not affect basal 
expression from BDNF promoter IV, but specifically lacks the ability to downregulate 
expression from this promoter, leading to an increased level of BDNF only during specific 
periods. While it is at the moment unknown what causes the reduction of inhibitory inputs 
in both these models, these studies suggest that BDNF promoter IV plays a central role in 
the regulation of inhibitory connectivity of pyramidal neurons.
In addition to changes to the synaptic connectivity, we also found an increased intrinsic 
excitability of pyramidal neurons in Ehmt1+/- mice. This increase was caused by a 
hyperpolarization of the AP threshold, leading to a reduced rheobase and an increased 
number of APs evoked by current injection. Hyperpolarization of the AP threshold can be 
caused by various changes. An interesting possibility is downregulation of the expression 
of specific voltage gated potassium channels, like Kv1.129, that are enriched in the axon 
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initial segment30. Experiments using the Kv1 inhibitor dendrotoxin might establish if Kv1 
channels play a role in the altered AP threshold. Previous studies have found increased 
levels of H3K9me2 of different voltage gated potassium channels following nerve injury 
to be regulated by EHMT231. While EHMT1 and EHMT2 do function together10, the direct 
function of EHMT1 in the regulation of these potassium channels remains to be established. 
Another possible cause for the hyperpolarized threshold is a distal relocation of the axon 
initial segment. Positioning of the axon initial segment has been shown to be regulated in 
response to changes in activity, and to correlate with AP threshold32,33. Immunohistochemical 
staining would allow to quantify the distance between the soma and the axon initial segment 
of CA1 pyramidal neurons and could answer this question.
Changes in AP threshold might not be a ubiquitous effect of reduced H3K9me2. A previous 
study using an Ehmt2 knock-out mouse looked at the intrinsic properties of D2-positive 
medium spiny neurons in the striatum, but revealed no differences34. While these 
experiments have not been done in our Ehmt1+/- mouse model, these data suggest that 
changes in intrinsic properties following changes in H3K9me2 might be cell type specific. 
A possible reason for this might lie in the mechanisms these cells use to homeostatically 
regulate their activity, and the role for H3K9me2 in these different pathways.
In conclusion, CA1 pyramidal neurons of Ehmt1+/- mice show increased excitability. This 
increased excitability is caused by a relative increase in excitatory compared to inhibitory input, 
and a hyperpolarized AP threshold. While we only investigated the effects in hippocampal CA1 
pyramidal neurons, similar changes could be present in other cell types, and together contribute 
to the cognitive and behavioural phenotypes observed in Kleefstra syndrome patients.
4.5 Material and Methods
Animals
All mice were bred and reared in the Central Animal Facility of the Radboud University 
Nijmegen, Nijmegen, the Netherlands. Food pellets and water were provided ad	libitum. The 
experimental procedures were approved by the Animal Ethics Committee of the Radboud 
University Nijmegen and conducted in accordance with Dutch legislation. Animals of both 
genders were used at the ages indicated in the text, i.e. P6-8 (P7), P13-15 (P14) or P20-22 
(P21). Every effort was made to minimize the number of animals used and their suffering.
Fluorescent	immunohistochemistry:
Animals were anesthetized with isoflurane. Following decapitation, the brain was 
removed and fixated for 24 hours (h) in 4% paraformaldehyde at 4⁰C before being stored 
in phosphate buffered saline (PBS) at 4⁰C. Brains were embedded in agarose (2%, in PBS) 
and 100 µm coronal sections were cut using a vibratome (Leica, VT1000S). Free floating 
slices were incubated in blocking buffer overnight (O/N) before incubation with primary 
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antibody (EHMT1, 1:100, Abcam; and parvalbumin, 1:250, SWANT or somatostatin, 1:100, 
Santa Cruz) O/N at 4⁰C. Sections were incubated with secondary antibody (goat anti-rabbit 
Alexa fluor 488, 1:2000, Invitrogen; goat anti-mouse Alexa fluor 568, 1:2000, Invitrogen) for 
3h at room temperature (RT) and counterstained with Hoechst stain. Sections where then 
mounted using DAKO mounting medium and imaged using an apotome on an Axio Imager 
Z1 fluorescence microscope (Zeiss).
Electrophysiology
Mice of indicated ages were anesthetized with isoflurane before decapitation. 350 μm-
thick horizontal slices containing the ventral hippocampus were prepared (HM650V 
vibratome, Thermo Scientific, Waltham, MA, USA) in ice cold artificial cerebrospinal fluid 
(ACSF) containing (in mM): 87 NaCl, 11 glucose, 75 sucrose, 2.5 KCl, 1.25 NaH
2
PO4, 0.5 
CaCl
2
, 7 MgCl
2
, 26 NaHCO
3
, continuously oxygenated with 95% O
2
/5% CO
2 
and incubated 
for 1 h at 32°C after which they were allowed to cool down to room temperature. Before 
recording, slices were transferred to the recording setup and incubated in recording 
ACSF containing (unless otherwise stated) (in mM): 124 NaCl, 1.25 NaH
2
PO
4
, 3 KCl, 26 
NaHCO
3
, 10 glucose, 2 CaCl
2
, 1 MgCl
2
 and continuously oxygenated with 95% O
2
/5% CO
2
 
at RT. Slices were incubated 15 minutes prior to recording. Cells were visualized using an 
upright microscope (Olympus). Patch pipettes (3-5 MΩ) were made from borosilicate glass 
capillaries and filled with intracellular solution containing (in mM): 115 CsMeSO
3
, 20 CsCl, 
10 HEPES, 2.5 MgCl
2
, 4 Na
2
ATP, 0.4 NaGTP, 10 Na-Phosphocreatine, 0.6 EGTA (pH 7.2-7.3, 
285-295 mOsm) for voltage clamp recordings, (in mM): 130 K-Gluconate, 5 KCl, 10 K-HEPES, 
2.5 MgCl
2
, 4 Na
2
ATP, 0.4 Na
3
GTP, 10 Na-phosphocreatine, 0.6 EGTA (pH 7.2-7.3, 285-295 
mOsm) for current clamp recordings or recording ACSF for cell attached recordings. Traces 
were recorded using a Multiclamp 700B amplifier (Molecular Devices, Wokingham, United 
Kingdom), sampled at 10 kHz and filtered at 2 kHz. Cells were excluded from analysis if the 
access resistance exceeded 25 MΩ. mEPSCs were recorded at -60 mV in the presence of 
Tetrodotoxin (TTX, 1 µM) and Picrotoxin (PTX, 100 µM). mIPSCs were recorded at +10 mV 
in the presence of TTX, 6-Cyano-7-nitroquinoxaline-2,3-dione (CNQX, 5 µM) and D-(-)-2-
Amino-5-phosphonopentanoic acid (D-APV, 100 µM). Excitatory paired pulse ratios were 
recorded at -60 mV in the presence of 4 mM CaCl
2
 and 4 mM MgCl
2
 following electrical 
stimulation of the indicated region in the presence of PTX (for excitatory paired pulse ratios) 
or CNQX and D-APV (for inhibitory paired pulse ratios). mEPSCs and mIPSCs were analysed 
using Mini Analysis Program (Synaptosoft, Decatur, GA, USA). Intrinsic properties were 
analysed using Clampfit 10.7 (Molecular Devices, Wokingham, United Kingdom). Resting 
membrane potential was recorded directly after achieving a whole cell conFig.uration. For 
other recordings the membrane potential was biased to -60 mV and analysed as described 
previously23. Spontaneous action potentials were recorded during a 10 minute recording 
and analysed using Mini Analysis Program.
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5.1 Abstract
Schizophrenia is a complex disorder that affects cognitive function and has been linked, 
both in patients and animal models, to dysfunction of the GABAergic system. However, 
the pathophysiological consequences of this dysfunction are not well understood. Here, 
we examined the GABAergic system in an animal model displaying schizophrenia-relevant 
features, the apomorphine-susceptible (APO-SUS) rat and its phenotypic counterpart, the 
apomorphine-unsusceptible (APO-UNSUS) rat at postnatal day 20-22. We found changes in 
the expression of the GABA-synthesizing enzyme GAD67 specifically in the prelimbic- but 
not the infralimbic region of the medial prefrontal cortex (mPFC), indicative of reduced 
inhibitory function in this region of APO-SUS rats. While we did not observe changes in 
basal synaptic transmission onto LII/III pyramidal cells in the mPFC of APO-SUS compared 
to APO-UNSUS rats, we report reduced paired-pulse ratios at longer inter-stimulus intervals. 
The GABA
B
 receptor antagonist CGP 55845 abolished this reduction, indicating that the 
decreased paired-pulse ratio was caused by increased GABA
B
 signaling. Consistently, we find 
an increased expression of the GABA
B1
 receptor subunit in APO-SUS rats. Our data provide 
physiological evidence for increased presynaptic GABA
B
 signaling in the mPFC of APO-SUS 
rats, further supporting an important role for the GABAergic system in the pathophysiology 
of schizophrenia.
APO-SUS/APO-UNSUS 147
5
5.2 Introduction
Schizophrenia is a complex mental disorder thought to result from a combination of genetic 
and environmental factors that provide vulnerability to early- and later-life stressors1–3. 
Growing evidence suggests that schizophrenia may arise from abnormal connectivity 
between various integrative brain regions, especially the prefrontal cortex (PFC), the 
medial temporal lobe, and striatal regions4–7. For several decades, schizophrenia research 
was guided by the dopamine hypothesis8. However, this hypothesis has expanded more 
recently into a view including other neurotransmitters such as serotonin9, glutamate10 and 
γ-aminobutyric acid (GABA)11. 
Dysfunction of the GABAergic system in schizophrenia has been well documented by 
postmortem studies showing alterations in a number of pre- and post-synaptic markers 
of inhibitory neurotransmission thought to be most prominent in parvalbumin positive 
(PV+) neurons12. For example, reduced densities of calbindin-positive (CB+) and PV+ 
GABAergic interneurons have been observed in the prefrontal cortex of schizophrenia 
patients13–15. In addition, protein levels of GABA transporter 1 (GAT1) are reduced in the 
PFC of schizophrenia patients16. Also, PFC levels of the GABA synthesizing enzyme GAD67 
are reduced in schizophrenia, which can be attributed to reduced expression in PV+ cells 
specifically17 and is indicative of  reduced GABAergic signaling18. At the synaptic level, the 
GABAAα2 subunit, which is prominently expressed in synapses formed by chandelier cells 
on the axon initial segment of pyramidal neurons, is upregulated in schizophrenia patients19. 
In line with these results, a genetic model of schizophrenia, the Erbb4 knock-out mouse, 
shows changes in GABAAα2 and GAT1 density as well as a reduced number of inhibitory 
synapses on excitatory pyramidal cells12,20. Conversely, excitatory inputs onto PV+ cells are 
decreased in these mice12,20. 
To explore the pathophysiological mechanisms underlying schizophrenia, we used 
the apomorphine-susceptible (APO-SUS) rat model and its phenotypic counterpart, 
the apomorphine-unsusceptible (APO-UNSUS) rat. These two rat lines have been 
pharmacogenetically selected and bred from an outbred Wistar population based on their 
stereotypical gnawing responses to the dopamine D1/D2 agonist apomorphine21. The APO-
SUS rat is a well-characterized animal model that displays schizophrenia-relevant features 
during adulthood, such as altered density of central dopamine receptors22, high sensitivity 
to dopaminergic drugs (i.e., apomorphine and amphetamine)21,23,24, decreased prepulse 
inhibition and diminished latent inhibition24,25, increased novelty-induced exploration and 
accumbal dopamine response21,23,26, and an increased HPA-axis response to stress22, as 
well as learning and memory deficits27,28. However, the pathophysiology underlying the 
phenotypes observed in this model remains unknown.
In the present study, we compared the inhibitory system in the medial PFC (mPFC) of APO-
SUS and APO-UNSUS rats at postnatal day (PND) 20-22. We found a decrease in the protein 
level of GAD67 as well as a reduced cell-count for GAD67+ cells specifically in the prelimbic 
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region (PRL) of the mPFC. While basal synaptic transmission onto LII/III pyramidal cells was 
not different between the two rat lines, we report a decrease in the paired-pulse ratio in 
APO-SUS rats at longer (≥150 ms) intervals compared to APO-UNSUS rats. Importantly, this 
decrease could be abolished by application of the GABA
B
 antagonist CGP 55845, indicating 
that the decreased paired-pulse ratio was caused by an increased activity in GABA
B
 signaling. 
We indeed observed an increase in GABA
B
 receptor expression in the mPFC of APO-SUS rats 
compared to APO-UNSUS rats. Collectively, our data identify GABA
B
 receptor signaling as a 
possible player in the etiology of schizophrenia.
5.3 Results
5.3.1 Reduced levels of GAD67 in the mPFC of APO-SUS rats
Previous studies have reported altered levels of specific interneuron markers in schizophrenia 
patients13–17,29. In order to determine whether the number of GABAergic interneurons is 
altered in APO-SUS compared to APO-UNSUS rats, we performed western blot analysis to 
measure the protein expression levels of GAD67, CB and CR in punches from the mPFC of 
PND 22-22 rats (Fig. 1). We found protein levels of GAD67 to be reduced by ~35% in APO-
SUS rats (Fig. 1a,d; p=0.04). Conversely, we found no change in the level of CB (Fig. 1b,d; 
p=0.33) and CR (Fig. 1c,d; p=0.99) between the two rat lines.
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Fig. 1. Reduced expression of GAD67, but not Calbindin (CB) and Calretinin (CR) in the medial prefrontal cortex 
(mPFC) of APO-SUS rats. 
(a-c) Representative immunoblot images for GAD67 (a), CB (b) and CR (c) and (d) quantification of western blot 
analysis for CB, CR and GAD67 on APO-UNSUS and APO-SUS. Expression is normalized to APO-UNSUS expression 
of the respective protein. Sample size (n) in indicated in the bars. Data is presented as mean ± SEM, * p<0.05. 
Student’s t-test.
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5.3.2 Reduction of GAD67+ cells in the prelimbic region, but not the infralimbic region, of 
the mPFC of APO-SUS rats
Next, we wanted to assess whether the decrease in GAD67 protein levels in the mPFC 
was due to a decreased amount of GAD67 per cell or to a decrease in the total number of 
interneurons. To this end we performed immunohistochemistry to assess the number of 
interneurons positive for GAD67. We also assessed the number of CB+, CR+ and PV+ cells, 
which together label ~90% of GABAergic interneurons30. We used coronal sections of the 
mPFC and analyzed the number of positive cells separately for the prelimbic (PRL)- and 
infralimbic (IL) region, two subregions of the mPFC. 
We found a significant decrease of GAD67+ cells specifically in the PRL (APO-UNSUS 6.12 ± 
0.25 cells/mm2; APO-SUS 5.25 ± 0.15 cells/mm2, p=0.012; Fig. 2a,b,i), but not the IL (APO-
UNSUS 7.25 ± 0.29 cells/mm2; APO-SUS 6.60 ± 0.28 cells/mm2, p=0.13; Fig. 2a,b,j) in APO-
SUS rats. We found no changes in the levels of CB+, CR+ and PV+ cells in both the PRL (CB+: 
APO-UNSUS 9.32 ± 0.79 cells/mm2; APO-SUS 9.82 ± 0.60 cells/mm2, p=0.64; CR+: APO-UNSUS 
3.06 ± 0.16 cells/mm2; APO-SUS 3.43 ± 0.22 cells/mm2, p=0.19; PV+: APO-UNSUS 2.32 ± 0.11 
cells/mm2; APO-SUS 2.49 ± 0.21 cells/mm2, p=0.47), or IL (CB+: APO-UNSUS 10.36 ± 0.70 
cells/mm2; APO-SUS 9.33 ± 0.59 cells/mm2, p=0.33; CR+: APO-UNSUS 4.12 ± 0.32 cells/mm2; 
APO-SUS 3.85 ± 0.37 cells/mm2, p=0.58; PV+: APO-UNSUS 0.99 ± 0.08 cells/mm2; APO-SUS 
1.13 ± 0.11 cells/mm2, p=0.30; Fig. 2c-j)). The fact that we did not observed changes in the 
CB+ CR+ and PV+ population, which together label ~90% of all interneurons30, suggests the 
reduction in GAD67 is due to a reduced level of GAD67 per cell, rather than a reduction in 
the total amount of interneurons, specifically in the PRL.
5.3.3 Unaltered basal synaptic input on LII/III pyramidal neurons in the mPFC 
Since reduced levels of GAD67 are indicative of reduced interneuronal activity31,32, we 
subsequently tested if the observed changes in GAD67 protein levels would be accompanied 
by changes at the electrophysiological level. In order to assess basal synaptic input we used 
whole-cell voltage clamp to record miniature inhibitory postsynaptic currents (mIPSCs) 
from layer (L) II/III pyramidal neurons in the mPFC (Fig. 3a-c). We found no difference in 
both mIPSC amplitude (APO-UNSUS 23.04 ± 0.32 pA; APO-SUS 22.33 ± 0.37 pA, p=0.16) 
and frequency (APO-UNSUS 1.20 ± 0.12 Hz; APO-SUS 1.16 ± 0.14 Hz, p=0.83). Similarly, no 
differences were found in miniature excitatory postsynaptic currents (mEPSCs) between the 
two rat lines (amplitude: APO-UNSUS 16.20 ± 0.31 pA; APO-SUS 15.34 ± 0.31 pA; p=0.08; 
frequency: APO-UNSUS 2.99 ± 0.26 Hz; APO- SUS 2.98 ± 0.42 Hz, p=0.98) (Fig. 3d-f).
Previous studies have shown that changes in postsynaptic GABA receptor subunit 
composition are reflected in the decay time of mIPSC33,34. We found no changes in the 
mIPSC decay time in APO-SUS rats (APO-UNSUS 15.58 ± 0.52 ms; APO-SUS 13.46 ± 0.93 ms, 
p=0.06), indicating the postsynaptic receptor content of inhibitory synapses was unaltered 
(Fig. 3g). Next, we measured the maximal response to bath application of 20 µM GABA (Fig. 
3h). No difference was observed between APO-UNSUS and APO-SUS rats (APO-UNSUS 154.1
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Fig. 2. Reduced number of GAD67+cells in the PRL, but not the IL. Representative images of a staining for GAD67 
(a,b), Calbindin (CB) (c,d) Calretinin (CR) (e,f) and parvalbumin (PV) (g,h) and quantification in the prelimbic (PRL) 
(i) and infralimbic (IL) region (j) of the medial prefrontal cortex. GAD67, CB, CR and PV staining in green, propidium 
iodide in red. Sample size (n) in indicated in the bars. Scale bar: 200 µm. Data is presented as mean ± SEM. ** 
p<0.01. Student’s t-test.
APO-SUS/APO-UNSUS 151
5
± 48.3 pA; APO-SUS 163.9 ± 51.2 pA, p=0.78), indicating that the total number of GABA
A
 
receptors was identical. Together, these data show that there is no difference in basal 
synaptic inhibitory and excitatory input connectivity onto LII/III pyramidal cells in the mPFC 
between APO-UNSUS and APO-SUS rats.
We then analyzed pyramidal cell morphology of cells that were filled with biocytin during 
the recordings. All cells had a typical pyramidal morphology, hallmarked by a skirt of basal 
dendrites radiating ~200 µm from the soma, and a single long apical dendrite that reached 
into upper LI (Fig. 3i). The apical dendrite mostly branched close to the soma, and had an 
apical tuft close to the pia mater, mainly within LI, consistent with previous reports35. The 
dendritic morphology of both apical and basal dendrites did not differ between pyramidal 
cells from APO-UNSUS and APO-SUS rats (Table 1). 
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Fig. 3. No changes in basal synaptic transmission and morphology in LII/III pyramidal cells in the medial prefrontal 
cortex (mPFC). 
(a) Representative traces of miniature inhibitory post-synaptic currents (mIPSCs) recorded from LII/III pyramidal cells 
from acute brain slices from APO-UNSUS and APO-SUS rats. (b,c) Cumulative distributions of mIPSC amplitudes (b) 
and inter-event intervals (IEI) (c) from APO-UNSUS. (d) Representative traces of miniature excitatory post-synaptic 
currents (mEPSCs) recorded from LII/III pyramidal cells from acute brain slices from APO-UNSUS and APO-SUS rats 
(e,f) Cumulative distributions of mEPSC amplitudes (e) and inter-event intervals (f) from APO-UNSUS and APO-SUS. 
(g) Representative traces (scaled) and distribution of mIPSC decay time (h) Representative traces and quantification 
of systemic GABA (20 µM) application from APO-UNSUS and APO-SUS rats. Black bar indicates GABA application. 
(i) Representative reconstructions of LII/III pyramidal neurons from mPFC. Sample size (n) is indicated in the bars as 
number of cells/number of animals. Bar graphs are presented as mean ± SEM. Student’s t-test.
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Table 1. Dendritic morphological analysis of reconstructed layer II/III pyramidal cells. 
Student’s t-test with Holm-Sidak correction for multiple comparisons. Data is presented as mean ± SEM. Sign: 
significance; n.s: not significant
Morphology UNSUS SUS   p-value Sign
Basal 
Dendrites
Quantity 6.0 ± 0.9 9.3 ± 1.4 0.029 n.s.
Nodes 18.5 ± 2.1 20.8 ± 2.5 0.404 n.s.
Ends 24.3 ± 2.6 29.8 ± 1.8 0.060 n.s.
Length(µm) 2339.9 ± 407.5 2659.7 ± 189.1 0.433 n.s.
Mean length 397.2 ± 59.1 312.8 ± 54.4 0.224 n.s.
Apical 
Dendrite
Nodes 15.0 ± 1.7 22.0 ± 4.0 0.093 n.s.
Ends 16.0 ± 1.7 23.0 ± 4.0 0.093 n.s.
Length(µm) 1775.9 ± 183.1 2617.7 ± 490.4 0.085 n.s.
Max Branch Order 8.0 ± 0.5 11.0 ± 0.8 0.009 n.s.
Convex Hull
Area (µm²) 43375.2 ± 2899.2 55194.9 ± 8447.3 0.143 n.s.
Perimeter (µm) 831.0 ± 20.8 929.5 ± 66.6 0.116 n.s.
5.3.4 Reduction in paired-pulse ratio through GABAB receptor signaling in the mPFC of 
APO-SUS rats
Next, we investigated the release probability of inhibitory synapses onto LII/III pyramidal 
cells by recording the paired-pulse ratio following stimulation in the same layer in the PFC. 
We recorded paired-pulse ratios at different inter-stimulus intervals (ISI) (Fig. 4a,b) and 
found that the paired-pulse ratio were indistinguishable between both rat lines for short 
ISIs (≤ 100 ms) (50 ms APO-UNSUS 0.96 ± 0.03; APO-SUS 0.94 ± 0.04, p=0.67; 100 ms APO-
UNSUS 0.92 ± 0.03; APO-SUS 0.89 ± 0.04, p=0.65), whereas LII/III pyramidal cells from APO-
SUS rats showed a reduced paired-pulse ratio at longer ISIs (≥150 ms) (150 ms APO-UNSUS 
0.88 ± 0.03; APO-SUS 0.77 ± 0.02; p<0.01; 200 ms APO-UNSUS 0.81 ± 0.03; APO-SUS 0.71 ± 
0.02; p<0.01; 500 ms APO-UNSUS 0.82 ± 0.02; APO-SUS 0.75 ± 0.02; p<0.05; Fig. 4b). 
Whereas changes at short ISIs are indicative of an altered release probability, changes in 
paired-pulse ratios for longer ISIs can be indicative of reduced presynaptic calcium inflow36. 
Previous studies have shown that a reduced presynaptic calcium inflow can be caused by 
increased retrograde signaling via nitric oxide37 and endocannabinoids38, or through binding 
of GABA to presynaptic GABA
B
 receptors, which upon activation negatively influence 
Ca2+ inflow through voltage gated Ca2+-channels39. Since only GABA
B
 receptors act at the 
sub-second time range, we investigated the involvement of GABA
B
 receptor signaling by 
recording the paired-pulse ratio in the presence of the GABA
B
 receptor antagonist CGP 
55845. In APO-SUS rats, the paired-pulse ratio at 50 ms and 100 ms was unaffected by CGP 
55845, consistent with GABA
B
 receptor activation time40. Interestingly, we found that the 
reduced paired-pulse ratio at longer ISIs (150, 200 and 500 ms) was completely abolished in 
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the presence of CGP 55845 (50 ms APO-UNSUS 0.90 ± 0.03; APO-SUS 0.89 ± 0.05, p=0.75; 
100 ms APO-UNSUS 0.88 ± 0.02; APO-SUS 0.84 ± 0.02, p=0.29; 150 ms APO-UNSUS 0.81 ± 
0.01; APO-SUS 0.82 ± 0.04, p=0.68; 200 ms APO-UNSUS 0.79 ± 0.02; APO-SUS 0.82 ± 0.03, 
p=0.38; 500 ms APO-UNSUS 0.81 ± 0.02; APO-SUS 0.83 ± 0.02, p=0.24; Fig. 4c,d), indicating 
that increased GABA
B
 receptor signaling underlies the decreased paired-pulse ratio in APO-
SUS compared to APO-UNSUS rats. Of note, blocking of GABA
B
 receptors with CGP 55845 had 
no effect on the paired-pulse ratio of APO-UNSUS rats at all ISIs tested (Fig. 4e,f), indicating 
that GABA
B
 receptor signaling does not play a role in these experiments in APO-UNSUS rats.
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Fig. 4. APO-SUS rats show a reduced paired-pulse ratio at long ≥150 ms inter-stimulus intervals (ISI). 
(a,b) Representative traces (a) and quantification (b) of the paired-pulse ratio at different ISIs from APO-UNSUS 
(n=14/3) and APO-SUS (n=15/4) rats. (c,d) Representative traces (c) and quantification (d) of the paired-pulse ratio 
at different ISIs in the presence of the GABA
B
 antagonist CGP 55845 from APO-UNSUS (n=10/3) and APO-SUS 
(n=12/3) rats. (e,f) Comparison between APO-UNSUS in the absence or presence of CGP 55845, note that these 
traces are the same as in a,b and c,d. Representative traces show an overlay of all 5 individual inter-stimulus 
intervals. Sample size (n) is shown as number of cells/number of animals. Data are presented as mean ± SEM. 
*p<0.05; **p<0.01. Student’s t-test with Holm-Sidak correction for multiple comparisons.
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5.3.5 Increased expression of GABAB receptors, but not GAT1, in the mPFC of APO-SUS rats
The increase in GABA
B
 receptor signaling could be caused either by an increase of GABA
B
 
receptor activation, through increased levels of extracellular GABA, or by an increase in 
the number of GABA
B
 receptors. Increased levels of extracellular GABA could be caused by 
a reduction in the expression of GAT1, the main GABA transporter in the central nervous 
system41. GAT1 reduces the amount of extracellular GABA in the synapse, which reduces 
spillover41. GABA
B
 receptors are located perisynaptically, and are activated by GABA 
spillover. In addition, reduced GAT1 expression has been found in schizophrenia patients42 
and animal models12 of schizophrenia. We therefore first assessed the levels of GAT1 in 
punches from the mPFC of APO-SUS and APO-UNSUS rats by performing western blot 
analysis. However, we found no significant difference between APO-SUS and APO-UNSUS 
rats (p=0.73; Fig. 5a,b). We next studied the protein expression levels of GABA
B
 receptors. 
Western blot analysis using an antibody against the GABA
B1
 subunit, which together with 
the GABA
B2
 receptor forms an active GABA
B
 receptor43, revealed that the levels of GABA
B1
 
were increased by ~110% in the mPFC of APO-SUS rats compared to APO-UNSUS mPFC 
(p<0.05; Fig. 5a,b). Together, our data suggest that increased GABA
B
 receptor signaling in 
APO-SUS rats is accompanied by increased expression of the GABA
B1
 subunit, and underlies 
the decreased paired-pulse ratio in APO-SUS rats.
5.4 Discussion
The GABAergic system plays an important role in the pathophysiology of schizophrenia44,45. 
Here, using the APO-SUS/APO-UNSUS rat model at PND 20-22 we further highlight the 
importance of dysfunctional GABA signaling in schizophrenia-related traits. We provide 
several lines of evidence for deficits in the inhibitory circuitry within the PRL of APO-SUS
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Fig. 5. The expression of GABAB1, but not GAT1, is increased in the medial prefrontal cortex of APO-SUS rats. 
(a) Representative blot and (b) quantification of western blot analysis for GAT1 and GABA
B1
 on APO-UNSUS and 
APO-SUS. Expression is normalized to APO-UNSUS expression of the respective protein. Sample size (n) in indicated 
in the bars. Data is presented as mean ± SEM, * p<0.05. Student’s t-test.
APO-SUS/APO-UNSUS 155
5
rats: (i) a reduced level of GAD67 in interneurons in the mPFC of APO-SUS rats, specifically 
in the PRL; (ii) a reduced paired-pulse ratio at longer (≥ 150ms) ISIs in APO-SUS rats; and 
(iii) increased GABA
B
 signaling due to an increased expression of the GABA
B1
 subunit of the 
GABA
B
 receptor. Finally, we were able to reverse the increased GABA
B
 signaling in APO-SUS 
rats by the application of the GABA
B
 antagonist CGP 55845.
In our present study on the GABAergic system in the APO-SUS rats, we observed a decreased 
protein level of GAD67 in the PRL. Also, we found a reduced number of GAD67+ cells in 
this region. However, the number of CB+, CR+ and PV+ neurons, which together account 
for ~90% of interneurons30, remained unchanged in the APO-SUS rat, indicating the total 
number of interneurons is unaltered. The reduced number of GAD67+ cells could result from 
a reduction of GAD67 levels per cell, causing these interneurons to be under the detection 
threshold of our analysis. Indeed, reduced levels of GAD67 have been reported before in 
schizophrenia both in animal models and post-mortem patient studies17,46,47.
A number of studies has shown that reduced prefrontal inhibitory transmission induces 
various cognitive, emotional and dopaminergic abnormalities that resemble aspects 
of schizophrenia48. More specifically, reduced GABAergic activity in the PRL of the rat 
PFC results in deficits in speed of processing information, cognitive flexibility, recall of 
relevant information and enhanced dopamine activity49,50. In this respect, it is of interest 
to note that GABAergic interneurons in the mPFC receive direct input from mesocortical 
dopaminergic fibers, and this control matures during adolescence and appears crucial for 
cortical network activity at adulthood51. Moreover, together with the genetic background 
and environmental stress the developmental ingrowth of dopaminergic fibers may lead 
to an abnormal functioning of the GABAergic interneurons at adulthood, especially under 
stressful conditions that also alter the dopamine system52. A functional dysregulation of the 
mesostriatal dopaminergic neurons in schizophrenia has indeed been well established8,53,54. 
Given that we found altered levels of GAD67 in the mPFC of APO-SUS rats, indicative of a 
reduced inhibitory drive, we studied changes in the basal synaptic input connectivity of 
LII/III pyramidal neurons. Surprisingly, mIPSC amplitude and frequency on these neurons 
were unaltered, as was the presynaptic release probability for GABA, indicating that the 
changes in interneuron composition were not accompanied by changes in basal synaptic 
input. Additionally, we did not observe any changes in the response to bath application of 
GABA, indicating that the total number of GABA
A
 receptors was unaltered. Together, these 
results suggest that the total number and strength of inhibitory synapses are not different 
between APO-SUS and APO-UNSUS rats. However, this study does not include a measure of 
excitability of the individual classes of interneurons within the mPFC and it is conceivable 
that the reduced inhibitory activity is due to a reduced excitability of one or more subclasses 
of interneurons. The use of reporter rodent lines will allow the targeted exploration of the 
excitability of specific interneuron subclasses in future studies. 
While we did not observe differences at the level of synaptic transmission and morphology 
of LII/III pyramidal cells, we found a clear reduction in the paired-pulse ratio in the APO-SUS 
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compared to APO-UNSUS rats. This reduction was specific for ISIs longer than 150 ms, and 
was not observed in ≤100 ms ISIs. The reduced paired-pulse ratio at ≥150 ms ISIs indicates 
a reduced release of neurotransmitter at the second pulse. We show that enhanced GABA
B
 
receptor signaling, at least in part, underlies this reduction. Indeed, the paired-pulse ratio 
in the APO-SUS rats could be restored to the levels observed in the APO-UNSUS rats by 
application of the GABA
B 
receptor antagonist CGP 55845. GABA
B
 receptors are metabotropic 
G-protein-coupled GABA receptors, and are located perisynaptically at both the pre- and 
postsynapse55. Presynaptic GABA
B
 receptors reduce calcium inflow mainly by inhibiting 
N- type and P/Q type voltage-gated calcium channels and to a lesser extent by activating 
inward-rectifying potassium channels such as Kir3, causing a hyperpolarization55. Both 
pathways reduce the inflow of calcium, and occur with a delay of ~150 ms and slow decay 
of ~1 s40 consistent with the maximal effect that we observed at the 150 ms ISI. Postsynaptic 
GABA
B
 receptors mediate opening of potassium channels, but both the absence of an 
outward current in our recordings as well as the use of a cesium-based intracellular 
recording solution exclude the possibility of a postsynaptic contribution of GABA
B
 receptors 
to our recordings and point to presynaptic GABA
B
 receptor activity underlying the observed 
changes. Activation of presynaptic GABA
B
 receptors reduces calcium conductance and 
subsequent GABA release, and therefore provides a negative feedback to the GABAergic 
system56,57. Interestingly, a reduced inhibitory input onto excitatory pyramidal cells has been 
found in models for schizophrenia20 and autism58, and underlines the notion that a proper 
tuning of excitation and inhibition is required for proper brain function11. Importantly, a 
number of studies have highlighted a crucial link between GABA transmission and cognitive 
dysfunction in schizophrenia, indicating that reduced prefrontal inhibitory transmission 
induces various cognitive, emotional and dopaminergic abnormalities that resemble aspects 
of this disorder48. 
Consistent with our finding of increased GABA
B
 signaling, we show that the expression 
of GABA
B1
 is increased in the mPFC of APO-SUS compared to APO-UNSUS rats. However, 
our results do not show if the increase in GABA
B1
 is due to an increase in the number of 
GABA
B1
-expressing cells, or an increase in the amount of GABA
B1
 per cell. Thus far, no 
comparative studies are available describing the levels of GABA
B
 receptors in individual 
interneuron subtypes. Interestingly, a reduction in GABA
B
 subunit expression has been 
observed in various brain regions of schizophrenia patients59–61. In humans, stimulation 
of cortical GABA
B
 receptors in the fronto-parietal network has led to better attentional 
allocation in reinforcement learning62. In addition, GABA
B
 receptor manipulation has been 
shown to reverse behavioral changes related to psychosis63, improve pre-pulse inhibition 
deficits and ameliorate sensorimotor gating in rodent models64. Combining the results 
of the present animal study with the results of the previously reported patient studies 
suggests that both reduced as well as increased GABA
B
 signaling may underlie some of the 
aspects of schizophrenia. Of note, most schizophrenia research on patients is hampered by 
the use of medication, whereas the rat model used in this study is drug naive. Additional 
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preclinical studies are warranted to further evaluate the hypothesis that the GABA
B
 receptor 
represents a promising pharmacological target for treating appropriately stratified subsets 
of individuals with schizophrenia.
It is important to notice that schizophrenia is a disorder with an onset during adolescence 
or early adulthood 65. The PND 20-22 rats used for this study are in their early adolescence, 
and therefore do not necessarily display the schizophrenia-relevant features that 
have been described in adult rats21–26. Even though the exact mechanisms underlying 
neurodevelopmental disorders, including schizophrenia, are unknown, many theories 
exist about a distorted balance between neuronal excitation and inhibition during 
development51,66,67. While it is difficult to distinguish primary effects from homeostatic- and 
compensatory mechanisms, a substantial amount of evidence points in the direction of 
disrupted inhibitory signaling as an important factor in the etiology of schizophrenia12,51,68. 
Our data suggest a possible role for GABA B receptor signaling in the development of the 
schizophrenia-relevant features observed in adult APO-SUS/APO-UNSUS rats.
In conclusion, our findings highlight the importance of GABAergic signaling for inducing 
schizophrenia-related phenotypes, and identify GABA
B
 receptors as potential new key 
players in the distorted network functioning in this disorder.
5.5 Methods
Animals
All experiments were performed with male Wistar (PND20-22) rats pharmacogenetically 
selected for high susceptibility (APO-SUS) or low susceptibility (APO-UNSUS) to apomorphine. 
The generation of APO-SUS and APO-UNSUS rat lines has been described previously21. In 
short, upon injection of apomorphine, a bimodal distribution of the gnawing response 
was found, i.e. approximately 40% of the Wistar rats showed a weak gnawing response 
(<10 counts/45min) and a similar percentage showed an intense gnawing response (>500 
counts/45min). Following this initial selection, the nine males and females with the highest 
scores, and the nine males and females with the lowest scores were paired and their 
offspring was again tested for their gnawing response. For each new generation, nine new 
pairs of rats were selected out of the four male and female litters showing the highest (APO-
SUS) and the lowest (APO-UNSUS) mean gnawing response per gender, with the condition 
that brother/sister pairing was not allowed. APO-SUS rats are defined as animals born from 
an APO-SUS mother and father; APO-UNSUS rats are likewise defined as animals born from 
an APO-UNSUS mother and father. The present experiments were performed with naive male 
APO-SUS and APO-UNSUS rats belonging to the 38th and 40th generation, i.e. apomorphine was 
used only during the procedure to select and generate the APO-SUS and APO-UNSUS lines. 
All rats were bred and reared in the Central Animal Facility of the Radboud University 
Nijmegen. The animals were reared and housed in macrolon cages (42 × 26 × 15 cm) in 
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a controlled (20 ± 2 °C) and enriched environment under a 12 h light/dark cycle (lights on 
at 7:00 A.M). Food pellets and water were provided ad libitum. Experimental procedures 
were performed between 9:00 A.M. and 5:00 P.M. The experimental procedures were 
approved by the Animal Ethics Committee of the Radboud University Nijmegen (Nijmegen, 
the Netherlands) and conducted in accordance with the Dutch legislation. Every effort was 
made to minimize the number of animals used and their suffering.
Western	blotting
For the western blot experiments the animals were decapitated and the brains were 
collected quickly, frozen on dry ice, and kept at -80°C. The brains were sliced into 200 μm 
coronal sections using a cryostat (Microm HM 500OM) at -15°C and mounted on glass slides. 
Punches from 6 sections of the mPFC (prelimbic and infralimbic region) were taken with a 2 
mm diameter micropunch needle (Harris Inc.) between the first appearance of the corpus 
callosum and the start of the caudate putamen. The coordinates were determined according 
to the atlas of Paxinos and Watson69. Samples from each hemisphere were pooled. All the 
samples were stored at −80°C before protein extraction took place. 
Brain punches were homogenized in 50 μl of lysis buffer (50 mM Hepes pH 7.4, 140 mM NaCl, 
0.1% Triton-X100, 1% Tween 20, 0.1% deoxycholate) supplemented with protease inhibitor 
mix (Roche Diagnostics). The protein levels were assessed using the Bradford assay. After 
protein measurement, sodium dodecyl sulfate polyacrilamide gel electrophoresis (SDS-
PAGE) on 10% (w/v) at 100V for 90 minutes was carried out using a Mini-Protean system 
(Bio-Rad, USA). Protein (40 μg) was loaded in each lane with loading buffer (0.25 M Tris-HCl, 
pH 6.8, 2% SDS, 10% glycerol, 0.25% bromophenolblue, 4% beta-mercaptoethanol). After 
electrophoresis, proteins were transferred to a polyvinylidene fluoride membrane (PVDF, 
Amersham, Hybond-P), using an electrophoretic transfer system (Bio-Rad, USA) at 400 mA 
for 90 minutes. The membranes were then blocked with 5% skimmed milk dissolved in 0.1 
M PBS for one hour. The membranes were incubated overnight at 4˚C with the primary 
antibodies diluted in blocking buffer containing 5% skimmed milk dissolved in a PBS Tween 
20 mixture (5%) (PBS-T, Sigma-Aldrich). The primary antibodies were the following: mouse 
monoclonal antibodies for CB D-28K (1:1000, Swant), CR (1:1000, Swant), GAD67 (1:1000, 
Abcam), GAT1 (1:500, Abcam), GABAB1 (1:500, Abcam), and gamma-tubulin (1:10000, 
Sigma). After being washed for one hour with 1% skimmed milk in PBS-T (0.05%), the 
membranes were incubated for one hour in the dark at room temperature with goat-anti-
mouse secondary antibody (1:10.000; LI-COR Biosciences Inc; IRDye 680). The membranes 
were imaged using an Odyssey IR-scanner (LI-COR Biosciences, Inc.) and the generated 
pictures were quantified using the Odyssey software (Li-COR Biosciences Inc.). The levels of 
protein expression were normalized to beta-tubulin. Protein expression values normalized 
to APO-UNSUS values (relative intensity).
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Immunohistochemistry
For the fluorescent immunohistochemistry experiments, rats were sacrificed by direct 
decapitation without anesthesia, after which the brains were extracted and post-fixated by 
immersion in 2% paraformaldehyde (PFA) in 0.1 M PBS, pH 7.4 for 48 hours. After post-
fixation, the brains were transferred to a 30% sucrose solution for cryoprotection. Coronal 
sections (10 µm) were cut on cryostate, collected on SuperFrost glass slides and stored at 
-20°C until further processing. 
Sections (10 µm) were incubated for 1 h in blocking buffer (5% normal goat, horse and 
donkey serum, 1% BSA, 1% glycine, 0,1% lysine, 0,4% Triton X-100) to minimize nonspecific 
labeling. Tissue sections were then incubated overnight at room temperature with mouse 
monoclonal primary antibodies diluted in blocking buffer against CB D-28k (1:2000; CB300; 
Swant), CR (1:3500; CR-6B3, Swant), or PV (1:8000; PV-235, Swant); for GAD67 (1:5000; K-87, 
Abcam), incubation was done for 4h at room temperature, followed by a 65h incubation at 
4 ˚C. The next morning, sections were washed in PBS and placed for 1.5h in a 1:500 dilution 
of goat-anti-mouse Alexa-fluor 488 secondary antibody (Invitrogen). Hoechst (bisBenzimide 
dye, No 33342, Sigma B-2261; 1 µg/mL prepared in 0.1 M PBS) staining was performed 
for nuclear staining. After overnight drying of the sections at room temperature, they 
were coverslipped with FluorSaveTM Reagent (Merck Millipore). The next day, slides were 
visualized with an automated high content epifluorescence microscope with digital image 
acquisition (Leica DMI6000B inverted microscope, Leica EL6000 illumination source). The 
pictures were manually analyzed and quantified at 10X magnification using FIJI3 in a blinded 
fashion. The values obtained for each animal represent the average of measurements taken 
from 3-4 equally spaced sections for each brain area. Nomenclature of the brain was based 
on the atlas of Paxinos and Watson69.
Electrophysiology
Rats were anesthetized with isoflurane before decapitation. Coronal slices (350 µm) were cut 
using a HM650V vibration microtome (Thermo Scientific) in ice cold artificial cerebrospinal 
fluid (ACSF) containing (in mM): 124 NaCl; 11 Glucose; 3 KCl; 1.25 NaH
2
PO
4
; 1 CaCl
2
; 4 MgCl
2
; 
26 NaHCO
3
, continuously oxygenated with 95% O2/5% CO
2
 and incubated for 1h at room 
temperature. Slices were transferred to the recording setup 15 minutes prior to recording 
and incubated at 30°C while being continuously oxygenated with 95% O
2
/5% CO
2
 in recording 
ACSF containing (unless otherwise stated)(in mM): 124 NaCl, 1.25 NaH
2
PO
4
, 3 KCl, 26 
NaHCO
3
, 10 Glucose, 2 CaCl
2
, 1 MgCl
2
. Patch pipettes (3-5 MΩ) were made from borosilicate 
glass capillaries and filled with intracellular solution containing (in mM): 115 CsMeSO
3
; 20 
CsCl; 10 HEPES; 2.5 MgCl
2
; 4 Na
2
ATP; 0.4 NaGTP; 10 Na-Phosphocreatine; 0.6 EGTA. Traces 
were recorded using a Multiclamp 700B amplifier (Molecular Devices), sampled at 10 kHz 
and filtered at 2 kHz. Cells were excluded from analysis if the series resistance exceeded 25 
MΩ. Paired-pulse ratio (PPR) was recorded following stimulation in LII/III of the PFC in the 
presence of CNQX and D-APV, in ACSF containing 4 mM CaCl
2
 and 4 mM MgCl
2 
to increase
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the stimulated responses, at a holding potential of -60 mV. Stimulation strength was set to 
evoke a ~200pA response to the first stimulus. Two 1 ms pulses were given with a 50 ms, 100 
ms, 150 ms, 200 ms or 500 ms interval. PPR was calculated as peak2/peak1 after correcting 
for any residual current at the second pulse. CGP 55845 was used at a concentration of 10 
µM70. For GABA application, cells were allowed to stabilize their holding current, after which 
20μM GABA was washed in. We quantified the maximal change in holding current as the 
maximal response to the washed in GABA. Miniature recordings were analyzed using Mini 
Analysis Program (Synaptosoft). Other traces were analyzed using Clampfit 10.2. All drugs 
were purchased from Tocris.
Morphological	reconstructions
For morphological reconstructions, the internal solution was supplemented with 0.4% 
biocytin (Sigma-Aldrich). Following single-cell electrophysiology, the slices with biocytin-
filled neurons were fixated in 4% paraformaldehyde in 0.1 M PBS overnight at 4°C, and 
subsequently processed following a modified staining protocol based on Marx et al.5.  In 
brief:  after fixation, slices were rinsed in 0.1 M PB, incubated in 3% H2O2 in 0.1 M PB for 30 
minutes at room temperature to quench endogenous peroxidases, rinsed in 0.1 M PBS, then 
incubated in Avidin-Biotin-Peroxidase solution (Vectastain Elite, with 1% v/v Triton-100) 
overnight on a shaking platform at 4°C. The next day, slices were washed with 0.1M PBS 
and pre-incubated with Di-Aminobenzidine (DAB) solution with Nickel enhancer (Vector 
Peroxidase substrate kit, SK-4100) for 30 min. Then, the DAB solution was replaced with the 
same solution plus H2O2 and incubated for ca. 30 seconds. Slices were then rinsed in 0.1 M 
PB, mounted on gelatinized coverslips, and dried for 3-6 h in a custom-made moist chamber 
at room temperature. Slices were dehydrated in an ethanol series and Xylene, put on 
coverslips and sealed with Eukitt (Sigma). Slices were imaged on a Zeiss Axioskop 1 upright 
brightfield microscope with 20x and 40x objectives (Zeiss EC Plan-Neofluar, NA 0.5 and 0.75, 
respectively) and motorized stage (MicroBrightField). The camera and motorized stage were 
connected to a Neurolucida workstation (MicroBrightField). Cells were selected based on 
position in the cortical layer II/III of the prefrontal cortex, pyramidal morphology, and staining 
intensity. Somata, apical and basal dendrites were reconstructed in Neurolucida as three-
dimensional drawings. Reconstructions were analysed in NeuroExplorer (MicroBrightField) 
for intrinsic parameters and Sholl analysis.
Statistical	analysis
Statistical analysis was performed using Prism (Graphpad). Significance was tested with a 
two-sided Student’s t-test. Correction for multiple comparisons was performed using the 
Holm-Sidak method where indicated. Data is expressed as mean ± SEM. Significance was 
defined as p<0.05 (*) or p<0.01 (**).
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6.1 Introduction
The brain is a complex organ in which numerous neurons form a highly interconnected 
network in order to allow for proper function. Individual neurons integrate afferent 
information, and send their output to the neurons they, in turn, are connected to. Proper 
wiring of the many different types of neurons, as well as the strength of the formed 
connections is vital for normal network function. Neurons are connected to each other 
via synapses, and abnormalities in both the number and strength of synaptic connections 
have been consistently identified in different neurodevelopmental disorders such as Autism 
Spectrum Disorders (ASD), Attention Deficit Hyperactivity Disorder (ADHD) but also in 
mental disorders such as Schizophrenia and Bipolar Disorder. Interestingly, abnormalities in 
neuronal connectivity seem to focus on a particular cell type: parvalbumin-expressing (PV+) 
interneurons.
In this thesis I investigated the role of the inhibitory system in rodents, modelling three 
different neurodevelopmental disorders. Together with my colleagues, I have consistently 
found alterations affecting the inhibitory system which, at least partially, underlie these 
conditions. Here I will discuss the observed changes, and attempt to put these findings 
into a context of the consequentially disrupted network function. Finally, I will discuss the 
inhibitory system as a possible target for therapeutic intervention.
6.2 Inhibitory interneurons as a point of convergence in neurodevelopmental 
disorders
In this thesis I have investigated three rodent models for neurodevelopmental disorders. I 
will first summarize these models and describe the alterations we identified (Fig.1). 
CDH13
The first model studied in this thesis is the Cadherin 13 knock-out (Cdh13-/-) mouse (Chapter 
1 and 2). Cadherins are a large family of cell-adhesion molecules that are expressed in all 
vertebrates, and many lower species1. Cadherins have been shown to be important for 
migration2–4, axon guidance5,6, spine regulation7 and synapse formation and maintenance8–10 
(for review see Basu et al.11). Also, genome-wide association studies have linked various 
cadherins to neurodevelopmental disorders12. Cadherins are believed to convey a code of 
neuronal identity, such that pre- and postsynaptic compartments can recognize each other 
and only form connections if they express compatible cadherins13. Indeed, cadherins are 
expressed in an orderly pattern, seemingly respecting borders of brain regions14, cortical 
layers15 and hippocampal sub-fields16. Neuronal hippocampal culture experiments show that 
dissociated neurons preferentially form synapses with those cells they would connect to in 
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vivo, showing the existence of a molecular code8. Furthermore, loss of cadherin 9 (CDH9) 
disrupts synapse formation between dentate gyrus granule cells and CA3 pyramidal neurons 
in	 vitro8. In addition, reduced expression of CDH9 disrupts the formation of mossy fiber 
synapses, the synapses between dentate gyrus granule cells and CA3 pyramidal neurons, in 
vivo8. Together, these data show that cadherins play an important role in network formation.
Mutations and copy-number variations in Cdh13 have been implicated in various 
neurodevelopmental disorders, primarily in ADHD17–21 and comorbid disorders, such as 
substance use and dependence22 and extremely violent behaviour23. In addition, studies 
have shown a link between Cdh13 and ASD21, schizophrenia24, bipolar disorder25 and 
depression26. We show that CDH13 expression is limited to interneurons, mainly the PV+ 
and somatostatin-positive (SOM+) subtypes, and find that Cdh13-/- mice show an increase 
in the number of inhibitory, but not excitatory, inputs onto hippocampal CA1 pyramidal 
neurons. This increase is caused by an increase in the number of inhibitory synapses (Fig. 
1B). In order to investigate the contribution of PV+ interneurons we conditionally deleted 
Cdh13 from all PV cells (Cdh13PV-/-), and observed an increase in the number of perisomatic 
PV+ synapses onto CA1 pyramidal neurons. These data show that loss of Cdh13 from PV+ 
interneurons is sufficient to increase the number of synaptic contacts onto pyramidal 
neurons, and indicated that an increase of PV+ synapses at least contributes to the synaptic 
phenotype observed in the Cdh13-/-	mice.
Mechanistically, we propose that CDH13 regulates inhibitory synaptic strength via its 
interaction with Integrin β1 (ITGβ1) and Integrin β3 (ITGβ3) since acute pharmacological 
disruption of ITGβ1 and ITGβ3 function leads to reduced inhibitory strength in wild-type 
(WT) mice, but not in Cdh13-/- mice, indicating a role in the regulation of inhibitory synaptic 
strength for CDH13 via ITGβ1 and ITGβ3.
While we show an important role for PV+ interneurons in the phenotypes observed in 
these mice, we do not know to what extend PV+ interneurons contribute to the behavioural 
alterations. For future research, it would be very interesting to see if the ADHD related 
phenotypes observed in the Cdh13-/- mice can be recapitulated in Cdh13PV-/-	mice.
EHMT1
The second model I investigated is the Ehmt1+/- mouse (Chapter 3) a model for Kleefstra 
syndrome (KS). KS patients have intellectual disability and ASD27–30 as consistent mental 
manifestations. We studied the development of synaptic connectivity during development 
at postnatal day (P) 7, P14 and P21 onto hippocampal CA1 pyramidal neurons. Excitatory 
synaptic number and strength were unaltered throughout development. Conversely, we 
found an abnormal development of inhibitory connectivity in Ehmt1+/- mice. Inhibitory 
synaptic strength was reduced at all time-points. The number of inhibitory synaptic contacts 
was increased at P7, unaltered at P14, and reduced at postnatal day P21 (Fig. 1C). While we did 
not look into the reasons for this distorted developmental pattern, it is interesting to note that 
the change from an increased to a decreased number of inhibitory synaptic contact around 
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Fig. 1: Overview of the results described in this thesis. 
alterations to inhibitory input, alterations to excitatory input, alterations to plasticity, alterations to intrinsic 
properties and the proposed effect of our findings on the E/I balance compared between (A) Wild-type, (B) 
Cdh13-/- mice, (C) Ehmt1+/- mice and (D) APO-SUS rats. ADHD, Attention Deficit Hyperactivity Disorder; ASD, Autism 
Spectrum Disorders; BD, Bipolar Disorder; ID, Intellectual Disability, E, Excitation; I, Inhibition.
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P14 coincides with the switch of GABAergic action from excitatory to inhibitory around that 
same age31. Also, distortion of GABAergic inhibitory function at birth has been associated 
with the development of ASD32,33. The fact that inhibitory connectivity is not consistently 
reduced or increased suggests that the inhibitory phenotype is not caused by a direct 
disruption of the synapse, but rather by an alteration in the signalling for synapse formation. 
BDNF is an interesting candidate in this respect. BDNF has been linked to the regulation of 
inhibitory synapses34 and maturation of the inhibitory system35. In addition, a previous study 
from our lab has shown that EHMT1 is required for the methylation of promotor region IV for 
of the Bdnf gene36. Bdnf expression from promotor IV has previously been shown to play an 
important role in activity-dependent expression of BDNF37,38, while other studies report that 
activity-dependent expression of BDNF is important for the regulation of PV+ interneuron 
connectivity39,40. Indeed, PV+ interneurons alter their inhibitory strength onto individual 
pyramidal neurons dependent on the pyramidal neurons’ activity in a homeostatic manner41.
While it is interesting to speculate about the involvement of PV+ interneurons in the 
phenotypes, both synaptically and behaviourally, observed in Ehmt1+/- mice, this hypothesis 
remains to be experimentally tested. Expression of channelrhodopsin in PV+ interneurons 
in Ehmt1+/- mice and mice in which Ehmt1 is disrupted specifically in PV+ interneurons 
(Ehmt1PV+/-), could address the contribution of PV+ interneurons to the synaptic phenotypes. 
In addition, behavioural experiments using Ehmt1PV+/-	mice would address the contribution of 
PV+ interneurons to the behavioural phenotypes observed in this model. Together, Ehmt1+/- 
mice show a disrupted development of inhibitory contacts, and the reduced inhibitory drive 
at P21 onto the pyramidal neurons shifts the excitatory/inhibitory (E/I) balance towards 
excitation. In addition to this shift, pyramidal neurons show an increased excitability caused 
by a hyperpolarization of the action potential threshold, further adding to a hyper-excitable 
network.
APO-SUS
The third model studied in this thesis is the APO SUS/UNSUS rat. The APO-SUS rat has many 
features resembling schizophrenia (Chapter 4). The APO-SUS/UNSUS model was generated 
over 25 years ago by injecting rats with the dopamine agonist apomorphine42. Rats that 
showed very responsive to apomorphine were selected and bred (apomorphine susceptible; 
APO-SUS). Also, rats unresponsive to apomorphine were bred (apomorphine unsusceptible 
(APO-UNSUS). APO-SUS rats have subsequently been shown to model schizophrenic 
phenotypes besides increased sensitivity to dopamine, both behaviourally (reduced pre-
pulse inhibition)43,44 and neurologically45.
In this model we did not find changes in either excitatory or inhibitory synaptic connectivity 
onto cortical layer 2/3 pyramidal neurons (Fig. 1D). Inhibitory and excitatory release 
probabilities were also indistinguishable between these two rat lines. However, APO-SUS 
rats showed a reduced inhibitory paired pulse ratio at longer (≥ 150 ms) inter-stimulus 
intervals, which we identified to be caused by an increased expression of presynaptic GABA 
B
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receptors. So, while basal inhibitory connectivity is not affected in this model, we identified 
changes in inhibitory plasticity in APO-SUS rats.
Presynaptic GABA
B
 receptor expression has been shown in perisomatic synapses formed by 
PV+46,47 and cholecystokinin-positive (CCK+)48 basket cells, where they reduce presynaptic 
release46. Inhibitory transmission is stronger reduced in CCK+ than in PV+ interneurons 
following application of the GABA
B
 receptor agonist baclofen48. In addition, multiple 
interneuron subtypes are known to express GABA
B
 receptors, even though their subcellular 
localization to the presynapse has not been shown49. Because of the general expression of 
GABA
B
 receptors in various interneuron subtypes, it is difficult to discuss about the specific 
inhibitory connections affected by altered GABA
B
 signalling to underlie the phenotypes 
observed in APO-SUS rats. Since he APO-SUS/UNSUS rats are not a (mono)genetic model, 
cell type specific targeting is not possible. However, cell type specific optogenetic stimulation 
could be used to address the effects of increased GABAB signalling on specific interneuron 
subpopulations.
The involvement of non-PV+ interneurons in neurodevelopmental disorders
It has to be noted that this discussion does not attempt to claim that PV+ interneurons 
underlie all phenotypes observed in the rodent models. As mentioned above, GABA
B
 
receptor expression is not limited to PV+ interneurons, suggesting that other interneuron 
subtypes could play a role in the altered phenotype of APO-SUS rats. In addition, while 
we show an increased GABA
B
 signalling at the inhibitory presynaptic compartment, we do 
not show that the increased GABA
B
 expression is limited to inhibitory presynapses. GABA
B
 
receptors are also expressed in postsynaptic cells, where they inhibit action potential 
back-propagation50, regulate rhythmic activity51 and regulate tonic inhibition via δ-subunit 
containing GABA
A
 receptor expression52,53. Postsynaptic GABA
B
 expression can be increased 
alongside presynaptic GABA
B
 expression, leading to alterations in these processes.
Altered function of interneuron subtypes other than PV+ interneurons might contribute 
to the phenotypes in the Cdh13 and Ehmt1 models. While we show that both genes are 
expressed in PV+ interneurons, they are also expressed in other interneuron subtypes, 
mainly SOM+ interneurons. Previous studies have shown that non-PV+ interneurons can play 
important roles in the generation of phenotypes equivalent to patient symptoms in rodent 
models54. Also, SOM+ interneurons have been identified to play a role in cortical gamma 
synchronization55, alteration of which is a common phenotype in neurodevelopmental 
disorders56.
Because of the importance of PV+ interneurons in neurodevelopmental disorders, it 
would be interesting to see to what extent PV+ interneurons are responsible for the 
phenotypes observed in our models. For the Cdh13 and Ehmt1 models, deletion of these 
genes specifically from PV+ interneurons would show if both electrophysiological as well 
as behavioural phenotypes are caused by PV+ cell dysfunction. This approach does not 
work for the APO-SUS rat, since this is not a genetic model. However, for all three models, 
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expression of channelrhodopsin in PV+ interneurons would allow for specific stimulation of 
these cells. Via this approach it is possible to isolate the contribution of PV+ interneurons 
and investigate if the observed changes in our models are indeed caused by alterations to 
the synaptic connectivity, strength or plasticity of PV+ synapses.
Alterations to PV+ interneurons alone are not sufficient to explain patient symptoms
The three models investigated in this thesis represent distinct disorders, yet all show 
alterations to inhibitory, but not excitatory, input onto pyramidal neurons. However, the 
changes to the inhibitory input are distinct for each model: increased inhibitory synapse 
number (Cdh13), decreased inhibitory synapse number (Ehmt1) and increased presynaptic 
GABA
B
 receptor signalling (APO-SUS). While it is tempting to link the specific inhibitory 
change to a specific disorder, there are a few reasons why this might be an oversimplification.
First, while many studies focus on changes to the inhibitory system in models of 
neurodevelopmental disorders, these studies, including the ones presented in this thesis, 
always focus on a subset of network parameters. For example, the studies discussed 
in this thesis all focus on inhibitory input onto pyramidal neurons, but do not address 
changes to the inhibitory neurons themselves. Changes to interneurons can greatly impact 
network behaviour. For example, decreased interneuron excitability following disruption of 
the Scn1a gene, underlying Dravet syndrome57, leads to a reduced inhibitory drive onto 
downstream targets. Indeed, previous studies have identified a multitude of changes to the 
intrinsic properties of interneurons57–60, or their inputs61–65 in different disorders, showing 
that changes besides altered synaptic function onto pyramidal neurons play a role in these 
disorders. The fact that the studies in this thesis focus on inhibitory inputs onto pyramidal 
neurons means these studies most likely present only a ‘snapshot’ of all the alterations 
that together lead to the symptoms associated with a specific condition. In addition, while 
expression of CDH13 is limited to interneurons, EHMT1 is expressed ubiquitously. It is 
therefore expected that other functions besides inhibitory connectivity are affected in these 
mice. Indeed, previous studies have shown disruption of homeostatic plasticity in pyramidal 
neurons36, which plays an important role in maintenance of the E/I balance of these cells. 
Since APO-SUS rats are not a genetic, but a pharmacologically selected model, it is likely that 
the phenotypes in these rats are caused by changes in various parts of the network, including 
the dopaminergic system42. It is likely this more complete, complex interplay of multiple 
alterations, both to the inhibitory system as well as to other aspects of the network, that 
leads to specific changes in information processing and ultimately give rise to the symptoms 
observed in the specific disorders. 
Secondly, the inhibitory alterations we identify in our three disease models are found in 
related conditions, but lead to distinct symptoms. For example, while we observe an increased 
number of inhibitory synapses formed in Cdh13 mice, a similar inhibitory phenotype is 
found in mice with mutations in Shank3, which has been linked to ASD and schizophrenia66. 
In addition, the reduced number of inhibitory contacts we observe in the Ehmt1 model is 
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also found in mice with mutations in ErbB4, which has been linked to schizophrenia61, and 
mice with mutations in Tsc167, Ube3a68, Nlgn269, Nlgn370 and Cntnap271, all of which are 
mainly associated with ASD. So, while these models all show changes to inhibitory function 
onto pyramidal neurons, it is very likely that it is the combination of these inhibitory changes 
together with changes to different aspects of the network (e.g. interneuron excitability and 
received inputs, excitatory input to pyramidal neurons) that together distort the balance 
between excitation and inhibition that is required for proper network function, and give rise 
to the patient phenotypes observed in the different disorders.
6.3 Network alterations following interneuron dysfunction
The link between the inhibitory synaptic alterations observed in our models and the patient 
symptoms are found in the effects these alterations have on the functioning of the network. 
Interneurons are a group of highly varying neurons, a diversity which is believed to reflect 
the different function these cell types have72. In this section I will discuss the observed 
phenotypes, attempt to put these in a context of altered network function.
Cdh13
Cdh13-/- mice show an increase in perisomatic PV+ synapses onto pyramidal neurons. 
These synapses are formed by PV+ basket cells, a subtype of PV+ interneurons73. The 
somatic targeting of these interneurons allows for a strict control of the excitability of the 
postsynaptic pyramidal neuron, and creates a coincidence detection window for excitatory 
synaptic input74. Indeed, the connectivity of PV+ basket cells is tailored to this function (Fig. 
1 in chapter 1). In hippocampus, excitatory input from CA3 pyramidal neurons impinges 
onto the dendrites on CA1 pyramidal neurons and, via different axon terminals, PV+ basket 
cells. The PV+ basket cells in turn form their inhibitory synapses onto the soma of the 
pyramidal neuron. Since the pyramidal à PV+ basket cell à pyramidal pathway contains 
an extra synapse, PV+ basket cell inhibition reaches the CA1 pyramidal cell with a short 
delay. Experimental studies have found this delay to be around 2 ms74. It should be noted 
that one CA1 pyramidal neuron receives excitatory input from multiple CA3 pyramidal 
neurons, all of which are also wired in the feed-forward pathway as described above. The 
delay between excitatory and inhibitory input allows the excitatory input from multiple 
cells to summate and reach action potential threshold before the inhibitory input at the 
soma hyperpolarizes the cell and prevents action potential initiation. Via this feed-forward 
inhibition, only time-locked input of sufficient strength is able to evoke an action potential in 
a CA1 pyramidal neuron. Conversely, sparse, weak, and uncorrelated input will not summate 
to action potential threshold before inhibition arrives, and therefore will not evoke an 
action potential in the CA1 pyramidal cell. So, PV+ basket cells are integrated in a network 
that is optimized for feed-forward inhibition, and in this way contribute to increasing the 
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signal-to-noise ratio of the network. The importance of this connectivity in the regulation 
of pyramidal cell excitability shows further from the fact that the strength of feed-forward 
inhibition via PV+ interneurons is regulated in response to the activity of the pyramidal 
neuron, such that more active pyramidal neurons receive a stronger feed-forward inhibition 
from PV+ interneurons41.
The increased perisomatic inhibitory connectivity onto CA1 pyramidal neurons observed in 
Cdh13-/- mice suggests a disruption of this pathway. While we show that the number of PV+ 
interneurons is unaltered in Cdh13-/- mice, it is not known if this increase in PV+ synapses is 
the result of (1) an increase of the number of synaptic contacts per PV+ interneuron, or (2) 
of more PV+ interneurons contacting an individual pyramidal neuron. 
In the first scenario, PV+ interneuron activation would lead to a larger inhibitory transmission 
compared to WT mice. However, since the timing of the connection is not affected by the 
number of presynaptic terminals, this would not lead to a shortening of the coincidence 
detection window, but instead to a larger inhibitory effect. This in turn could mean that a 
smaller number of PV+ interneurons is required to prevent a pyramidal neuron from firing 
an action potential.
In the second scenario, pyramidal neurons receiving inhibitory input from more PV+ 
interneurons, the effects depend on the origin of the inhibitory contacts. If these cells 
receive input from the same CA3 pyramidal cells as do the CA1 pyramidal cell they inhibit, 
inhibition will still be time-locked, and therefore lead to a larger inhibitory effect, as seen 
in scenario 1. If, however, these contacts are formed by non-related PV+ interneurons, 
the inhibition from these cells will not be correlated with the feed-forward inhibition, and 
create an additional source of inhibitory input which could affect the time window of the 
coincidence detection window. 
Regardless of the correct scenario, increase of this feed-forward inhibitory circuit will 
negatively affect signal integration as well as the excitability of CA1 pyramidal neurons. Since 
the intrinsic properties of CA1 pyramidal neurons are unaltered in Cdh13-/- mice, it is likely 
that CA1 pyramidal neurons in Cdh13-/- mice are less excitable by CA3 excitatory inputs.
Does this finding of increased inhibitory drive fit with patient symptoms? The Cdh13 
mouse is a model for ADHD, and indeed shows increased locomotor activity and cognitive 
function associated with ADHD. In addition, CDH13 is strongly expressed in the thalamic 
reticular nucleus (TRN), a region consisting exclusively of inhibitory neurons, that is linked 
to attention75,76.
Previous studies have shown the role of PV+ interneurons in the regulation of gamma-
frequency oscillations (γ-oscillations)77,78, and that increased PV+ interneuron activity leads 
to an increase in the power of γ-oscillations79. While we have not measured γ-oscillations 
in Cdh13-/- mice, the increased inhibitory drive from these cells suggests an increase in 
the power of these oscillations. Interestingly, studies with ADHD patients found increased 
γ-oscillations both in children80,81 and adults82, consistent with the increased PV+ interneuron 
activity. These data indicate that mutations affecting Cdh13 could affect PV+ interneuron 
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inhibition leading to ADHD symptoms observed in patients. However, direct recording of the 
EEG of Cdh13-/- mice, as well as the study of PV+ interneurons synapses in ADHD patients will 
be important to fully understand this link.
Ehmt1
Ehmt1+/- mice are a model for Kleefstra syndrome which recapitulates the hypoactive and 
autistic-like features observed in patients83. In Ehmt1+/- mice we observed a reduction 
in inhibitory drive at P21, stemming from both a reduction in the strength of inhibitory 
synapses as well as a reduction in the number of inhibitory synapses. However, we cannot be 
sure that these inhibitory contacts originate from PV+ interneurons. KS patients have a high 
chance of developing ASD27–29. ASD is associated with a reduced power of γ-oscillations84,85, 
which could be explained by a reduced PV+ interneuron function. However, some studies 
also report an increase in the power of γ-oscillations in ASD86. 
Reduced inhibition onto CA1 pyramidal neurons would lead to an increased excitability of 
these cells. In addition, we also find the action potential threshold to be hyperpolarized in 
Ehmt1+/- mice, leading to a further increase in excitability. KS patients have a higher chance of 
epilepsy29, a condition often comorbid with intellectual disability87, which seems to worsen 
with increasing severity88. Epilepsy is a common comorbidity with neurodevelopmental 
disorders89, and is believed to stem from impaired inhibitory function90, or alteration to the 
E/I balance91. Our data, showing an increased intrinsic excitability and a reduced inhibitory 
drive, fits with this model. For future studies, is would be interesting to see if Ehmt1+/- mice 
are more prone to epileptic seizures.
APO-SUS
The APO-SUS rat is a model for schizophrenia44. In our study, we probed the inhibitory 
connectivity onto layer (L) 2/3 pyramidal neurons in the prefrontal cortex (PFC), a region 
strongly linked to this condition92,93. We identified an increase in GABA
B
 receptor signalling 
and a concomitant increase in GABA
B1
 subunit expression. This is surprising, since previous 
post-mortem studies on brains of schizophrenia patients had found a reduction in GABA
B
 
receptor expression in the PFC94, and lateral cerebellum95. The fact that schizophrenia has 
an onset during adolescence or early adulthood96, as well as the complicating factor that 
patient material often comes from patient receiving medication during their lives97 could 
play a role in this discrepancy with our young adolescent (P21), drug naïve rats.
Presynaptic GABA
B
 receptors play a role in short-term plasticity of inhibitory synapses. They 
are located perisynaptically and are activated by GABA spill-over from the synaptic cleft98. 
GABA
B
 receptors then, via the Gβγ subunit of G
i/o 
proteins, inhibit the presynaptic calcium 
channels (P/Q- or N-type) that are required for vesicle release99. Via this mechanism, GABA
B
 
receptors act as a negative feedback mechanism for GABA release. 
Since it is unknown which cells show the increased GABA
B
 receptor expression, it is difficult 
to identify specific changes in network function. In general, GABA
B
 receptor activity will 
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reduce the inhibitory drive onto the L2/3 pyramidal neurons. If this is originating from 
PV+ basket cells, this will lead reduced perisomatic inhibition and reduced power of 
γ-oscillations, as discussed before. Interestingly, reduced power of γ-oscillations is often 
observed in schizophrenia patients during negative symptoms100. If the overexpression 
originates from chandelier cells, targeting the axon-initial segment of pyramidal neurons, 
increased GABA
B
 receptor signalling could lead to a reduced neural synchrony101. Finally, 
if SOM+ interneurons were mainly affected, alterations the regulation of local dendritic 
calcium spikes could affect dendritic integration of excitatory inputs102. So, while disruptions 
in GABA
B
 receptor expression have been previously identified in schizophrenia patients, 
more research is required to see which neurons are affected by this increased expression, 
and to assess the resulting effects on network function.
Together, the alterations to the inhibitory system that we identified in the different models 
are consistent with previous findings in patients of the different disorders. However, it 
is difficult to make a one-to-one translation of the inhibitory phenotypes in rodents to 
EEG recordings and behavioural changes in humans. The studies presented in this thesis 
therefore can function as a starting point from which human-oriented research can move 
forward. For example, is there a reduced inhibitory drive in Kleefstra syndrome patients, 
and are pyramidal neurons more excitable? And if yes, is this only true for KS, or does this 
apply also to other forms of intellectual disability? The research presented here could prove 
a useful starting point to answer these questions.
6.4 A developmental role for interneurons in neurodevelopmental disorders
If proper wiring of neuronal networks is important for proper brain function, development 
of these networks is an important period for the development of, as the name suggests, 
neurodevelopmental disorders. Brain development is a long-lasting process that in humans 
lasts over 20 years103. However, the period in which brain regions, including auditory, visual 
and somatosensory cortices104, are most plastic is restricted to relatively short periods 
of time called critical periods105. During this period, disruptions to normal input severely 
alter the development of the network, whereas a similar alteration at adult stages has no 
lasting effect. For example, in mouse visual cortex, the critical period starts a week after 
eye opening106. Four days of monocular deprivation from the start of the critical period, 
but before P28, causes permanent loss of visual acuity in the closed eye107. However, the 
same treatment at later time points did not affect visual acuity107. BDNF expression plays 
an important role in this mechanism, since increased BDNF expression shortens the critical 
period through the accelerated maturation of GABAergic inhibition35,108, specifically of 
PV+ interneurons109, the maturation of which is correlated with the closing of the critical 
period35. PV+ interneurons are enwrapped by perineural nets (PNNs)110, a specialization of 
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the extracellular matrix which consists of chondroitin sulfate proteoglycans111, which are 
believed to regulate the local milieu112, and have been shown to play an important role in 
PV+ interneuron plasticity113. Maturation of PNNs coincides with the closing of the critical 
period114. Interestingly, disruption of perineural nets in adult mice reactivates the critical 
period115,116. Together, these data underline the important role PV+ interneurons play in 
proper network development.
Animal models for neurodevelopmental disorders show changes to the critical period. 
Fragile X syndrome (FXS) is a common cause of intellectual disability and ASD caused by 
reduced expression of fragile X mental retardation protein (FMRP). A prominent feature 
of FXS is an alteration in sensory processing with an onset in early infancy117. FMRP is 
coded by the FMR1 gene, and Fmr1 mutant mice show a delay in the timing of the critical 
period in multiple cortical areas including somatosensory cortex118,119, barrel cortex120 and 
auditory cortex121. On the other hand, Mecp2-/y mice, a model for Rett syndrome, an X-linked 
disorder associated with ASD and intellectual disability, show a precocious maturation of 
PV+ interneurons, PNN formation, increased GAD67 expression, and a concomitant shift of 
the critical period in visual cortex to earlier time points122. At P30, Mecp2-/y mice showed a 
reduced matching of orientation preference compared to control mice, suggesting a lasting 
alteration in the neuronal network122. Reduction of the expression of GAD67 to control levels 
restored PNN development and PV expression to levels comparable to control, as it did the 
timing of the critical period122, underlining the role of the inhibitory system in the regulation 
of critical period plasticity. 
Both the delayed critical period plasticity observed in Fmr1 mutant mice and the precocious 
critical period plasticity observed in Mecp2-/y lead to clear phenotypes in the respective 
models, for example in inhibitory input. Interestingly, these phenotypes are largely 
reduced or absent in older mice119,122. The fact that these phenotypes are less pronounced 
in older animals, while these animals still display the symptoms of the disorders, suggest 
that homeostatic mechanisms are influencing network connectivity following the altered 
development, but are not able to restore the disrupted development. This underlines the 
importance of the developmental period in neurodevelopmental disorders, and suggests 
that studies aiming to alleviate the burden of patients should, in addition to treatment of 
symptoms, focus on the developmental period in order to prevent the disrupted network 
formation observed in animal models.
6.5 The inhibitory system as a target for the treatment of neurodevelopmental 
disorders
The notion that intervention during development might help towards ameliorating the 
symptoms observed in neurodevelopmental disorders is exciting, but also comes with 
constraints. For instance, if critical periods play an important role in the development of 
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neurodevelopmental disorders, treatment should start before or during these periods. 
However, if symptoms develop during adolescence or adulthood, as for example in 
schizophrenia96, identification of patients at an early age is problematic. Two-thirds of people 
with an ultra-high risk for psychosis do not develop psychotic disorders123. The absence of 
good biomarkers to predict the development of neurodevelopmental symptoms does not 
allow us to distinguish between these groups at this moment. Since treatment of healthy 
individuals could disturb normal development, better biomarkers are required in order to 
consider pre-emptive treatment124.
However, other disorders already manifest recognisable symptoms during developmental 
stages. ASD have an onset during early childhood125, and therefore allows for identification 
of patients during the developmental period. Since ASD is believed to arise for a large 
part from the shift in the E/I balance towards excitation, increasing GABAergic drive might 
restore this balance and improve ASD symptoms. Indeed, clinical trials testing treatment via 
various pre-clinically identified GABAergic alterations have been reported in recent years 
(for review, see Braat et al.126). Treatment of Dravet syndrome with Clobazam127, Fragile X 
syndrome with ganaxolone128, target GABA
A
 receptors, while targeting of GABA
B
 receptors 
with arbaclofen is a possible treatment for Fragile X syndrome129. However, the results 
obtained in these trials are only mildly positive, possibly because of genetic heterogeneity 
of patients126 and future research with increased patient cohorts is warranted.
An alternative approach to restore the E/I balance in patients is to increase the inhibitory 
drive of GABA. Bumetanide is a diuretic that inhibits NKCC1, a chloride importer, and via this 
pathway increases the inhibitory drive of GABA31. Recently, a clinical trial with Bumetanide 
application to children (aged 3 - 11 years) with autism showed a reduction in severity of autism 
symptoms compared to placebo treated patients on the Childhood Autism Rating Scale130,131. 
However, the improvement did not last after Bumetanide application had stopped130, 
suggesting that increasing inhibitory drive does ameliorate the symptoms, but is not able to 
restore the network alterations underlying ASD in these patients. A possible explanation is 
that the critical period giving rise to ASD in these patients has taken place at a younger age, 
and the symptoms are a result of an already disrupted network development. Increasing 
the inhibitory drive after the critical period in this case seems unable to alter connectivity, 
and as a result stopping the application of Bumetanide also stops the amelioration of the 
symptoms. Of note, while other studies reported improved ASD symptoms after treatment 
with Aripiprazole132 or Risperidone133, these studies have not investigated the improvement 
during the discontinuation phase. Inclusion of this phase in future studies would greatly 
benefit our understanding of the effects of ASD treatment, or treatment of other disorders, 
during development.
Even though symptom improvement did not last during the discontinuation phase, these and 
other studies do show that manipulation of the inhibitory system works towards improving 
patient symptoms. This indicates that the idea of prevention via intervention before the 
critical period (and onset of symptoms) and symptom amelioration at later stages are two 
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distinct routes towards the treatment of neurodevelopmental disorders. While prevention 
of the development of neurodevelopmental disorders is of course the preferred route, 
problems with early diagnosis are a constraining factor, and the development of better early 
biomarkers is required for this approach124. Symptom treatment via tuning of the inhibitory 
drive to ameliorate patient symptoms is an exciting development that could greatly benefit 
patients, also at adult stages. Improving our knowledge of the role of the inhibitory system, 
particularly PV+ interneurons, play in neurodevelopmental disorders, and understanding the 
mechanisms these neurons use to regulate their activity and connectivity will be required to 
develop effective therapies in the future.
6.6 Future directions
Alterations to the inhibitory system are identified in patient studies and animal models 
of neurodevelopmental disorders. PV+ interneurons seem to play a central role in the 
development of these disorders. As discussed above, PV+ interneurons, specifically PV+ 
basket cells, regulate signal integration via feed-forward inhibition. In WT mice, the strength 
of feed-forward inhibition is tuned to the individual pyramidal neurons, in such a way that 
more active pyramidal neurons receive more feed-forward inhibition41. In this way, the E/I 
balance is maintained at the level of individual pyramidal neurons. This balance is most 
likely required for proper signal integration in pyramidal neurons, and acts as a filter to allow 
or prevent action potential initiation. 
Regulation of neuronal excitability is achieved by a process called homeostatic plasticity134,135. 
During this process, neuronal activity is kept within a range by altering the strength of 
excitatory134 or inhibitory136,137 synaptic input, or via regulation of the neuron’s intrinsic 
properties138. Neuronal activity is proposed to be assessed by the cell via action potential 
mediated calcium influx, signalling the amount of activity, which can then be compared to 
an, until now unknown, set-point139.
It is important to note that the set-point for the E/I balance is not fixed. PV+ interneuron 
activity levels increase or decrease depending on the environment or task an animal is 
presented with140. Environmental enrichment reduced PV+ interneuron activity, while 
conditional fear conditioning increases PV+ interneuron activity140. Also, learning tasks lower 
PV+ interneuron activity, and experimentally increasing PV+ interneuron activity prevents 
learning140. It is interesting to draw a parallel here with the closing of the critical period 
during PV+ interneuron maturation114, however, it is not known if these two findings are 
related. Regardless, while maintenance of the E/I balance is important for proper network 
function, the exact point of balance is not a fixed point, but can be regulated depending on 
the needs of the network.
The fact that neuronal activity is regulated toward a certain set-point of activity, and that 
this set-point is variable, opens up the possibility to manipulate this set-point in order to 
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influence a neurons’ activity. If it would be known how PV+ interneurons regulate their 
activity, these pathways could be ‘hijacked’ in order to manipulate PV+ interneuron activity 
and consequently restore the altered PV+ interneuron inhibition observed in patients.
Until now only a few studies have addressed homeostatic plasticity of PV interneurons. 
Chronic enhancement of network activity in hippocampal cultures increased excitatory 
synaptic strength onto PV+ interneurons. Conversely, excitatory synaptic strength 
was decreased following activity blockade141. In	 vivo studies show that increased PV+ 
interneuron activity during a learning task coincides with increased formation of excitatory 
synapses, while reduced PV+ interneuron activity during fear conditioning coincides with 
increased formation of inhibitory synapses140. While these studies provide valuable insights 
in the regulation of PV+ interneuron activity, it should be noted that these studies assess 
the nature of PV+ interneuron activity regulation following network alteration. Therefore, 
it is not possible to distinguish between cell-autonomous (homeostatic) mechanisms, and 
network effects, for example via BDNF signalling34,142–144.
In order to specifically manipulate PV+ interneuron activity, it is important to study the 
mechanism of cell-autonomous activity regulation in these cells. Therefore, it would ideally 
be possible to manipulate exclusively PV+ interneurons, in such a way that network activity 
is not, or minimally, affected. Development of new tools now allows for this approach. 
Sparse viral infection with Kir2.1 potassium channel, archaerhodopsin or the hM4di 
DREADD would allow for silencing of a small population of PV+ interneurons. Conversely, 
activating these cells could be achieved by sparse expression of NaChBac sodium channel, 
channelrhodopsin or the hM3Dq DREADD. This approach would allow for the study of cell-
autonomous mechanisms of activity regulation in PV+ interneurons, and would open the 
door to unravelling the molecular pathways that underlie this regulation. In the future, 
identified mechanisms and molecular pathways of activity regulation could be utilized to 
manipulate PV+ interneuron activity, and consequently the E/I balance in patients. For 
example, if a patient suffers from a condition which involves a reduced inhibitory drive from 
PV+ interneurons onto pyramidal cells, alteration of the activity set-point for PV interneurons 
to a higher point will increase PV+ interneuron activity. This would increase the inhibitory 
drive on pyramidal neurons and restore the E/I balance.
While there is still a long way to go before this approach could possibly be used for the 
treatment of human patients, the first steps towards understanding the mechanisms 
underlying PV+ interneuron activity regulation are now within reach. 
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6.7 Conclusions
In this thesis I have investigated the inhibitory system in three different rodent models 
of neurodevelopmental disorders. While all three models show clear alterations to the 
inhibitory system, the nature of these alterations differs between models. This underlines 
the importance of a properly functioning inhibitory system for normal network function, and 
suggests that a dysfunctional inhibitory system is an important factor for the development 
of psychiatric symptoms. PV+ interneurons are consistently identified to play a central 
role in neurodevelopmental disorders. In this thesis we have shown increased inhibitory 
function in Cdh13-/- mice to be caused by an increased connectivity of PV+ interneuron. 
While we have not investigated the origin of interneuron dysfunction in the Ehmt1+/- and 
APO-SUS/UNSUS models, it is conceivable that PV+ interneurons play a central role in these 
conditions. However, further research is required to confirm this hypothesis.
The notion that the inhibitory system, and PV+ interneurons in particular, play a central role 
in neurodevelopmental disorders point to these cells as a possible target for therapeutic 
intervention. Previous studies have shown that manipulation of inhibitory drive improves 
patient symptoms in ASD130. However, this treatment affects all neurons. The identification 
of PV+ interneurons as a point of convergence in many neurodevelopmental disorders 
raises the exciting possibility to specifically alter the activity or connectivity of these 
neurons. Therefore, it is vital for future studies to focus on the mechanisms via which PV+ 
interneurons regulate their activity and connectivity in order to develop strategies for the 
specific manipulation of this interneuron class. Via this strategy, specific manipulation of 
PV+ interneurons, without adverse effects via manipulation of other neuronal subtypes, 
it will hopefully be possible in the future to treat patients suffering from these debilitating 
conditions. I hope the studies presented in this thesis will contribute to achieving this goal.
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SUMMARY
The aim of this thesis was to investigate changes in neuronal connectivity onto excitatory 
pyramidal neurons in rodent models of distinct neurodevelopmental disorders. I found 
that all investigated models show a strong alteration in inhibitory synaptic function, while 
excitatory function was unaffected. These findings suggest that changes to the inhibitory 
system play a central role in the symptoms observed in patients of neurodevelopmental 
disorders, and that the shift in inhibitory/excitatory balance observed in these conditions is 
primarily caused by alterations of the inhibitory system.
In chapter 1 I provide an overview of the current view on the topic of the role of the 
inhibitory system in neurodevelopmental disorders. I discuss previous studies that have 
identified alterations in different aspects of interneuron function and connectivity which 
are believed to underlie neurodevelopmental disorders.
In chapter 2 I investigate the Cdh13-/- mouse. Mutations and copy-number variations of 
Cdh13 has been implicated primarily in ADHD and comorbid disorders, but also in autism 
spectrum disorders (ASD), schizophrenia, bipolar disorder and depression. I show that 
CDH13 is expressed exclusively in interneurons, mainly the parvalbumin-positive (PV+) and 
somatostatin-positive (SOM+) subtypes, where it localizes to the presynaptic compartment. 
Electrophysiological recordings reveal an increase in inhibitory inputs in Cdh13-/- mice, which 
is caused by an increased number of synaptic contacts.
In chapter 3 I look in further detail at CDH13. I show that deletion of Cdh13 in PV+ interneurons 
leads to an increase in perisomatic inhibitory synapses, indicating that the increase in 
inhibitory synapses in Cdh13-/- mice is, at least in part, caused by changes in PV+ interneuron 
connectivity. Using a cell-adhesion assay, I show that CDH13 binds transsynaptically with 
integrin β1 (ITGβ1) and integrin β3 (ITGβ3). Interestingly, coexpression of the GABAA-
receptor subunit α1 disrupted interaction of CDH13 with ITBβ3, but not ITGβ1, suggesting 
these integrins have a differential function in the regulation inhibitory synapses. Finally, I 
show that the integrin inhibitor echistatin acutely reduces evoked inhibitory inputs onto 
pyramidal neurons, showing a functional role of integrins in inhibitory synapses.
In chapter 4 I investigated the Ehmt1+/- mouse, a model for intellectual disability and 
ASD. Besides previously reported expression in excitatory neurons, I show that EHMT1 
is expressed in PV+ and SOM+ interneurons. Functionally, I find a disruption in the 
development of inhibitory synaptic input onto pyramidal neurons, leading to reduced 
inhibition at postnatal day (P) 21. Excitatory synaptic input was unaltered at all investigated 
time points. In addition to the reduced inhibitory synaptic input at P21, pyramidal neurons 
displayed an increased intrinsic excitability, which was caused by a hyperpolarization of the 
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action potential threshold. Together, these changes lead to increased spontaneous action 
potential frequency of pyramidal neurons. 
In chapter 5 I investigate the APO-SUS rat, a model for schizophrenia. I find that APO-SUS 
rats show reduced levels of the GABA-synthesizing protein GAD67 compared to APO-UNSUS 
(control) rats. This is most likely caused by reduced expression of this protein, suggestive of 
reduced interneuron activity. However, miniature inhibitory and excitatory synaptic input 
are unaltered in APO-SUS rats. In addition, inhibitory release probability did not show any 
changes between the two rat lines. However, APO-SUS rats display a reduced inhibitory 
paired pulse ratio at longer (≥150 ms) inter-stimulus intervals, which I identified to be 
caused by increased GABA
B
 receptor signalling. Consistently, western-blot analysis revealed 
an increased expression of the GABA
B1
 subunit of the GABA
B
 receptor.
In chapter 6 I discuss the findings in this thesis in the context of neurodevelopmental 
disorders and excitatory-inhibitory balance. In addition, I discuss possible alterations to 
network function and subsequent information processing that may play a role in these 
conditions. Finally, I discuss the possibility of the inhibitory system as a target for therapeutic 
intervention in the treatment of neurodevelopmental disorders.
In this thesis I show that alterations to the inhibitory system are consistently identified in 
neurodevelopmental disorders. However, the exact alterations are specific to the models 
investigated. These findings underline the importance of the inhibitory system for normal 
network function, and suggest that specific alterations may underlie specific patient 
symptoms.
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Het doel van deze thesis was het onderzoeken van de veranderingen in neuronale 
verbindingen op excitatoire piramidecellen in knaagdiermodellen van verschillende 
neurologische ontwikkelingsstoornissen. Ik heb aangetoond dat alle onderzochte 
modellen een duidelijke afwijking in de inhibitoire synaptische functionaliteit hebben, 
terwijl excitatoire synaptische functionaliteit geen verandering liet zien. Deze bevindingen 
suggereren dat veranderingen in het inhibitoire systeem een centrale rol spelen in patiënten 
met neurologische ontwikkelingsstoornissen en dat een verschuiving van de excitatie/
inhibitie balans in deze aandoeningen primair veroorzaakt wordt door veranderingen in het 
inhibitoire systeem.
In hoofdstuk 1 geef ik een overzicht van de huidige ideeën in het veld over de rol van het 
inhibitoire systeem in neurologische ontwikkelingsstoornissen. Ik bespreek voorgaande 
onderzoeken waarin veranderingen in verschillende aspecten van inhibitoire functie 
en connectiviteit zijn gevonden en waarvan wordt aangenomen dat ze causaal zijn voor 
neuronale ontwikkelingsstoornissen.
In hoofdstuk 2 heb ik de Cdh13-/- muis onderzocht. Mutaties in copy-number variaties van 
Cdh13 worden voornamelijk geassocieerd met ADHD en comorbide stoornissen, maar ook 
met autisme spectrum stoornissen (ASS), schizofrenie, bipolaire stoornis en depressie. Ik 
heb aangetoond aan dat CDH13 exclusief tot expressie komt in interneuronen, voornamelijk 
de parvalbumine positieve (PV+) en somatostatine positieve (SOM+) subtypen, waar het 
zich bevindt in het presynaptische compartiment. Electrofysiologische metingen hebben 
een toename van inhibitoire input in Cdh13-/- muizen laten zien, welke veroorzaakt werd 
door een toename van het aantal synaptische verbindingen.
In hoofdstuk 3 heb ik in meer detail naar CDH13 gekeken. Ik heb aangetoond dat deletie van 
CDH13 in PV+ interneuronen leidt tot een toename in het aantal perisomatische inhibitoire 
synapsen, wat erop wijst dat de toename van inhibitoire synapsen in de Cdh13-/- muis in 
ieder geval deels wordt veroorzaakt door veranderingen in de connectiviteit van PV+ 
interneuronen. Door gebruik te maken van een cel-adhesieassay heb ik aangetoond dat 
CDH13 een trans-synaptische interactie aan kan gaan met integrine β1 (ITGB1) en integrine β3 
(ITGB3). Coëxpressie van de GABA
A
-receptor subunit α1 verstoorde de interactie van CDH13 
met ITGB3, maar niet met ITGB1, wat suggereert dat deze integrines een verschillende rol 
spelen in de regulatie van inhibitoire synapsen. Tot slot heb ik aangetoond dat de integrine-
inhibitor echistatine leidt tot een acute afname van gestimuleerde inhibitoire input op 
pyramidecellen. Dit wijst erop dat integrines een functionele rol spelen in inhibitoire 
synapsen.
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In hoofdstuk 4 onderzoek ik de Ehmt1+/- muis, een model voor verstandelijke beperking en 
ASS. Naast de eerder aangetoonde expressie in excitatoire neuronen heb ik aangetoond dat 
EHMT1 ook tot expressie komt in PV+ en SOM+ interneuronen. Op functioneel niveau heb 
ik een verstoring in de ontwikkeling van de inhibitoire synaptische input op pyramidecellen 
gevonden die leidt tot een verlaging van de inhibitie op postnatale dag (P) 21. Excitatoire 
synaptische input was onveranderd op alle onderzochte tijdspunten. Naast de verminderde 
inhibitoire synaptische input op P21 hadden pyramidecellen een toegenomen intrinsieke 
excitabiliteit, welke veroorzaakt werd door een hyperpolarisatie van de drempelwaarde van 
het actiepotentiaal. Samen leidden deze veranderingen tot een toename van de frequentie 
van spontane actiepotentialen in pyramidecellen.
In hoofdstuk 5 heb ik de APO-SUS rat, een schizophreniemodel, onderzocht. In vergelijking 
met APO-UNSUS (controle) ratten hebben APO-SUS-ratten een verlaagde expressie van 
het GABA-producerende eiwit GAD67. Dit wordt waarschijnlijk veroorzaakt door een 
verlaagde expressie van dit eiwit, wat wijst op verlaagde activiteit van interneuronen. Deze 
twee ratlijnen hebben echter geen verandering in zowel de miniatuur synaptische input 
als de afgiftekans van inhibitoire en excitatoire synapsen. APO-SUS-ratten lieten wel een 
verlaging zien in de inhibitoire afgiftekans bij langere (≥150 ms) inter-stimulatie intervallen, 
waarvan ik heb aangetoond dat dit veroorzaakt werd door een toename van GABA
B
 receptor 
activiteit. Western-blotanalyse toonde, consistent met deze hypothese, een toename van 
de expressie van de GABA
B1
 subunit van de GABA
B
-receptor aan.
In hoofdstuk 6 bespreek ik de bevindingen in deze thesis in de context van neuronale 
ontwikkelingsstoornissen en de excitatie/inhibitie-balans. Daarnaast bespreek ik hoe 
mogelijke verstoringen van de netwerkfunctie en de daaruit volgende verstoring van de 
informatieverwerking een rol kunnen spelen in deze aandoeningen. Tot slot bespreek 
ik de mogelijkheid om het inhibitoire systeem te gebruiken als aangrijpingspunt voor 
therapeutische manipulatie in de behandeling van neuronale ontwikkelingsstoornissen.
In deze thesis toon ik aan dat veranderingen in het inhibitoire systeem herhaaldelijk 
gevonden worden in neuronale ontwikkelingsstoornissen. De aard van deze veranderingen 
is echter afhankelijk van het onderzochte model. Deze bevindingen onderstrepen het belang 
van het inhibitoire systeem in het functioneren van het gezonde netwerk en suggereren 
dat specifieke veranderingen ten grondslag kunnen liggen aan specifieke symptomen in 
patiënten met neuronale ontwikkelingsstoornissen.
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